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 Chimeric antigen receptors (CAR) are synthetic receptors that combine the single 
chain variable fragment (scFv) of a monoclonal antibody with the ζ-chain and 
costimulatory domains from the T cell receptor complex. Gene transfer of CARs into T 
cells redirects T cell antigen specificity through the scFv and promotes T cell activation 
and proliferation through costimulatory signals. The infusion of CAR-T cells in patients 
with B cell malignancies has led to durable complete remission. However, there is still 
considerable work to be done to improve the efficacy of CAR-T cell therapy.  
 In this dissertation we propose two strategies to address resistance to adoptive 
CAR-T cell therapy. In Chapter 1, we begin by summarizing the progress made in the 
field of adoptive T cell therapies and the drawbacks of the achievements that led to the 
development of CAR-T cell therapies. We then detail the evolution of CAR-T cell 
therapies and review the advances being made to improve the efficacy of CAR-T cells 
in the treatment of solid tumor malignancies. Chapter 1 ends with an account of the 
challenges still facing CAR-T cell therapy: tumor escape and tumor heterogeneity.  
 Tumor escape resulting from selective pressure by CAR-T cells is becoming an 
increasingly common cause of resistance to CAR-T cell therapy. The field has 
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addressed the need for multi-redirect CAR-T cells but with suboptimal strategies that 
significantly increase the cost or compromise the efficacy of adoptive CAR-T cells. 
Chapter 2 proposes a novel strategy to prevent relapse occurring from tumor escape by 
simultaneously targeting multiple tumor-associated antigens using single domain 
antibody mimics. In Chapter 3 we undertake the intrinsic tumor heterogeneity that is a 
root cause of resistance to adoptive CAR-T cell therapy. We identify B7-H3 as a tumor-
associated antigen that is universally expressed in malignancies across organs and 
tissues of diverse origin and demonstrate that a novel CAR targeting B7-H3 possesses 
robust anti-tumor activity and positive safety profile. In Chapter 4, we conclude with a 
discussion of how the proposed therapies provided a foundation upon which to refine 
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CHAPTER 1: INTRODUCTION 
 Since the time of their discovery, cytotoxic T cells (CTL) have been recognized 
as a powerful arm of the immune system. Their specific and powerful cytotoxic 
capabilities are critical in protecting hosts from intracellular bacterial [1] and viral 
pathogens [2] and can elicit long lasting protection against subsequent challenges [3]. In 
addition to providing defense against pathogens, CTLs are implicated in a number of 
disease processes and conditions. Notably, uncontrolled CTL responses can provoke 
immune pathologies [4], cause autoimmune disorders [5] and mediate allograft rejection 
[6]. Today it is well known that the activation and function of CTLs rely on a strict series 
of coordinated events. Initiation of the CTL response starts with two critical signals. The 
first signal arises when a CTL recognizes its cognate peptide antigen through the T cell 
receptor (TCR) [7-9]. The cognate peptide antigen must be presented to CTLs bound to 
major histocompatibility complex (MHC) molecules by antigen presenting cells (APC) 
[8]. Following the first signal, CTLs must also receive a costimulatory signal from APCs 
for optimal activation and interleukin 2 (IL-2) for the expression of cytotoxic effector 
molecules [10, 11]. Lastly, CTLs receive signals from inflammatory cytokines, such as 
interleukin-12 (IL-12) and interferon gamma (IFNγ), to sustain and promote their effector 
functions [12]. Inhibition at any step limits CTL responses and results in cell death [13] 
or anergy [14].  
 The theory that CTLs could mediate tumor rejection originated from the idea that 
immunity to tumors, or “adoptive immunity”, could be passively transferred to syngeneic 
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recipients [6, 15, 16]. Propelled by the discovery that lymphocytes mediate tissue 
transplant rejection, it was thought that residual heterozygosis in inbred strains, or MHC 
incompatibility, was the mechanism driving adoptive immunity. However, thorough 
investigations demonstrated, not only that lymphocytes from tumor draining lymph 
nodes are cytotoxic against syngeneic tumor cells in vitro, but also that they mediate the 
effects of adoptive immunity in vivo. [17, 18] Despite the revelation that lymphocytes 
have cytotoxic activity against tumor cells, further investigations were impeded by the 
inability to expand the lymphocytes in sufficient numbers for in vitro studies. However, 
an accidental discovery that the plant extract phytohemmaglutinin (PHA) induces 
mitosis in human leukocytes [19] resulted in the eventual discovery that IL-2 is a 
cytokine critical for the expansion of T cells in vitro and ex vivo [20-22]. These early 
seminal findings were crucial in improving our understanding of T cell biology and 
catapulted the field of adoptive immunotherapy to where it is today. Here, the historical 
developments that led to the evolution of chimeric antigen receptor (CAR)-T cells are 
discussed. 
THE HISTORY OF ADOPTIVE T CELL THERAPIES 
IL-2 is Identified as a T Cell Growth Factor 
 By 1960, it was clear that lymph node draining lymphocytes mediate the effects 
of adoptive immunity [18, 23]. However, further investigations could not be carried out to 
verify the role of lymphocytes ex vivo or the mechanism by which immunity to tumors 
could be transferred. The biggest limitation to these studies was the inability to expand 
and maintain long-term lymphocyte cultures in vitro. Furthermore, in vitro cultures could, 
at best, only maintain a concentration of cells that were similar to the starting 
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concentrations. Considering that it was all but impossible to expand lymphocyte 
populations in vitro for further studies, there was a precedence to identify a growth 
factor. [24]  
 The serendipitous discovery that the mitogen PHA induces mitosis in human 
leukocytes was key to identifying a growth factor for CTLs. In 1976, Morgan and 
colleagues reported that mitogen stimulated T cells released factors into the media that, 
when transferred to naïve T cells, could induce the proliferation of T cells that lacked 
effector functions for up to a year [25].  The notion that T cells could be induced to 
proliferate in an antigen-independent manner was highly controversial, as the dogma 
was that T cell growth factors (TCGF) released into the medium were intended to 
amplify signals originating from antigen recognition. Further, it was believed that 
because T cells are terminally differentiated, the TCGF could not induce indefinite 
proliferation of CTLs. [24] However, in a series of studies between 1977-78, Gillis and 
Smith challenged that notion.  
 Gillis and Smith demonstrated that tumor-specific murine CTLs could be 
generated and maintained in long-term culture using secondary allogeneic mixed tumor-
lymphocyte cultures and a TCGF that was provided from the supernatant of splenocytes 
stimulated with the mitogen concavalin A. The CTLs demonstrated high levels of 
specific cytotoxicity towards syngeneic tumors after more than four months in culture. 
Gillis and colleagues further demonstrated the feasibility of expanding large numbers of 
tumor-specific human CTLs in a TCGF-dependent manner, leading them to propose 
that identification of the TCGF could allow for the expansion of tumor-specific CTLs for 
adoptive immunotherapy in humans [21]. The identification of the TCGF to be a 15.5 
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kilodalton glycosylated protein that we now know as IL-2 [26] as well as its cloning [27] 
and purification for immunological assays [28], revolutionized the field of adoptive 
immunotherapy. 
IL-2 and Lymphokine Activated Killer (LAK) Cells for Adoptive Immunotherapy 
 It was predicted that CTLs isolated from tumor tissues, or tumor-infiltrating 
lymphocytes (TIL), could be used as an immunotherapy for patients with cancer, but 
investigators did not consider TILs isolated from tumor biopsies as a feasible treatment 
option because the techniques to successfully isolate and expand T cells in culture were 
not fully understood. In search of a more accessible source of autologous tumor-specific 
CTLs, investigators turned to peripheral blood lymphocytes (PBL) to generate 
therapeutic cells. By then, IL-2 had been identified and validated as a critical growth 
factor for T cells and it became rational to examine the effects IL-2 had on PBLs. 
 In 1981, Lotze and colleagues cultured normal murine splenocytes with 
recombinant IL-2 (rIL-2) and were surprised to find that the splenocytes were cytotoxic 
against syngeneic tumors. Much to their surprise, they discovered that the results could 
be replicated using human PBL from healthy donors and cancer patients, including 
patients diagnosed with melanomas and sarcomas. [29, 30] Due to the critical role rIL-2 
has in inducing the cytotoxic functions, PBL cultured in high does of rIL-2 ex vivo earned 
the name lymphokine activated killer (LAK) cells and indicated to be a promising 
adoptive immunotherapy in clinical trials. However, investigators observed that sufficient 
LAK cells could not be reproducibly expanded in patients. Furthermore, no tumor 
regression was observed in clinical trials administering LAK cells to patients with 
metastatic cancers. [28, 31] The costly and labor intensive process of generating LAK 
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cells ex vivo, as well as the notion that ex vivo manipulation was impeding the efficient 
expansion of PBLs, led investigators to attempt generating LAK cells in vivo by 
administering high doses of rIL-2 to patients. However, no tumor regression was 
observed and patients suffered from severe, life-threatening toxicity. [22] 
 The lack of observable tumor regression in patients treated with ex vivo 
expanded LAK cells or rIL-2 alone was a disappointing defeat. The clinical data were in 
contrast to in vitro data with human LAK cells and in vivo data with murine models of 
metastatic cancer [29, 32]. One suspected explanation for the lack of observable tumor 
regression was that LAK cells were not being provided growth factors critical for 
sustaining anti-tumor activity once infused back into patients. This hypothesis led 
investigators to evaluate a combination therapy consisting of LAK cells and systemic 
rIL-2 administration with the rationale that systemic rIL-2 could sustain and promote the 
anti-tumor activity of LAK cells in vivo. As expected, the combination therapy proved to 
be significantly more effective in regressing established tumors in murine models. [33, 
34] In clinical trial ≥ 50% tumor regression was observed in 11 of 25 (44%) patients with 
metastatic, nonresectable cancer for a follow up duration of ≥ six weeks [35]. As 
encouraging as the trial results were, the high doses of rIL-2 necessary for tumor 
regression was extremely toxic and the observed tumor regression were short lived [35, 
36]. 
Tumor Infiltrating Lymphocytes are More Potent than LAK Cells 
 The short-term tumor regression observed in patients treated with a combination 
of autologous LAK cells and systemic rIL-2 made clear that a more potent 
immunotherapy strategy would have to be utilized to elicit long-term tumor regression. 
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TILs had been described as early as the 1970s and immune surveillance in the tumor 
was thought to be associated with a favorable prognosis [37, 38]. Further, TILs had 
been isolated and characterized in numerous cancers such as neuroblastoma [39], 
melanoma [40], breast cancer [41], colorectal cancer and squamous carcinomas of the 
head and neck [42] indicating that the development of TIL therapy could be a widely 
applicable immunotherapy. It was hypothesized that TILS are composed of cluster of 
differentiation 3 (CD3)+ T cells, but it had not been formally demonstrated. Therefore, 
Rosenberg and colleagues treated irradiated mice with systemic rIL-2 and 
demonstrated that the irradiated mice were no better at regressing established 
pulmonary metastases compared to control mice. The same observation was made 
when thymectomized mice were reconstituted with bone marrow depleted of CD3+ T 
cells. [35] 
 With Rosenberg’s study results, it was indisputable that CD3+ T cells were critical 
and a clinical trial was initiated to compare the anti-tumor activity of autologous LAK 
cells and TILs. Not surprisingly, TILs were found to be 50-100 times more potent than 
LAK cells in regressing established tumors in clinical trials with melanoma patients [43]. 
These results launched numerous studies aiming to replicate the successes 
substantiated in melanoma patients in other malignancies. Clinical trials for patients with 
renal cell carcinoma [44, 45], small cell lung carcinoma [46] and epithelial ovarian 
cancer [47] showed modest to no tumor reduction or improved disease-free survival 
compared to standard chemotherapy alone and failed to replicate the successes seen in 
melanoma trials. In addition to the poor results, there were many limitations to TIL 
therapy. First, the presence of a resectable tumor limited TIL therapy to just a fraction of 
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patients. Second, the time consuming and labor intensive process required to obtain 
high numbers of TILs necessary for therapy was neither feasible nor reproducibly. [48-
50]  
T Cells Recognize Tumor Antigens  
 It had long been suspected that the antigens recognized by tumor-specific CTLs 
were peptide sequences resulting from cancer mutations. However, it was difficult to 
test whether TILs were tumor specific CTLs due to the limited numbers of TILs that 
could be isolated from biopsy samples, as well as the requirement for fresh viable 
autologous and allogeneic tumor cells for screening purposes [51]. Nevertheless, it was 
discovered that tumor variants failed to establish tumors when injected into syngeneic 
mice using a stable teratocarcinoma cell line and the mutagen nitroguanidine. When the 
tumor variants were injected into irradiated mice the variants grew as well as the WT 
tumor. These data suggested that mutagenized tumor variants express new antigens as 
a result of chromosomal deoxyribonucleic acid (DNA) mutations in order to elicit potent 
CTL responses. [52] 
 It took longer than a decade before Boon and Kellerman’s findings could be 
confirmed and validated in humans. In 1991, van der Bruggen and colleagues identified 
the melanoma-associated antigen (MAGE) gene family using cosmid libraries to select 
for cytotoxicity-resistant melanoma sublines. MAGE-1, they found, was expressed on 
established tumor cell lines of different histology, including lung and breast cancer, but 
not on normal tissues. Importantly, MAGE-1 was recognized by CTLs derived from 
patients in in vitro assays. The discovery of MAGE-1 sparked interest in using MAGE-1 
as a standard target antigen to generate CTLs for clinical trials. [53] Additional tumor 
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associated antigens (TAA) recognized by autologous CTLs were identified in the ‘90s 
and included: tyrosinase [54], MAGE-3 [55], MART-1 [56], gp100/PMEL [57] and NY-
ESO-1 [58].  
 With the knowledge that CTLs are tumor specific, various strategies were 
employed to elicit CTL responses against tumors expressing known TAAs. These 
methods included the adoptive transfer of TILs or PBLs isolated with peptide-MHC 
tetramers [59] and stimulated with autologous tumor [60] or TAA peptides [61, 62]. 
Melanoma patients were also vaccinated with adjuvant/TAA peptide emulsions with or 
without bolus injections of rIL-2 [63, 64] and even allogeneic melanoma cells transduced 
to constitutively produce IL-2 [65]. The above-mentioned strategies elicited weak and 
transient TAA-specific immune responses with variable success [63-65] due to two 
particular obstacles: a) the frequency of TAA-specific CTLs is low [66]; b) TAA specific 
CTLs have low affinity for tumor antigens due to negative selection of self-reactive T 
cells [59, 67-69]. 
Genetic Modification Generates T Cell Receptor (TCR) Engineered T cells  
 The difficulty investigators experienced trying to generate and expand TAA-
specific CTLs prompted a search for TCR clones that recognize TAAs. In 1994, Cole 
and colleagues identified two T cell receptor (TCR) clones that recognized a MART-1 
epitope [70]. In a proof-of-concept study, human PBL were transduced with a retroviral 
vector encoding the MART-1 TCR. Retroviral transduction of PBL generated a large 
population of TAA specific CTLs that showed anti-tumor reactivity in in vitro studies. [48] 
Like TILs, TCR engineered CTLs provided several advantages for use in the treatment 
of cancer. TCR engineered CTLs were already TAA specific. TCR affinity to tumor 
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antigens is generally in the micromolar range because self-reactive cells are eliminated 
by negative selection in the thymus [59, 67-69], but investigators had the ability to alter 
the receptor affinity [71, 72]. Importantly, investigators could more often reproducibly 
manufacture sufficient high avidity CTLs ex vivo to treat patients by using differential 
concentrations of stimulating Ag during expansion [73]. 
 TCR engineering allowed investigators to overcome a major hurdle in treating 
human patients with tumor specific CTLs, but TCR engineering presented new risks and 
challenges. First, TCR engineered T cell therapy was limited to patients with certain 
MHC haplotypes [48]. Second, TCR engineering came with the risk of TCR mispairing, 
in which the introduced and endogenous α and β chains incorrectly pair to dilute the 
expression of the therapeutic TCR and potentially induce autoreactivity [74, 75]. Third, 
and most importantly, adoptive transfer of TCR engineered T cells were still relatively 
transiently effective [76]. Examination revealed that one of the primary reasons that 
TCR engineered T cells have limited clinical responses is due to MHC restricted T cell 
activation through APC engagement. This was a major barrier to successful TCR 
engineered adoptive T cell therapy because not only are APCs poorly recruited to the 
tumor microenvironment [77], APCs also downregulate MHC molecules [78].  
 Considering the low applicability of TCR engineered T cells to patient populations 
and diseases, investigators sought to engineer CTLs to overcome the barrier of MHC 
restricted activation in the tumor microenvironment. In order to overcome the limitation 
of poor antigen presentation, MHC-independent artificial receptors were constructed to 
redirect T cell specificity. First described in 1989, Gross and colleagues used the 
specificity of monoclonal antibodies and components of the TCR complex to generate 
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what has now evolved to be known as the chimeric antigen receptor (CAR) [79]. In 
sections below, the evolution and clinical efficacy of adoptive CAR-T cell therapy will be 
discussed. 
Chimeric Antigen Receptors Allow for MHC Independent T Cell Activation 
 The observation that antibodies and the TCR are structurally similar led to the 
hypothesis that the variable regions of the TCR could be exchanged with variable 
regions of antibodies to redirect T cell specificity. Indeed, Gross and colleagues 
demonstrated that immunoglobulin variable heavy (VH) or variable light (VL) chains 
could be combined with constant regions from the TCR α or β chains and expressed on 
the surface of cells. When complementary TCR α and β constructs combined with a VH 
and VL chain were transfected into cytotoxic T cell hybridomas, the receptors mediated 
specific lysis of target cells and released IL-2. [79] This demonstration that T cells could 
be redirected with the specificity of a monoclonal antibody in an MHC-independent 
manner laid the foundation for further investigations to refine and improve the specificity 
and activity of T cells expressing the chimeric T cell receptor (cTcR). 
 The novelty of cTcRs promised to excite the field of adoptive immunotherapy. 
However, cells suffered from poor surface expression due to the need to transfect large 
gene sets encoding both the transgenic TCR α and β chains. Further, the cTcRs were 
optimally functional when the transfected α and β chains paired to form a heterodimeric 
receptor and the chimeric chains were prone to mispairing with endogenous α and β 
chains. [80] Therefore, it became obvious to devise compact and self-sustaining 
receptors. The resulting receptor, the CAR, was composed of a single chain variable 
fragment (scFv), where the VH and VL chains were joined with a flexible peptide linker 
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as the extracellular antigen recognition domain and the TCR ζ chain. In contrast to the 
cTcR, the CAR was a single, linear molecule that maintained native T cell signaling 
through the TCR ζ chain and could endow cells with the specificity and signaling 
necessary to activate cytolytic activity. [80] 
 Today, CAR-T cells have evolved from constructs relying on activation through 
the CD3ζ chain, known as a first-generation CAR, to more complex generations 
incorporating costimulatory domains and transgenes designed to improve the 
functionality of CAR-T cells. However, the overall structure of the CAR remains the 
same. The antigen-binding domain of CARs is composed of the scFv, which consists of 
the VH and VL chains joined by a flexible GSSS linker. The extracellular scFv is 
anchored to the surface by a hinge derived from native T cell molecules, such as CD8α 
and CD28, and stabilizes the expression of the scFv molecule on the surface of the cell, 
while the transmembrane domain anchors both the scFv and hinge to the surface of 
cells with hydrophobic α helices that span the membrane of the cell. An intracellular 
costimulatory molecule and the CD3ζ chain immediately follow the transmembrane 
domain to complete the construction of the widely used second generation CAR. [81] 
 Unfortunately, there is not one universal CAR format. Each CAR requires 
empirical testing to determine the combination of structures that result in optimal 
therapeutic outcomes. For instance, the optimal length of the GSSS linker, which can 
affect the stability and expression of the CAR [82], and the orientation of the VH and VL 
chains [83] are entirely dependent on the antigen of interest. Factors such as proximal 
or distal antigen location, expression pattern and density and in situ modifications must 
all be taken into account when constructing the extracellular CAR molecule so as to 
12 
achieve optimal antigen recognition [84, 85]. Crude construction of the CAR to mimic 
the TCR receptor complex has resulted in loss of sensitivity and a relatively lower 
activation threshold [86, 87]. However, these disadvantages have been negated by the 
advantage of using known monoclonal antibodies to redirect T cells, allowing significant 
empirical testing to take place to improve the recognition and function of T cells 
redirected with the CAR.  
 Today, advancements in the field of adoptive CAR-T cell therapy have led to 
revolutionary treatments for hematological malignancies. The most successful CAR to 
date has been against the CD19 antigen in B cell malignancies, particularly in pediatric 
patients with acute lymphoblastic leukemia (ALL). Recently, the field of adoptive CAR-T 
cell therapy achieved a monumental milestone when the Food and Drug Administration 
(FDA) approved CD19 CAR-T cell therapy for children and adults with refractory B cell 
malignancies. Studies against solid tumor malignancies have been conducted in an 
effort to replicate the success CD19 CAR-T cell therapy has achieved in B cell 
malignancies. However, trials treating solid tumors have failed to garner clinical results 
because the treatment of solid tumors presents with challenges absent in hematological 
malignancies [88]. Discussions in the following sections will describe the evolution of 
CAR-T cell therapy and the endeavors working to improve the function and safety of 
CAR-T cells against solid tumor malignancies. 
THE EVOLUTION OF CHIMERIC ANTIGEN RECEPTOR-T CELL THERAPY 
 CAR-T cells, like previous predecessors of adoptive immunotherapy, combine 
cutting edge technologies to manufacture a personalized and living drug for patients. 
CAR-T cells that engraft and persist afford patients life-long protection from tumor 
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occurrence. However, CAR-T cells differ from previous predecessors of adoptive 
immunotherapy because CAR-T cells can be activated independent of MHC molecules. 
This allows T cells to be redirected against any extracellular antigen of interest, 
including carbohydrates and lipids, without the need for APC processing and 
presentation. [89] 
 CAR-T cells are manufactured all over the world for clinical and laboratory stud. 
PBL are collected from patients eligible for clinical trial or healthy donors by 
leukapheresis. The T cells are then activated through the endogenous TCR with 
reagents such as CD3 and CD28 so that the CAR transgene can be introduced. [90] 
The empirically evaluated CAR format can be expressed on the surface of T cells 
transiently or permanently. Transient expression of the CAR is preferable when toxicity 
is expected or suspected and can be achieved with ribonucleic acid (RNA) transfection, 
which maintains CAR expression for up to one week [91, 92]. But, due to the non-
integrative nature of transfections, patients require multiple infusions of CAR-T cells for 
clinical efficacy. An integrative strategy to induce the expression of CAR molecules is to 
use transposon systems. The transposon system relies on a transposase to catalyze 
the insertion of transgenes into the genome of vertebrates, providing permanent but 
non-viral integration of the transgene [93]. The Sleeping Beauty [94] and piggyback 
transposon systems [95] are well-characterized methods of generating CAR-T cell 
products currently being tested in clinical trials.  
 Permanent CAR expression via retroviral integration is the most commonly used 
strategy to generate CAR-T cells. Gamma retroviral and lentiviral vectors, derived from 
the murine leukemia or human immunodeficiency virus respectively, supply the CAR 
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transgene in RNA form and the CAR transgene stably integrates into the genome upon 
reverse transcription to deoxyribonucleic acid (DNA). Among strategies used to express 
the CAR molecule, viral transduction is the most efficient. However, a concern with 
using viral vectors is the potential for insertional mutagenesis [96]. Thorough integration 
site analyses have been conducted and concluded that the transgene favors integration 
near regions of the genome that are actively being transcribed [97, 98]. There are no 
reports of insertional mutagenesis thus far and lingering concerns have been partially 
mitigated by using self-inactivating vectors [99, 100]. 
 T cells that are transduced to express the CAR are then expanded ex vivo with 
cytokines until sufficient cell numbers have been obtained for infusion into patients or in 
vitro studies. Meanwhile, patients undergo lymphodepleting chemotherapy to increase 
CAR-T cell engraftment and persistence in vivo. Lymphodepletion is thought to serve 
two purposes. One, lymphodepletion is thought to create a favorable environment for 
CAR-T cell engraftment by freeing up nutrients critical for CAR-T cell survival. Second, 
lymphodepletion reduces cell populations that inhibit CAR-T cell function. [101, 102] 
Following the infusion of CAR-T cells, patients are closely monitored for acute adverse 
effects.  
 B cell malignancies, particularly ALL, have proven that the principles behind 
CAR-T cell therapy are achievable, but there are significant improvements to be made 
in order to improve the efficacy of CAR-T cell therapy in other malignancies. The 
addition of costimulatory domains has significantly improved the persistence of CAR-T 
cells [103] in vivo [104]. However, further studies are being conducted to ensure that 
CAR-T cells also proliferate and form memory populations to provide surveillance 
15 
against tumor recurrence. Further, more comprehensive studies must be conducted to 
select for target antigens that minimize off-tumor side effects and address life-
threatening adverse effects. The treatment of solid tumors also poses unique 
challenges due to the presence of stromal elements and an inhibitory microenvironment 
[105]. Strategies being investigated to overcome the above mentioned challenges are 
discussed in the sections below.  
Persistence and Proliferation 
 Activation of CAR-T cells through the immunoreceptor tyrosine-based activation 
motif (ITAM) domains on CD3ζ, alone, was sufficient to demonstrate the functional 
capacity of first generation CD19 CAR-T cells in in vitro assays [63, 80]. These pre-
clinical data were compelling enough to warrant early-phase clinical trials at multiple 
academic institutions. However, first-generation CAR-T cells exhibited limited efficacy in 
vivo [106]. The failure to see CAR-T cells in the peripheral blood of patients led 
investigators to compare the biology of endogenous TCRs and the CAR. Optimal 
activation through the αβTCR requires a costimulatory signal in addition to an antigen-
specific signal. With the addition of just the CD3ζ chain, it was likely that first-generation 
CAR-T cells were undergoing anergy and cell death. [107] Thus, costimulatory domains 
were incorporated into the construction of the CAR to generate what is now known as 
the second-generation CAR [103]. 
 The addition of a costimulatory domain significantly improved the anti-tumor 
activity of CD19 CAR-T cells. Importantly, second-generation CD19 CAR-T cells could 
be identified in the peripheral blood of patients, indicating that the engrafted CAR-T cells 
were proliferating into effector and memory populations to prevent tumor recurrence 
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[104, 108-110]. In clinical trials with pediatric relapsed/refractory ALL patients, CD19 
CAR-T trials using either the CD28 [111] or 4-1BB (CD137) [112] domains achieved 
>70% complete remission in patients with relapsed/refractory ALL. Now, third-
generation CAR-T cells that incorporate two costimulatory domains are being tested in 
preclinical and clinical studies to determine the advantage of combining costimulatory 
domains [113] and include costimulatory domains such as OX-40 (CD134) [114], ICOS 
(CD278) [115] and CD27 [116]. However, persistence and proliferation in vivo is still a 
substantial barrier to successful CAR-T cell therapy.  
 When T cells encounter their cognate antigen, activated T cells undergo clonal 
expansion and differentiation. During the differentiation process, T cells gain effector 
functions that allow them to respond to repeated challenges rapidly and with vigor. In 
the absence of the antigen, clonally expanded T cells undergo contraction and the vast 
majority undergoes apoptosis. The few cells that remain following the contraction phase 
are long-lived memory cells from which additional short-lived effector T cells will 
differentiate from upon subsequent exposure to the antigen. [117] Therefore, the 
establishment of long-lived memory populations is critical for adoptive CAR-T cell 
therapy [109]. 
 While the entire differentiation spectrum of T cells is critical to the success of 
CAR-T cell therapy, certain subsets are necessary for the engraftment and persistence 
of CAR-T cells. Specifically, TSCM and TCM, are required as these cells possess the most 
self-renewal capacity. While TCM can be successfully isolated from the peripheral blood, 
TSCM do not circulate in numbers that are sufficient for the generation of CAR-T cells. 
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Therefore, substantial effort has been placed on how to best preserve and expand T 
cells from patients that have the most therapeutic efficacy in patients. [118] 
 The most cost-effective method of retaining and expanding cells from the TSCM 
and TCM subsets has been to modify the culture conditions in which T cells are 
expanded ex vivo. Groups have demonstrated that culture conditions including IL-7 and 
IL-15 preserve greater frequencies of T cells with a TSCM-like phenotype than IL-2 alone, 
and that these T cells have superior persistence in vivo [119, 120]. Others have used 
kinase inhibitors to block differentiation but not proliferation of T cells by targeting the 
WNT [121] or Akt [122] pathways. Sabatino and colleagues used a combination of IL-7, 
IL-21 and the glycogen synthase-3β (GSK-3β) inhibitor TWS119 to expand a population 
of T cells that are also TSCM in phenotype from naïve precursors [123]. In addition to 
changes in the culture conditions CAR-T cells are also being derived from defined ratios 
of CD4 and CD8 TSCM and TCM in preclinical and clinical studies to maximize the anti-
tumor activity of CAR-T cells [124]. Investigators have renewed focus on studying the 
epigenetic and transcriptional regulators of T cell differentiation to identify factors critical 
for stemness [118]. Identification of such factors, such as Tcf-7, will be crucial for the 
generation of CAR-T cells capable of persisting in vivo [125, 126]. 
Improving Antigen Recognition and Safety 
 In the early revolution of adoptive T cell therapy, the challenge investigators 
faced was to redirect T cells with CARs effective enough to achieve sustained complete 
remission in patients refractory for standard-of-care treatment regimens. Selecting a 
target antigen is one of the most significant hurdles investigators now face when 
treating patients with adoptive CAR-T cell therapy, which is only sustained by the 
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paucity of tumor-specific antigens [127]. The success of CD19 CAR-T cells arises from 
the restricted expression profile of the CD19 antigen to all B cell lineage populations 
[128, 129]. The absence of CD19 expression on cells outside of the B cell lineage has 
enabled safe and targeted elimination of tumor cells, while sparing normal tissue, and 
the effects of ablating all B cells can be compensated by intravenous immunoglobulins 
[130]. Unfortunately, target antigens such as CD19 are exceedingly rare, leading one 
group to propose that tumor vasculature be targeted as an alternative strategy to inhibit 
tumor growth when an appropriate target cannot be identified [131]. 
 Most often, the dilemma of which antigen to target is a choice between antigens 
that are overexpressed or modified on tumor cells. In both cases there are risks of 
severe on-tumor but off-target toxicity, where normal tissues that may happen to 
express the antigen at low levels are targeted as collateral damage. [132, 133] 
Therefore, investigators must carefully screen antigens to ensure that the antigen of 
choice is not expressed on critical tissues and organs such as the heart, lungs, liver and 
brain, but universally expressed on all tumor cells. A case of molecular mimicry in the 
muscles of the heart, despite careful screening for the targeted antigen on normal 
human tissues, has further illustrated the need for CARs that have improved recognition 
and safety [134].  
 Various constructs have been designed to address the need for improved tumor 
cell recognition. AND-CAR constructs can only efficiently activate T cells when both 
target antigens are expressed simultaneously. Split-CARs are an example of such 
constructs, where the intracellular domains necessary for the optimal activation of T 
cells is split between CARs recognizing two different antigens. The premise behind the 
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design of SPLIT-CARs is that a construct in which only one antigen is recognized, the 
CD3ζ chain or the costimulatory domain alone is insufficient to activate the effector 
functions of CAR-T cells. Only when both antigens are recognized can intracellular 
signals from both CARs come together to unleash the full activity of T cells. [135] The 
Synthetic Notch (Syn-Notch) CARs described by Morsut and colleagues is another 
example of an AND-CAR. Syn-Notch CARs activate the transcription and expression of 
a second CAR once the CAR recognizes the primary TAA. As such, T cells redirected 
with a Syn-Notch CAR can be designed to discriminate between healthy and diseased 
tissue. [136] 
 Inhibitory CARs were designed to countermeasure the recognition of healthy 
tissue. Inhibitory CARs are similar to SPLIT-CARs in that intracellular components are 
split between two different CAR constructs. However, in inhibitory CARs one CAR 
construct contains an activating costimulatory domain while the second CAR construct 
contains an inhibitory endodomain such as Cytotoxic T Lymphocyte-Associated Protein 
4 (CTLA-4) or Programmed Death-Ligand 1 (PD-L1). When both CARs are engaged, 
the inhibitory signals dampen the activation of T cells and mitigate off-tumor targeting. 
[137] Lastly, masked CARs have been designed in which the scFv of the CAR is 
masked behind a protein that can be cleaved by a protease found on the diseased 
organ or tissue [138]. 
 In addition to the severe off-target toxicity that can occur from infusion of CAR-T 
cells, anaphylaxis has been reported in a patient receiving intermittent infusions of CAR-
T cells. It is thought that the patient developed IgE antibodies to the murine derived 
scFv, highlighting the potential immunogenicity of CAR modified T cells [139]. Further, 
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acute adverse effects can arise from hyperactivation of the infused T cells [140]. This 
phenomenon is known as cytokine release syndrome, or CRS for short, and often leads 
to short-lived neurologic toxicity. On a molecular level, the hyperactivation of T cells 
results in the massive production of pro-inflammatory cytokines that activate other 
cellular compartments and promote a feed forward loop of activation. The classic 
hallmark of CRS in patients is elevated IL-6 in the serum. CRS is clinically treated with 
steroids, but the administration of steroids also ablates the presence of CAR-T cells in 
patients and diminishes the chances of CAR-T cells differentiating into long-lived 
memory cells. [141] Therefore, an alternative method to control the systemic toxicity 
caused by CAR-T cell is preferred.   
 Using genetic engineering, investigators have devised ways to selectively 
eliminate CAR-T cells. Called safety switches, transgenes are transduced into T cells to 
allow for the titration of cells in a dose-dependent manner. The first safety switch used 
in vivo required cotransduction of the herpes simplex virus-derived thymidine kinase 
(HSV-TK) and administration of its prodrug ganciclovir. Since HSV-TK selectively 
phosphorylates the nucleoside analog prodrug ganciclovir, the phosphorylated 
ganciclovir serves a competitive inhibitor of guanosine and leads to termination of DNA 
replication. Despite its efficacy, HSV-TK is immunogenic and the delayed elimination of 
T cells was a major limitation for use in the clinic. [142, 143] 
 The inducible caspase 9 (iCas9) system is a more effective strategy to eliminate 
CAR-T cells in vivo [144]. When a chemical inducer of dimerization (CID) is 
administered, CAR-T cells expressing the iCas9 are induced to conditionally dimerize 
and activate the apoptosis pathway. Administration of the CID safely eliminates iCas9 
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transduced T cells in a dose-dependent manner, with preference to T cells expressing 
the iCas9 transgene at high levels. The iCas9 system is advantageous over the HSV-
TK system, not only because of its efficacy, but also because the iCas9 system has low 
potential for immunogenicity. [145] As such, a clinical trial incorporating the iCas9 safety 
switch has been reported [146] and many more are underway (NCT03696784, 
NCT03594162, NCT03016377, NCT03721068, NCT02992210, NCT03098355). One 
way to mitigate toxicity without eliminating CAR-T cells altogether is to design switch-
mediated activation of CAR-T called ON-Switch CARs using AND-CAR constructs. In 
this approach, investigators titrate a heterodimerizing small molecule that is necessary 
for assembly of an activated complex that includes antigen engagement. This allows for 
in vivo control of the dosage and timing of CAR-T cell activity. [147] 
Improving Trafficking and Penetration 
 CAR-T cell infusions are most often administered intravenously. However, 
polyclonal T cells derived from the peripheral blood and redirected with the CAR do not 
possess the intrinsic ability to traffic and infiltrate tumors. Furthermore, it is known that 
in at least some malignancies, lymphocyte trafficking is altered as a result of 
dysfunctional blood vessels that were generated to support aberrant angiogenesis 
within the tumor [148, 149]. One solution to address the limitation of systemic CAR-T 
administration has been to administer CAR-T cells at the site of the tumor. Multiple 
groups have reported administering CAR-T cells locally for ovarian cancer [150] and 
mesothelioma [151], breast cancer [152] and brain cancer [153].  
 Another method investigators have strategized to overcome trafficking issues is 
to correct the chemokine/receptor mismatch between CAR-T and tumor cells [154, 155]. 
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Designing CAR-T cells to coexpress the receptor that matches the chemokine secreted 
by tumors can correct the mismatch. CCR2b coexpressed on T cells expressing CARs 
targeting mesothelin and GD2 in CCL2 secreting mesothelioma [156] and 
neuroblastoma [157] tumors were found to enhance tumor localization and eradication 
in xenograft models. Combining T cells with oncolytic viruses (OV) can further enhance 
CAR-T cell trafficking. An OV adenovirus encoding the RANTES (CCL5) transgene 
enhanced the migration of CAR-T cells to the tumor, enhancing the overall survival of 
mice bearing neuroblastoma tumors [93].  
 Even if few CAR-T cells do have the ability to traffic to the tumor, a significant 
hurdle that remains to be further studied is the efficient penetration of CAR-T cells into 
the tumor [158]. In some cancers, tumor cells receive significant contribution towards 
invasion and expansion from fibroblasts and endothelial cells that work together to 
generate a dense extracellular matrix composed primarily of heparan sulfate 
proteoglycans (HSP) [159]. As in vitro and ex vivo expanded T cells lack the enzyme 
necessary to break down HSPs, CAR-T cells were modified to coexpress the enzyme 
herparanase. Heparanase expressing CAR-T cells had improved tissue penetration and 
improved the overall survival of xenograft mice compared to non-heparanase control 
CAR-T cell groups. [158] Alternatively, T cells transduced to target fibroblast activation 
protein (FAP) expressed on cancer associated fibroblasts can be co-infused with 
antigen specific CAR-T cells to improve solid tumor penetration [160]. Tissue 
penetration is an understudied field in adoptive T cell therapy and merits further 
exploration. 
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Overcoming Immune Suppression and Enhancing Potency 
 Should CAR-T cells successfully migrate to the tumor, CAR-T cells must be 
equipped to overcome a tumor microenvironment that limits its anti-tumor activity. When 
a T cells recognizes its cognate antigen, it must prepare to divide into an army of 
effector cells [161, 162]. The process of dividing requires significant metabolic 
demands, of which the tumor microenvironment provides little [163]. Tumor cells 
consume glucose and critical amino acids, such as glutamine and tryptophan, at 
rampant amounts due to unrestrained growth [164]. As a result of dysregulated 
angiogenesis, critical metabolites are not replenished and the sink of toxic metabolic 
byproducts creates a hypoxic, low-nutrient, low pH environment that is unable to sustain 
the effector functions of T cells [165-167]. 
 Tumors exploit T cells by creating an environment that is unable to sustain and 
promote T cell function [168]. However, tumor cells also suppress T cell activity by 
recruiting myeloid-derived suppressor cells (MDSC) [169, 170], tumor-associated 
macrophages (TAM) [171] and regulatory T cells (Treg) [172, 173] to the 
microenvironment. Together, these cellular compartments cooperate to indirectly 
promote a tolerogenic environment by releasing inhibitory cytokines and metabolites 
such as IL-4 [174], IL-10 [175, 176], transforming growth factor β (TGFβ) [177], 
adenosine [178] and kynurenine [179]. MDSCs and TAMs can also directly inhibit CAR-
T function by engaging inhibitory receptors such as PD-L1 and CTLA-4 [180].  
 Efforts to overcome CAR-T cell immune suppression in the tumor 
microenvironment can be categorized into efforts to limit inhibitory signaling or convert 
inhibitory signaling. One such way that inhibitory signals have been limited is to 
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coexpress a dominant negative TGFβ receptor on CAR-T cells. By coexpressing a 
dominant negative form of the TGBβ receptor (dnTFGβR) in addition to the CAR, it has 
been shown that the dnTFGβR blocks inhibitory signaling and increases CAR-T 
proliferation and anti-tumor activity in mouse models of prostate cancer. [181, 182] 
Efforts have been also made to convert the inhibitory signals to activating signals. 
Mohammed and colleagues reconstructed the IL-4 receptor with the intracellular domain 
of the IL-7 receptor to generate an inverted cytokine receptor (ICR). Coexpression of 
the ICR in CAR-T cells enhanced anti-tumor activity in xenograft models of pancreatic 
cancer. [183] 
 Successful CAR-T cell therapy in solid tumors will require strategies to overcome 
suppression and enhance potency simultaneously. In that regard, investigators have 
devised a number of strategies to promote the anti-tumor activity of CAR-T cells. One of 
the earliest strategies devised to promote the proliferation and survival of CAR-T cells in 
vivo has been to construct TRUCK CARS, in which the incorporation of cytokines into 
the CAR cassette allows for constitutive release of the cytokine of interest. Constitutive 
expression of IL-15, for example, has significantly prolonged the persistence and 
proliferation of CAR-T cells in models of neuroblastoma [184]. In instances where the 
constitutive expression of a cytokine can be detrimental, T cells can be transduced with 
transgenic immune modifier under the form of an inducible promoter. IL-12 has been 
successfully incorporated into a TRUCK CAR to modify the tumor microenvironment 
under the NFAT promoter [185]. 
 While advances in CAR-T cell therapy have significantly improved the efficacy of 
CAR-T cell therapy in solid tumors, it is unlikely that CAR-T cells alone will be able to 
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overcome the many hurdles encountered in the tumor microenvironment. Therefore, 
CAR-T cell therapy is now being combined with cancer treatments that have 
complementary modes of action to improve clinical outcomes. OV therapy has received 
a lot of attention due to the potential for OVs to cooperate and improve the function of 
CAR-T cells. OVs selectively infect and lyse tumor cells, releasing TAAs and activating 
the innate immune system [186]. CAR-T cells are recruited and activated as a result of 
the proinflammatory environment [187]. Investigators have taken advantage of OVs 
capacity to carry transgenes and armed OVs with chemokines and cytokines necessary 
for CAR-T cell recruitment and persistence. To this effect, adenoviruses have been 
armed with IL-15 and the chemokine RANTES to improve the recruitment and survival 
of CAR-T cells in the tumor microenvironment. [93] 
 Another promising and common combination therapy with CAR-T cells is the 
administration of checkpoint blockade. In the tumor microenvironment, Tregs, TAMs 
and tumor cells engage with CAR-T cells through the PD-1/PD-L1 and the CD28/CTLA-
4 axis, inhibitory regulators of T cells [188, 189]. The consequence of PD1 and CTLA-4 
engagement has detrimental effects on the functionality of CAR-T cells as they inhibit 
CAR-T cell effector functions [137]. By combining the labor of CAR-T cells with 
checkpoint blockade antibodies, T cell exhaustion can be mitigated and stimulate potent 
anti-tumor activity.  
REMAINING CHALLENGES TO CHIMERIC ANTIGEN RECEPTOR-T CELL 
THERAPY 
 While the great successes of CD19 CAR-T cell therapy in ALL have laid the 
foundations for advancing cancer treatments, there are many challenges yet to be 
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overcome in order to make CAR-T cell therapy a more effective treatment strategy. 
Studies have reported that 30-50% of pediatric and 31-57% of adult ALL patients 
relapse within the first year of achieving remission [111, 124, 130, 190-194]. Though the 
factors contributing to the resistance are multifactorial, one increasingly reported 
mechanism is tumor resistance resulting from immune pressure by CAR-T cells. 
Addressing the mechanisms of acquired resistance will be critical for the durability of 
CAR-T cell therapy. In the sections below, the tumor intrinsic mechanisms of resistance 
to adoptive CAR-T cell therapy are discussed.  
Tumor escape 
 The enthusiasm surrounding the groundbreaking successes of CD19 CAR-T cell 
therapy in ALL patients came to a halt when it was demonstrated that the selective 
immune pressure being driven by CAR-T cells was leading to tumor evolution and 
escape. Maude and colleagues first reported that 3 of 27 (11%) relapsing CD19 CAR-T 
treated pediatric patients presented with a tumor variant in which the CD19 antigen 
could no longer be detected [130]. Studies from various academic institutions have 
since corroborated the study findings and demonstrated that antigen negative disease 
occurs in 7-25% of relapsing pediatric and adult patients being treated for ALL [111, 
124, 130, 190-194]. However, the phenomenon is not exclusive to ALL or the CD19 
CAR, as tumor escape has been reported for patients being treated for multiple 
myeloma with the BCMA CAR [195] and glioblastoma multiforme with the EGFRvIII 
[196] or IL-13Rα2 [197].  
 Today, there are several reported strategies being exploited by tumor cells to 
evade CAR-T cells. Tumor escape by antigen loss can refer to the complete loss of the 
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targeted antigen to reduced expression that is below the threshold necessary for CAR-T 
cell activity. Tumor escape by antigen loss can also refer to changes to the targeted 
antigen that renders the CAR unable to recognize the targeted antigen. In a pivotal 
study, Sotillo and colleagues demonstrated that splice variants are a mechanism by 
which pediatric patients acquire resistance to CD19 CAR-T cell therapy. One splice 
variant uncovered by Sotillo and colleagues lacked the exon encoding the epitope 
recognized by the CAR. Hence, this splice variant resulted in a modification that made 
the CD19 antigen unrecognizable to the CAR-T cell. Another splice variant discovered 
lacked the exons encoding the transmembrane domain, leading to the complete loss of 
the CD19 antigen on the surface of tumor cells. [198] 
 Post-transcriptional evasion strategies have also been reported. A study in which 
pediatric ALL patients were treated with a CD22 CAR-T cell found that 8 of 12 (67%) of 
patients relapsed within the 12 months. An analysis of 7 of those 8 patients assessed 
that there were no changes to the genomic or messenger RNA level, suggesting that 
the downregulation of the CD22 antigen occurs at the post-transcriptional level. [199] 
Lastly, tumor cells can evade CAR-T cells by means of lineage switching, in which 
tumor cells acquire a phenotype no longer characteristic of the original tumor [200].  
Tumor heterogeneity 
 While the evolutionary and molecular events that lead to the rise of clonally 
heterogeneous tumor cell populations is debated, it is well accepted that intra tumor 
heterogeneity is a common feature of all tumor types [201-204]. Due to the advent of 
more sophisticated sequencing and bioinformatics algorithms, genetic studies to 
support intra tumor heterogeneity have been accomplished in the last decade. In a 
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study by Andor and colleagues, two bioinformatics algorithms were applied to 1,165 
exome sequence data from 12 different tumor types in The Cancer Genome Atlas to 
estimate and quantify the prevalence of intra tumor heterogeneity. The results 
corroborated what has been known for some time by diagnostic immunohistochemistry 
and Hematoxylin and Eosin staining studies of tumor samples—intra tumor 
heterogeneity exists at the genetic level in all tumor types. [205] 
 As it has been described in previous section, redirection of T cells with the CAR 
has had some drawbacks. For instance, T cells expressing the CAR have a lower 
activation threshold as a result of loss of sensitivity. Therefore, T cells expressing the 
CAR require a relatively high level of antigen expression. [206, 207] This requirement is 
problematic when it comes to the treatment of solid tumor malignancies, where antigens 
are heterogeneously expressed at low levels [201-204]. Durable and effective CAR-T 
cell treatment against solid tumor malignancies will therefore require an antigen that is 
universally expressed on all tumor cells at a high level.  
 This dissertation addresses the two leading causes of resistance to adoptive 
CAR-T cell therapy. It is thought that simultaneously targeting more than one TAA will 
be more effective in reducing the incidence of tumor escape. As such, Chapter 2 of this 
dissertation identifies a novel strategy to construct multi-redirected T cells. Chapter 2 
provides compelling evidence for the efficacy of the multi-redirected T cells and 
provides a rationale for further exploration. In Chapter 3 of this dissertation, a TAA that 
is uniformly and universally expressed is identified and proposed as a target antigen to 
tackle tumor heterogeneity. A CAR construct targeting the TAA is demonstrated to have 






CHAPTER 2: REDIRECTING T CELLS TO ACHIEVE BIEPITOPIC AND BISPECIFIC 




Tumors are inherently heterogeneous in antigen expression, and escape due to antigen 
loss remains one of the major limitations of targeted immunotherapy. Despite the 
remarkable clinical activity of adoptive therapy with chimeric antigen receptor (CAR) 
redirected T cells in lymphoblastic leukemia, treatment failure due to epitope loss 
occurs. Targeting multiple tumor-associated antigens (TAA) may thus significantly 
improve the outcome of CAR-T cell therapies. To achieve this goal and overcome 
                                            
 
1 This chapter contains a manuscript that previously appeared as an article in Cancer 
Immunology Research. The concept of using antibody mimics as antigen recognition 
domains for CARs is credited to Dr. Liu and Dr. Li. Dr. Li identified novel antibody 
mimics against the ErbB family of receptor tyrosine kinases and conducted the cloning 
to generate constructs. The cloned constructs were provided to me to generate 
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current drawbacks of the CAR technology in multiple targeting, we have engineered 
single domain antibody mimics to generate highly compact and stable ligands that, 
when combined with signaling molecules of T cells, redirect T cells with biepitopic or 
bispecific TAA recognition. Here we show that various classes of antibody mimics 
targeting EGFR and HER2 of ErbB receptor tyrosine kinases can be assembled into 
receptor molecules, which we call antibody mimic receptors (amR), and redirect T cells 
for biepitopic or bispecific TAA recognition in vitro and in vivo.  
INTRODUCTION 
 Chimeric antigen receptors (CARs) are synthetic receptors that combine the 
single chain variable fragment (scFv) obtained from a monoclonal antibody with the ζ-
chain signaling domain from the T cell receptor complex and costimulatory 
endodomains [80, 81]. Gene transfer of CARs into T cells redirects T cell antigen 
specificity through the scFv and promotes T cell activation and proliferation through 
costimulatory signals [105]. The infusion of CAR-T cells (CAR-Ts) in patients with 
lymphoid malignancies has led to durable complete remission [130, 208]. However, up 
to 20% of patients with acute lymphoblastic leukemia receiving CD19-specific CAR-Ts 
relapse due to the emergence of leukemic clones that have lost the targeted epitope 
[130, 198]. Furthermore, the heterogeneity of tumor-associated antigen (TAA) 
expression in solid tumors leads to CAR-T treatment failure when a single TAA is 
targeted [196].  
 The generation of multi-redirected CAR-Ts, namely by recognition of two non-
overlapping epitopes of a TAA or two different TAAs, may be necessary to effectively 
eradicate tumor cells. Several approaches have been proposed to achieve this goal 
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including: pooling CAR-T products targeting different TAAs, generating vectors 
encoding two different CARs that can be expressed simultaneously by each T cell and 
engineering cassettes in which two scFvs are assembled into a single CAR moiety [81, 
209, 210]. Although these approaches are feasible, one major challenge in using a 
scFv-based antigen receptor is the need for multiple VH and VL domains to 
appropriately pair and stabilize in complex structures. In addition to the complexity and 
costs of manufacturing multiple T cell products, reduced expression of CARs 
simultaneously expressed and compromised protein folding when several scFvs are 
linearly assembled in one single CAR format remain challenges to current methods of 
achieving multi-redirected CAR-Ts.  
 Because of the major undertaking in achieving multiple tumor targeting features 
using scFv-based CAR-Ts, we hypothesized that extracellular antigen receptors with 
simple structure, high stability and small size could address the challenge. Various 
small protein domains that are not structurally equivalent to the immunoglobulin 
domains have been utilized to evolve tumor-targeting ligands through various display 
technologies [211-215]. Tumor-homing ligands based on a small protein domain 
possess major advantages over those on a multi-domain, complex structure in terms of 
engineering higher modularity. Ideally, the scaffold should be a monomeric small protein 
domain with high solubility, stability, and minimal aggregation, yet tolerate high 
sequence variations and be amenable to directed molecular evolution to create antigen-
binding ligands with multiple functions [215].  
 Among numerous scaffolds that have been examined, three single domain 
antibody mimics are of particular interest for developing CARs with multiple tumor-
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targeting features: 1) monobody, based on the type III domain of fibronectin (FN3); 2) 
affibody, based on a three-helix bundle Z domain; 3) DARPin, based on the designed 
ankyrin repeat protein [213, 214, 216, 217]. Significantly, these engineered proteins can 
have high specificity and affinity, despite their simple structures and relatively small 
size. The FN3 domain is a highly stable protein with a MW around 10 kDa. Structurally, 
it has a β-sandwich scaffold similar to that of the immunoglobulin VH domain, with 
putative ligand-binding sites composed of three solvent accessible surface loops that 
are structurally analogous to the CDR H1, H2, and H3 of the VH domain [213]. The 
advantage of the FN3 domain is in their lack of disulfide bonds and post-translational 
modifications for biological functions. Affibodies (AFF) are based on the three-helix 
bundle Z domain derived from Staphylococcal protein A [218, 219]. Similarly to the FN3 
domain, AFF domains are also highly stable against both proteolysis and heat-induced 
denaturation and lack disulfide bonds. Finally, DARPins or leucine-rich repeats in 
lamprey antibodies contain consecutive copies of small structural repeats, which stack 
together to form a contiguous interacting surface [215]. Recently, DARPin-based 
targeting ligands, which bind to various targets including CD4, EGFR, and HER2 have 
been generated [220].  
 Taking into consideration the simplicity, stability and smaller size of these 
targeting ligands, as well as their current applications in therapeutics and diagnostics 
[221], we explored the use of these molecules in generating antigen-specific receptors 
for T cells. In particular, we investigated if a combination of these single domain 
antibody mimics allows the generation of a T cell surface antigen receptor that 
recognizes two different epitopes of the same tumor antigen or two different antigens, 
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aiming to develop T cells with biepitopic or bispecific redirection. As proof-of-principle, 
we have adapted high affinity antibody mimics specific for ErbB1 (EGFR) and ErbB2 
(HER2), to generate receptor molecules called antibody mimic receptors (amRs). 
MATERIALS AND METHODS 
Construction of biepitopic and bispecific CAR vectors. To construct biepitopic or 
bispecific CAR vectors, the codon-optimized (for expression in human cells) coding 
regions for a monomeric or heterodimeric EGFR- or/and HER2-binding ligand were 
fused through an optimized flexible linker. The final coding region was cloned into the 
SFG vector, resulting in a fusion protein that is composed of the signaling peptide from 
human IgG heavy chain, EGFR- or HER2-binding domain(s), a FLAG tag, a 45-residue 
hinge region from human CD8α extracellular domain, the transmembrane domain of 
human CD8α, the CD28-costimulatory endodomain, and the ζ chain of the TCR/CD3 
complex [222]. The CD8α hinge and transmembrane domains contain the native 
cysteine residues. Single domain antibody mimics (AFF, DARPin and FN3) were PCR 
amplified and cloned into the SFG vector. The scFv derived from the Cetuximab mAb 
was PCR amplified and cloned into the SFG vector. EGFR WT (Addgene plasmid 
#110110) and pBABE-puro-ErbB2 (Addgene plasmid #40978) were gifts from Matthew 
Meyerson. Full-length EGFR and HER2 were amplified by PCR and cloned into the 
SFG retroviral vector. A truncated form of HER2 lacking an intracellular domain was 
amplified by PCR and also cloned into the SFG retroviral vector. All retroviral 
supernatants were prepared as previously described [223].  
Expression and purification of recombinant EGFR and HER2 binding protein 
domains. Coding sequences codon-optimized for expression in E. coli with a C-terminal 
34 
His tag were cloned into the pET28b vector. To express the ligands, vectors were 
transformed into E. coli BL21 (DE3) Rosetta cells and positive clones were selected on 
LB plates containing 50 µg/mL kanamycin and 34 µg/mL chloramphenicol. Single 
colonies were picked and grown overnight at 37°C. Overnight cell cultures were added 
to 1 L of LB media and grown at 37°C. When the OD 600 was between 0.6-0.8, 1 mM 
IPTG was added to induce expression for 4h at 37°C. To purify the binding ligands, the 
cell pellet was resuspended in buffer A (25 mM HEPES pH 7.4 and 300 mM NaCl) 
supplemented with 1 mM phenylmethylsulfonyl fluoride (PMSF) and sonicated on ice for 
10 min on a Sonifier 450 sonicator (Branson). After cell lysis, the soluble fraction was 
recovered by centrifugation at 4°C. The resulting soluble fraction was loaded onto an 
IMAC Ni-charged affinity column (Bio-Rad) pre-equilibrated with buffer A. The column 
was washed with Buffer A containing 20 mM imidazole (Buffer B) and then 50 mM 
imidazole (Buffer C) and the proteins were eluted with buffer D (buffer A and 200 mM 
imidazole). Following dialysis against 1×PBS, the quality of the purified proteins was 
verified by SDS-PAGE.  
Characterization of target-binding features. BLI analyses of the monomeric and 
heterodimeric EGFR and HER2-binding domains were performed on a Octet QK system 
(FortéBio LLC., Menlo Park, CA) against recombinant EGFR-Fc and HER2-Fc 
(AcroBiosystems, Newark, NJ) [17, 23] using 96-well microplates (Greiner Bio-One) at 
30°C. Streptavidin biosensors (FortéBio) were used to immobilize concentrations of 
biotinylated ErbB-binding domains and samples resuspended in an assay buffer (1× 
PBS, 1% BSA, 0.05% Tween 20, pH 7.4) were applied to the 96-well microplate. 
Assays run in triplicate were acquired and analyzed on the FortéBio Data Acquisition 
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6.4 software. Savitzky-Golay filtering was applied to the averaged reference biosensors 
and then globally fitted at a 1:1 model. 
Cell lines. Tumor cell lines Panc-1, BxPC-3, HPAF-II and AsPC-1 (pancreatic cancer), 
MCF-7 (breast cancer), BV173 (B cell lymphoma) were purchased from American Type 
Culture Collection (ATCC). BxPC-3 and BV173 were cultured in RPMI1640 (Gibco). 
AsPC-1 was cultured in RPMI1640 supplemented with 1 mM sodium pyruvate (Gibco). 
HPAF-II and MCF-7 were cultured in MEM (Gibco). Panc-1 was cultured in DMEM 
(Gibco). All media were supplemented with 10% FBS (Sigma), 2 mM GlutaMax (Gibco) 
and penicillin (100 units/mL) and streptomycin (100mg/mL) (Gibco). All cells were 
maintained at 37°C with 5% CO2. Panc-1 cells were transduced with a retroviral vector 
encoding the eGFP-Firefly-Luciferase (eGFP-FFluc) gene [222]. BV173 cells were 
transduced with a retroviral construct encoding full-length human EGFR to generate 
BV173-EGFR cells or a truncated form of HER2 to generate BV173-HER2 cells. Panc-1 
cells were transduced with a retroviral vector encoding HER2 to make Panc-1-HER2. All 
cell lines were regularly tested for mycoplasma and the identity of the cell lines were 
validated by flow cytometry for relevant cell surface markers.  
Generation of redirected T cells. T cells expressing CAR and amRs were generated 
in accordance to standard operating procedures currently used to manufacture CAR-Ts 
for clinical use at our institution [224, 225]. Peripheral blood mononuclear cells (PBMCs) 
were isolated from discharged buffy coats (Gulf Coast Regional Blood Center, Houston, 
TX) using Lymphoprep medium (Accurate Chemical and Scientific Corporation) and 
activated on plates coated with 1 µg/mL CD3 (Miltenyi Biotec, Bergisch Gladback, 
Germany) and CD28 (BD Biosciences, San Jose, CA) mAbs. Activated T cells were 
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transduced with retroviral supernatants on retronectin-coated 24-well plates (Takara Bio 
Inc., Shiga, Japan) 2-3 days post-activation. Transduced T cells were expanded in 50% 
Click’s Medium (Irvine Scientific, Santa Ana, CA) and 50% RPMI-1640 supplemented 
with 10% Hyclone FBS (GE Healthcare, Chicago, IL), 2 mM GlutaMax (Gibco) and 
penicillin (100 units/mL) and streptomycin (100mg/mL) (Gibco) with 10 ng/mL IL-7 and 5 
ng/mL of IL-15 (Peprotech, Rocky Tech, NJ) for 10-14 days of culture before being used 
for functional assays [120, 224, 225]. 
Flow cytometry. We used mAbs specific for human CD3 (APC-H7; SK7; 560176), 
CD45 (BV510; HI30; 563204), CD4 (BV711; SK3; 563028), CD8 (APC; SK1; 340584), 
CD19 (FITC; SJ25C1; 340409), CD45RA (PE; HI100; 555489), CD45RO (BV786; 
UCHL1; 564290), CD69 (FITC; L78; 347823), HER2 (PE; Neu24.7; 340879) from BD 
Biosciences (San Jose, CA), CCR7 (FITC; 150503; FAB197F-100) from R&D 
(Minneapolis, MN) and EGFR (PE; AY13; 352904) from BioLegend (San Diego, CA). 
We detected the expression of the EGFR.CAR or amRs using α-FLAG mAb (APC; L5; 
637308). An anti-idiotype mAb was used to detect the expression of the CD19.CAR as 
previously described [222].  All samples were acquired on a BD LSRFortessa and a 
minimum of 10,000 events was acquired per sample. Samples were analyzed on 
FlowJo 9 (FlowJo LLC, Ashland, OR).   
Western Blot analysis. T cell lysates were resuspended in 2x Laemelli Buffer (Bio-
Rad) in reducing or non-reducing conditions. To assess signaling through the CAR or 
amR, T cells on ice were incubated with 1 µg of α-FLAG Ab (clone M2) for 15 minutes 
and then 1 µg of goat α-mouse secondary Ab (BD Biosciences, San Jose, CA) for an 
additional 15 minutes. Cells were then transferred to a 37° C water bath for the 
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indicated time points and lysed with 4x Laemelli buffer. All lysates were separated in 4-
15% sodium dodecyl sulfate polyacrylamide (SDS-PAGE) gels and transferred to 
polyvinylidene diflouride membranes (all Bio-Rad). Blots were probed for human CD3ζ 
(Santa Cruz Biotechnology, Dallas, TX), p-Y142 CD3ζ (Abcam, Cambridge, MA), pan-
ERK (BD Biosciences) and pan-Akt, p-S473 Akt and p-T202/Y204 MAPK (all Cell 
Signaling, Danvers, MA) diluted 1:1000 in TBS-Tween/5% skim milk. Membranes were 
then incubated with HRP-conjugated goat α-mouse or goat α-rabbit IgG (both Santa 
Cruz) at a dilution of 1:3000 and imaged using the ECL Substrate Kit on a ChemiDoc 
MP System (both Bio-Rad) according to manufacturer’s instructions. 
In vitro activation. Biotinylated recombinant EGFR and EGFRvIII protein 
(AcroBiosystems) were added to 96-well plates coated with 1 µg of avidin (Thermo 
Fisher Scientific) at a 3:1 ratio. Recombinant EGFR-Fc and HER2-Fc (R&D Systems) 
were coated on 96-well plates overnight at a concentration of 1 µg/well. T cells were 
seeded in duplicate or triplicate for 6 hours and supernatant was collected for IFNγ and 
T cells were assessed for CD69 by flow cytometry.  
Proliferation assay. T cells were labeled with 1.5 mM carboxyfluorescein diacetate 
succinimidyl ester (CFSE) (Invitrogen) and plated with irradiated AsPC-1 at 4:1 E:T in 
the absence of exogenous cytokines. CFSE dilution of CAR+ or amR+ T cells was 
analyzed on day 5 using flow cytometry [222]. The proliferation index was quantified 
using FlowJo 9. 
Long-term in vitro cytotoxicity. Tumor cells were seeded at 2.5 × 105 per well in 24-
well plates. Donor-matched T cells normalized for transduction efficiency were added at 
1:5 effector to target (E:T) ratio. On day 5 of co-culture, cells were collected and the 
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frequency of T cells and residual tumors cells was measured by flow cytometry. Tumor 
cells were identified as CD19+ for BV173 tumor cells or CD4– CD8– in the case of all 
adherent tumor cell lines [226].  
Repetitive co-culture assay. For multiple rounds of co-culture, tumor cells were 
seeded at 5 × 105 per well in 24-well plates. Donor-matched T cells normalized for 
transduction efficiency were added at 1:2 effector to target (E:T) ratio. On day 3 of co-
culture, a fraction of the cells were collected and the frequency of T cells and residual 
tumors cells were measured by flow cytometry. Between co-cultures, T cells were 
washed and resuspended in fresh medium, without the addition of exogenous 
cytokines, and left to rest for 3 days [226]. 
Cytokine analysis. Supernatant was collected from 5 × 104 CAR-Ts or amR-Ts plated 
in in vitro cytotoxicity assays at 1:5 E:T ratio after 24 hours. IFN-γ and IL-2 levels were 
measured by ELISA per manufacturer’s instructions (R&D) in duplicate. 
Xenograft murine models. Six to eight-week-old male or female non-obese diabetic 
severe combined immunodeficiency/γc-/- (NSG) mice were injected with the Panc-1 
tumor cell line (1 × 106 cells/mouse) transduced with the GFP-FFLuc reporter 
intravenously by tail vein (iv.) injection [227]. In other experiments HPAF-II GFP-FFLuc 
tagged cells were suspended in Matrigel and inoculated intraperitoneally (ip.) (1 x 106 
cells/mouse) [158]. In re-challenge experiments Panc-1 GFP-FFLuc cells (1 × 106 
cells/mouse) were injected 10 days prior to T cell injection. Upon clearance of the Panc-
1 tumor cells, mice were then infused with BV173-HER2 cells (2 x 106 cells/mouse). 
Mice were matched based on the bioluminescence intensity and injected with 5 × 106 or 
1 × 107 T cells iv 12 - 14 days post tumor cell engraftment. The IVIS-Kinetic Optical 
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System (Perkin Elmer, Waltham, MA) was used to monitor tumor burden. Mice were 
monitored and euthanized according to UNC-IACUC Standards. 
Statistical Analyses. Data are reported as the mean and standard deviation, unless 
otherwise reported. To compare significant differences between 2 samples a two-tailed 
Student’s t-test was applied. An ANOVA with Tukey’s post-hoc analysis was applied 
when a comparison between multiple groups was required. A p value of less than 0.05 
was considered statistically significant. All figures were generated using GraphPad 
Prism (GraphPad Software, La Jolla, CA). 
RESULTS 
Generation and characterization of soluble single domain antibody mimics 
targeting EGFR in a biepitopic manner. To develop a single domain-based tumor 
antigen binding moiety that targets two different epitopes of EGFR, we assembled the 
previously identified Z domain-based EGFR-binding affibody ZEGFR:1907 and an FN3-
based EGFR-binding monobody [218]. To retain the target-binding affinity, specificity, 
and independent folding of each EGFR-binding domain, the length and flexibility of the 
linker between the two EGFR-binding domains were carefully tuned and optimized. We 
observed that when the linker is too short, the target binding of both domains was 
abolished. Similarly, the use of a longer linker resulted in the loss of the bivalent effect, 
as well as instability of the ligands. Since the linker length appeared to be antigen and 
binder dependent, we only used the linker length that worked well in this proof-of-
concept work. In this study, the two antigen-binding moieties were separated by a 25-
residue flexible linker. The resulting biepitopic affinity molecule, from now on referred as 
Bi-EGFR, binds to the extracellular domain of human EGFR at two non-overlapping 
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epitopes with an affinity (Kd) around 0.38 ± 0.07 nM (Fig. 2.1A), which is approximately 
10-times higher than that of the monomeric EGFR-binding FN3 domain (FN3.EGFR: 3.1 
± 0.9 nM, Fig. 2.1B) or Z domain (AFF.EGFR: 3.2 ± 0.3 nM, Fig. 2.1C).  
T cells expressing the Bi-EGFR.amR are comparable to T cells expressing a 
conventional EGFR-specific CAR. To construct the CAR vector, the sequence of 
biochemically optimized Bi-EGFR was fused to the CD28 and CD3ζ-chain signaling 
domains via the CD8α hinge and transmembrane domains [222]. To detect the 
expression of the Bi-EGFR.amR in T cells (Bi-EGFR.amR-Ts) following transduction, 
we included a FLAG-tag into the Bi-EGFR.amR cassette (Fig. S2.1). A conventional 
EGFR-specific CAR (EGFR.CAR) generated using the scFv derived from Cetuximab 
(Fig. S2.1), and the CD19-specific CAR (CD19.CAR) [222] were used as controls. 
AmRs composed of either the EGFR-A binding moiety (FN3.EGFR.amR) or the EGFR-
B binding moiety (AFF.EGFR.amR) alone were also constructed (Fig. S2.1). Upon 
retroviral gene transfer, T cells stably expressed the Bi-EGFR.amR (Fig. 2.1D, E), 
expanded in vitro in response to exogenous cytokines (Fig. 2.1F), and maintained T cell 
composition comparable to EGFR.CAR-Ts and CD19.CAR-Ts (Fig. 2.1G). Western blot 
(WB) analysis of lysates from Bi-EGFR.amR-Ts detecting the CD3ζ chain under 
reducing conditions showed the native z-chain (17 kDa) and a band at the expected 
size of 55 kDa, indicating the integrity of the assembled Bi-EGFR.amR (Fig. 2.1H). We 
then analyzed proximal and distal signaling in EGFR.CAR-Ts and Bi-EGFR.amR-Ts 
upon receptor cross-linking. As shown in Fig. 2.1I, receptor cross-linking in both Bi-
EGFR.amR-Ts and EGFR.CAR-Ts triggered similar phosphorylation of proximal (CD3ζ) 
and distal (Akt and ERK) signaling molecules. 
41 
T cells expressing the Bi-EGFR.amR demonstrate activity against EGFR+ tumor 
cells in vitro and in vivo. To demonstrate that Bi-EGFR.amR-Ts specifically target 
EGFR, we used the EGFR– tumor cell line BV173 (BV173-WT) and transduced it to 
express EGFR (BV173-EGFR) with a retroviral vector encoding the full-length human 
EGFR (Fig. S2.2A). We then co-cultured BV173-WT or BV173-EGFR cells with control 
non-transduced T cells (NTs), CD19.CAR-Ts, EGFR.CAR-Ts and Bi-EGFR.amR-Ts. 
NTs did not eliminate neither BV173-WT nor BV173-EGFR cells, CD19.CAR-Ts 
eliminated both cell types (Fig. S2.2B, C), whereas Bi-EGFR.amR-Ts and EGFR.CAR-
Ts only eliminated BV173-EGFR cells (Fig. S2.2B, C), indicating the antigen specificity 
of the redirected T cells. Anti-tumor activity was then tested against tumor cell lines that 
physiologically express EGFR (Fig. S2.2D). In co-culture experiments, Bi-EGFR.amR-
Ts and EGFR.CAR-Ts demonstrated similar anti-tumor activity in vitro (Fig. 2.2A) and 
released comparable amounts of IFNγ (Fig. 2.2B) and IL-2 (Fig. 2.2C). Using a CFSE 
dilution assay, we demonstrated the proliferation of Bi-EGFR.amR-Ts in response to 
EGFR-expressing targets (Fig. 2.2D, E). Finally, we evaluated the anti-tumor activity of 
Bi-EGFR.amR-Ts in a metastatic model of EGFR-expressing pancreatic cancer in NSG 
mice (Fig. 2.2F). Bi-EGFR.amR-Ts and EGFR.CAR-Ts equally controlled human Panc-
1 tumor cell growth as assessed by measurement of tumor bioluminescence intensity 
(Fig. 2.2G, H). 
Bi-EGFR.amR-Ts recognize two non-overlapping epitopes of EGFR. AmRs 
composed of either the FN3.EGFR.amR or the AFF.EGFR.amR alone were transduced 
in T cells (Fig. S2.3A). Both AFF.EGFR.amR-Ts and FN3.EGFR.amR-Ts showed 
comparable activity in vitro against tumor cells expressing the full length EGFR (Fig. 
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S2.3B-F) and proliferated in response to EGFR-expressing targets (Fig. S2.3G, H). To 
demonstrate the biepitopic feature of the Bi-EGFR, we analyzed the binding of Bi-EGFR 
and each of its monomeric domains using the recombinant extracellular domain of the 
wild-type EGFR (wtEGFR) and the EGFRvIII (EGFRvIII) mutant, a constitutively active 
and ligand-independent variant of EGFR with deletions in exons 2-7. We found that Bi-
EGFR and Z domain-based AFF.EGFR bound both wtEGFR and EGFRvIII. However, 
FN3 domain-based FN3.EGFR bound to wtEGFR but not EGFRvIII (Fig. S2.4A), 
suggesting that it recognizes an antigen encoded in the 267 AA that are absent in 
EGFRvIII. To assess recognition of two different EGFR epitopes, we used the 
extracellular domain of wtEGFR and EGFRvIII mutant recombinant proteins. Control, 
AFF.EGFR.amR-Ts, FN3.EGFR.amR-Ts and Bi-EGFR.amR-Ts were seeded in tissue 
culture plates coated with either wtEGFR or EGFRvIII, and the CD69 expression and 
IFN-γ release by T cells were measured. Both wtEGFR and EGFRvIII recombinant 
proteins activated AFF.EGFR.amR-Ts and BiEGFR.amR-Ts, while only the wtEGFR 
protein activated FN3.EGFR.amR-Ts (Fig. 2.3A-C), indicating that the epitope 
recognized by the FN3.EGFR binding moiety is either located in the 267 AA region 
deleted in EGFRvIII, or the mutation has altered the epitope accessibility due to the 
deletion-induced conformational changes. In contrast, the AFF.EGFR binding moiety 
recognizes an epitope that is conserved between EGFR and EGFRvIII (Fig. 2.3A-C). To 
ensure that both AFF.EGFR and FN3.EGFR binding moieties can induce the activation 
of T cells when assembled into the Bi-EGFR.amR, we generated an AFF.EGFR.amR 
mutant-binding moiety (mAFF.EGFR.amR) in which critical residues at the EGFR-
binding alpha helices were mutated to alanine to reduce binding to EGFR. As shown in 
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Fig. S2.4B, mAFF.EGFR.amR was expressed in T cells, but mAFF.EGFR.amR-Ts did 
not eliminate BV173-EGFR cells (Fig. S2.4C, D), indicating that the mutations had 
abrogated binding to EGFR. However, T cells expressing a Bi-EGFR.amR constructed 
with the FN3.EGFR and mAFF.EGFR binding moieties (mBi-EGFR.amR) upregulated 
CD69 and released IFN-γ when seeded in wells coated with wtEGFR recombinant 
protein, but not in response to EGFRvIII protein, indicating that the FN3.EGFR binding 
moiety alone can induce T cell activation when the function of the other EGFR-binding 
moiety (AFF.EGFR) is abolished in the mBi-EGFR.amR (Fig. 2.3D-F). 
Biepitopic amR against HER2 demonstrates anti-tumor activity in vitro and in 
vivo. We also constructed an amR receptor against another member of the ErbB family 
of receptor tyrosine kinase, HER2, to demonstrate the applicability of this technology to 
other TAAs. Using a similar approach to the construction of Bi-EGFR, a tumor antigen 
binding moiety that targets two different epitopes of HER2 (Bi-HER2) was generated, 
which showed a HER2-binding affinity (Kd) around 0.25 ± 0.04 nM (Fig. 2.4A), 
compared to 1.8 ± 0.6 nM (Fig. 2.4B) of a HER2-binding DARPin [217] and 1.3 ± 0.4 
nM of a HER2-binding Z domain [219] (Fig. 2.4C), respectively. Based on this novel 
HER2-binding ligand, a biepitopic Bi-HER2.amR was constructed (Fig. S2.5A). T cells 
stably expressed the Bi-HER2.amR (Bi-HER2.amR-Ts) upon retroviral transfer, 
expanded in vitro in response to exogenous cytokines (Fig. S2.5B) and maintained T 
cell composition comparable to control T cells (Fig. S2.5C). Bi-HER2.amR-Ts 
demonstrated specific targeting of HER2-expressing cells (Fig. S2.5D-F). Furthermore, 
Bi-HER2.amR-Ts exhibited anti-tumor activity (Fig. 2.4D) and released IFNγ (Fig. 2.4E) 
and IL-2 (Fig. 2.4F) in a HER2-dependent manner when co-cultured with tumor cell 
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lines expressing HER2, but not with HER2-negative cells lines (Fig. S2.5D). We also 
evaluated the efficacy of Bi-HER2.amR-Ts in a metastatic tumor model of HER2-
expressing human HPAF-II pancreatic cancer in NSG mice (Fig. 2.4G). Bi-HER2.amR-
Ts and EGFR.CAR-Ts equally controlled tumor cell growth as assessed by 
measurement of tumor bioluminescence intensity (Fig. 2.4H, I).  
Bispecific EGFR-HER2.amR-Ts have anti-tumor activity against EGFR+HER2+ 
tumor cells. To generate amRs targeting two different TAAs, we integrated the EGFR 
specific FN3 binding moiety and the HER2 specific DARPin binding moiety and created 
the EGFR-HER2.amR with a 27-residue flexible linker between the two antigen-binding 
moieties (Fig. S2.6A). T cells stably expressed the EGFR-HER2.amR (Fig. S2.6B, C), 
expanded in vitro in response to exogenous cytokines (Fig. S2.6D) and maintained T 
cell composition comparable to monospecific FN3.EGFR.amR-Ts and 
DARPin.HER2.amR-Ts (Fig. S2.6E). To establish the bispecificity of EGFR-HER2.amR-
Ts, we seeded control, FN3.EGFR.amR-Ts, DARPin.HER2.amR-Ts and EGFR-
HER2.amR-Ts in tissue cultures plates coated with either the extracellular domain of 
rhEGFR or rhHER2 recombinant proteins and assessed CD69 expression and IFN-γ 
release by T cells. EGFR-HER2.amR-Ts expressed CD69 (Fig. S2.6F) and secreted 
IFN-γ (Fig. S2.6G) when seeded in wells coated with either rhEGFR or rhHER2 
proteins, while FN3.EGFR.amR-Ts and DARPin.HER2.amR-Ts were only activated by 
rhEGFR and rhHER2, respectively. Next, we evaluated the functionality of EGFR-
HER2.amR-Ts against BV173-WT, BV173-EGFR and BV173-HER2 cells (Fig. S2.6H). 
We performed a series of co-cultures in which T cells were plated with its respective 
BV173 target cells, and 3 days later T cells were collected and re-plated with the same 
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BV173 tumor cell line or BV173 cells expressing a non-specific target (Fig. 2.5A). As 
shown in Fig. 2.5B-D, FN3.EGFR.amR-Ts and DARPin.HER2.amR continued to 
eliminate only BV173-EGFR and BV173-HER2, respectively, while EGFR-HER2.amR-
Ts eliminated both BV173-EGFR and BV173-HER2 targets in both the primary and 
secondary co-cultures. In order to demonstrate the bispecificity of the EGFR-
HER2.amR-Ts in vivo, mice were engrafted with the EGFR+HER2- human Panc-1 cell 
line labeled with FF-Luc, and infused either with EGFR.amR-Ts or EGFR-HER2.amR-
Ts. Tumor growth was equally controlled by both EGFR.amR-Ts and EGFR-
HER2.amR-Ts (Fig. 2.5E-G). However, when these mice were re-challenged with the 
EGFR-HER2+ BV173 tumor cell line, EGFR.amR-T treated mice developed limb 
paresis due to growth of the BV173 tumor within the spinal cord, while EGFR-
HER2.amR-Ts treated mice remained healthy (Fig. 2.5H).   
DISCUSSION 
 The generation of multi-redirected CAR-Ts may be necessary to effectively 
eradicate tumors in which TAAs of interest can be lost or are heterogeneously 
expressed in tumor cells. Here we demonstrated that highly modular single domain 
antibody mimics are a practical alternative to the conventional scFvs to generate T cells 
with engineered multiple antigen-targeting features. We constructed antibody mimics 
that can be assembled with signaling molecules of the T cell receptor and costimulatory 
endodomains. We have further demonstrated the functionality in vitro and in vivo of T 
cells expressing antibody mimics showing their ability to recognize simultaneously two 
epitopes of the same antigens or two distinct antigens.  
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 In this proof-of-principle study, we have extended and in depth assessed whether 
single domain antibody mimics can be used to redirect the specificity of human T 
lymphocytes [138, 228]. We integrated single domain antibody mimics binding to the 
non-overlapping regions of EGFR to create a novel EGFR-binding ligand with 
biepitopicity. We showed that T cells expressing the single domain AFF.EGFR.amR or 
FN3.EGFR.amR have comparable activity in vitro and in vivo to the conventional scFv-
based Cetuximab EGFR.CAR. To further demonstrate the broad applicability of 
redirecting T cell specificity by using antibody mimics we also validated the approach by 
targeting HER2 expressing tumors using a Bi-HER2 targeting ligand. 
 Targeting two epitopes of the same molecule may help prevent tumor escape 
when the targeted antigen can be expressed by alternative mRNA splicing, which may 
cause loss of the targeted epitope [198]. When the AFF.EGFR and FN3.EGFR were 
combined in one single amR cassette, we demonstrated that two epitopes of EGFR can 
be targeted without causing detrimental effects in T cells. Targeting two distinct antigens 
expressed by tumor cells remains challenging. We demonstrated that single domain 
antibody mimics can be assembled in one single cassette to efficiently target two 
different antigens.  As a proof of principle, we showed that both EGFR and HER2 can 
be effectively targeted by dual-specific amRs neither with impairing targeting of each 
single antigen nor with detrimental effects of engineered T cells. 
 In summary, we provided proof of concept that antibody mimics can be used to 
generate combinatorial targeting of engineered T cells. Taking in consideration that 
antibody mimics are generated synthetically, our proposed approach can be adapted to 
a systematic screening of combinatorial antigens to be tested in human malignancies. 
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Figure 2. 1. Bi-EGFR.amR-Ts and conventional EGFR.CAR-Ts show comparable 
activity. (A-C) Bio-layer Interferometry (BLI) was used to measure the affinity of the 
monomeric or heterodimeric single domain antibody mimics binding to recombinant Fc-
EGFR on the FortéBio Octet system. 100 nM biotinylated antibody mimics were 
immobilized onto a streptavidin biosensor. Binding kinetics were measured against 
various concentrations of EGFR (0, 25, 50, 100 nM). The Kd was calculated based on 
kinetic fitting. (D) Representative expression of the Bi-EGFR.amR, EGFR.CAR or 
CD19.CAR in T cells as assessed by flow cytometry. Activated T cells were transduced 
with retroviral vectors encoding the Bi-EGFR.amR, EGFR.CAR or CD19.CAR. With the 
exception of the CD19.CAR, all constructs were detected using an α-FLAG Ab. The 
CD19.CAR was detected using an anti-idiotype Ab. Shaded and unshaded histograms 
indicate non-transduced and specific mAb, respectively. (E) Summary of amR or CAR 
expression (n=4). (F) Expansion kinetics of Bi-EGFR.amR-Ts, EGFR.CAR-Ts or 
CD19.CAR-Ts NT (n=4). (G) Phenotypic composition of Bi-EGFR.amR-Ts, EGFR.CAR-
Ts or CD19.CAR-Ts 10 days post-transduction (n=4). (H) Reducing immunoblots of Bi-
EGFR.amR-T and EGFR.CAR-T cell lysates. Immunoblots were probed with an α-CD3ζ 
Ab. Upper panel and lower panels represent detection of the receptors and endogenous 
z-chain, respectively. (I) EGFR.CAR-Ts and Bi-EGFR.amR-Ts were incubated at the 
indicated time points with the α-FLAG Ab and cross-linked with a secondary Ab to 
induce the aggregation of the receptors. Cell lysates were immunoblotted to detect 
proximal (CD3ζ p-Y142) and distal (Akt p-S473 and ERK p-T202/204) phosphorylation 
events following receptor cross-linking. Total CAR.CD3ζ or amR.CD3ζ and endogenous 
CD3ζ were used as loading controls. Data are representative of 4 experiments.  
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Figure 2. 2. Bi-EGFR.amR-Ts show activity against EGFR-expressing tumor cells 
in vitro and in vivo. (A) Control T (NTs or CD19.CAR-Ts), Bi-EGFR.amR-Ts and 
EGFR.CAR-Ts were co-cultured with MCF-7 cells (EGFR negative) or EGFR-
expressing pancreatic adenocarcinoma cell lines (AsPC-1, BxPC-3, HPAF-II and Panc-
1) at 1:5 E:T. Cells were collected and quantified by flow cytometry on day 5. The 
frequency of residual tumor cells was identified as CD4-CD8- live cells (n=3-4), p<0.01 
when Bi-EGFR.amR-Ts or EGFR.CAR-Ts are compared with control T cells. (B) IFN-γ 
and (C) IL-2 released in the co-culture supernatant by Bi-EGFR.amR-Ts, EGFR.CAR-
Ts and control T cells after 24 hours of co-culture with tumor cells as assessed by 
ELISA (n=3-4), p<0.01 when Bi-EGFR.amR-Ts or EGFR.CAR-Ts are compared with 
control T cells. (D) Bi-EGFR.amR-Ts, EGFR.CAR-Ts or control T cells were labeled 
with CFSE and stimulated with irradiated EGFR-expressing AsPC-1 cells at 4:1 E:T. 
Representative CFSE dilution on day 5. (E) Proliferation index as assessed by CFSE 
dilution (n=4), p<0.01 when Bi-EGFR.amR-Ts or EGFR.CAR-Ts are compared with 
control T cells. (F) Schematic representation of a metastatic pancreatic cancer model in 
NSG mice using the FFLuc-labeled human Panc-1 cell line. Representative images of 
tumor bioluminescence (BLI) (G) and kinetics (H) of tumor growth as assessed by BLI 
measurements. Data are representative of two independent experiments with 5 mice 
per group; p<0.01 when Bi-EGFR.amR-T or EGFR.CAR-T cells are compared with 
control T cells.  
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Figure 2. 3. Bi-EGFR.amR-Ts are activated by recognition of two non-overlapping 
epitopes on EGFR. Control (NTs), AFF.EGFR.amR-Ts, FN3.EGFR.amR-Ts and Bi-
EGFR.amR-Ts were seeded in tissue culture plates coated with either recombinant 
human EGFR WT protein (rEGFR) or the truncated mutant EGFRvIII recombinant 
protein (rEGFRvIII). (A) Representative expression of CD69 on NTs, AFF.EGFR.amR-
Ts, FN3.EGFR.amR-Ts and Bi-EGFR.amR-Ts 6 hours post-stimulation with plate-
bound rEGFR or rEGFRvIII protein as assessed by flow cytometry. Shaded and dashed 
histograms indicate media and PMA/Iono controls, respectively. Solid and dashed lines 
indicate rEGFR and rEGFRvIII protein stimulation, respectively. (B) Summary of CD69 
expression on total live T cells (n=4), p<0.01 when comparing FN3.EGFR.amR-Ts 
seeded in rEGFR and rEGFRvIII-coated wells. (C) IFN-γ released in the supernatant by 
AFF.EGFR.amR-Ts, FN3.EGFR.amR-Ts and Bi-EGFR.amR-Ts as assessed by ELISA 
(n=3), p<0.01 when comparing FN3.EGFR.amR-Ts seeded in rEGFR and rEGFRvIII-
coated wells. (D) mAFF.EGFR.amR-Ts or mBi-EGFR.amR-Ts were co-cultured with 
BV173-WT or BV173-EGFR cells at 1:5 E:T for 3 days. CD19.CAR-T cells were used as 
a positive control. Cells were collected and T cells (CD3+) and tumor cells (CD19+) 
were quantified by flow cytometry. Representative flow plots are illustrated. (E) 
Quantification of BV173-WT or BV173-EGFR cells remaining after 3 days of co-culture. 
(F) IFN-γ released in the supernatant by NT, CD19.CAR-T, mAFF.EGFR.amR-T and 
mBi-EGFR.amR-T cells as assessed by ELISA (n=2-4), p<0.01 when comparing the 
percentage of residual BV173-WT and BV173-EGFR cells remaining in the mBi-
EGFR.amR-T wells.  
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Figure 2. 4. Bi-HER2.amR-Ts have anti-tumor activity against HER2-expressing 
primary cells in vitro and in vivo. (A-C) Bio-layer Interferometry (BLI) was used to 
measure the affinity of the monomeric or heterodimeric single domain antibody mimics 
binding to recombinant Fc-HER2 using the FortéBio Octet system. 100 nM biotinylated 
antibody mimics were immobilized onto a streptavidin biosensor. Binding kinetics was 
measured against various concentrations of HER2 (0, 25, 50, 100 nM). The Kd was 
calculated based on kinetic fitting. (D) Control T (NT), Bi-HER2.amR-T and EGFR.CAR-
T cells were co-cultured with Panc-1 cells (HER negative) or HER2-expressing 
pancreatic adenocarcinoma cell lines (AsPC-1 and HPAF-II) at 1:5 E:T. Cells were 
collected and quantified by flow cytometry on day 5. The frequency of residual tumor 
cells was identified as CD4- CD8- live cells (n=3-6), p<0.01 when comparing Bi-
HER2.amR-Ts or EGFR.CAR-Ts with NTs. (E) IFN-γ and (F) IL-2 released in the co-
culture supernatant by NTs, Bi-HER2.amR-Ts or EGFR.CAR-Ts after 24 hours of co-
culture with tumor cells as assessed by ELISA (n=3-6), p<0.01 when comparing Bi-
HER2.amR-Ts or EGFR.CAR-Ts with NTs. (G) Schematic representation of a 
metastatic pancreatic cancer model in NSG mice using the using the FFLuc-labeled 
human HPAF-II cell line. Representative images of tumor bioluminescence (BLI) (H) 
and kinetics (I) of tumor growth as assessed by BLI measurements. Data are 
representative of two independent experiments with 5 mice per group; p<0.01 when Bi-
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Figure 2. 5. EGFR-HER2.amR-Ts show dual specificity. Co-culture experiment in 
which T cells were plated with its respective BV173 target cells, and 3 days later T cells 
were collected and re-plated with the same BV173 tumor cell line or BV173 cells 
expressing the non-specific target. (A) Schema of the repetitive co-culture experiments 
with control (CD19.CAR-Ts), monospecific FN3.EGFR.amR-Ts, DARPin.HER2.amR-Ts 
and bispecific EGFR-HER2.amR-Ts all plated at 1:2 E:T. (B) Representative flow plots 
of the repetitive co-culture experiments on the second round. Cells were collected and 
quantified by flow cytometry on day 3. The frequency of residual tumor cells was 
identified as CD3-CD19+ live cells. (C) Quantification of tumor cells remaining after the 
second co-culture (n=2-3), p<0.01 when comparing FN3.EGFR.amR-Ts and 
DARPin.HER2.amR-Ts and their respective targets against WT tumor cells. (D) IFN-γ 
released in the co-culture supernatant by CD19.CAR-Ts, FN3.EGFR.amR-Ts, 
DARPin.HER2-amR-Ts or EGFR-HER2.CAR-Ts after 24 hours of co-culture with tumor 
cells as assessed by ELISA (n=2-3), p<0.01 when comparing FN3.EGFR.amR-Ts and 
DARPin.HER2.amR-Ts and their respective targets against WT cells. (E) Schematic 
representation of the re-challenge tumor model in NSG mice using the EGFR+HER2- 
human Panc-1 cell line labeled with the FF-Luc and the EGFR-HER2 human BV173-
HER2 cell line. Representative images of the Pan-1 tumor BLI (F) and BLI kinetics (G) 
of tumor growth. (I) Survival curve of NSG mice aftre re-challenge with the BV173-
HER2 cell line; p<0.01 when EGFR.amR-Ts treated mice are compared with EGFR-
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Supplementary figure 1. Schematic diagram of antibody mimics receptors (amRs) targeting EGFR. 
Single domain antibody mimics (AFF and FN3) identified to bind to EGFR were adapted to generate amRs. 
All amRs were constructed with the CD8α hinge (H) and transmembrane domain (TM), the CD28 
endodomain (28) and CD3ζ chain and cloned into the SFG retroviral vector. A 25-residue PQPQ linker (solid 
line) was included to separate the antigen-binding domains of the bi-epitopic amR (Bi-EGFR.amR). A FLAG-
tag was included after the 25-residue GGGGS linker (dashed line) to detect the expression of the amR on 
the cell surface of T cells by flow cytometry. A conventional EGFR-specific chimeric antigen receptor 
(EGFR.CAR) was generated using the scFv from the Cetuximab mAb. 
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Supplementary Figure 2. 1. Schematic diagram of antibody mimics receptors 
(amRs) targeting EGFR. Single domain antibody mimics (AFF and FN3) identified to 
bind to EGFR were adapted to generate amRs. All amRs were constructed with the 
CD8α hinge (H) and transmembrane domain (TM), the CD28 endodomain (28) and 
CD3ζ chain and cloned into the SFG retroviral vector. A 25-residue PQPQ linker (solid 
line) was included to separate the antigen-binding domains of the bi-epitopic amR (Bi-
EGFR.amR). A FLAG-tag was included after the 25-residue GGGGS linker (dashed 
line) to detect the expression of the amR on the cell surface of T cells by flow cytometry. 
A conventional EGFR-specific chimeric antigen receptor (EGFR.CAR) was generated 
using the scFv from the Cetuximab mAb.  
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Supplementary Figure 2. 2 
 
  


























































Supplementary figure 2. Bi-EGFR-amR-Ts show specificity for EGFR. (A) Expression of EGFR on 
BV173-WT and BV173-EGFR tumor cells following retroviral gene transfer with a retroviral vector 
encoding the full-length EGFR. Dotted and solid lines indicate isotype and α-EGFR Ab, respectively. (B) 
Bi-EGFR.amR-Ts or EGFR.CAR-Ts were co-cultured with BV173-WT or BV173-EGFR cells at 1:5 E:T for 
3 days. CD19.CAR-T cells were used as a positive control. Cells were collected and T cells (CD3+) and 
tumor cells (CD19+) were quantified by flow cytometry. Representative flow plots are illustrated. (C) 
Quantification of BV173-WT or BV173-EGFR cells remaining after 3 days of co-culture (n=4), p<0.01 
when comparing remaining BV173-WT and BV173-EGFR cells in EGFR.CAR-Ts and Bi-EGFR.amR-Ts. 
(D) Expression of EGFR on human pancreatic adenocarcinoma cell lines: AsPC-1, BxPC-3, HPAF-II and 
Panc-1 as detected by flow cytometry. Dotted and solid lines indicate isotype and α-EGFR Ab, 























Supplementary Figure 2. 2. Bi-EGFR-amR-Ts show specificity for EGFR. (A) 
Expression of EGFR on BV173-WT and BV173-EGFR tumor cells following retroviral 
gene transfer with a retroviral vector encoding the full-length EGFR. Dotted and solid 
lines indicate isotype and α-EGFR Ab, respectively. (B) Bi-EGFR.amR-Ts or 
EGFR.CAR-Ts were co-cultured with BV173-WT or BV173-EGFR cells at 1:5 E:T for 3 
days. CD19.CAR-T cells were used as a positive control. Cells were collected and T 
cells (CD3+) and tumor cells (CD19+) were quantified by flow cytometry. Representative 
flow plots are illustrated. (C) Quantification of BV173-WT or BV173-EGFR cells 
remaining after 3 days of co-culture (n=4), p<0.01 when comparing remaining BV173-
WT and BV173-EGFR cells in EGFR.CAR-Ts and Bi-EGFR.amR-Ts. (D) Expression of 
EGFR on human pancreatic adenocarcinoma cell lines: AsPC-1, BxPC-3, HPAF-II and 
Panc-1 as detected by flow cytometry. Dotted and solid lines indicate isotype and α-
EGFR Ab, respectively. The breast cancer tumor cell line MCF-7 was used as a 
negative control for EGFR expression.  
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Supplementary Figure 2. 3 
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Supplementary Figure 2. 3. The AFF.EGFR and FN3.EGFR binding moieties 
individually have anti-tumor activity against EGFR+ tumors in vitro when 
generated into an amR. Activated T cells were transduced with retroviral vectors 
encoding AFF.EGFR.amR, FN3.EGFR.amR, EGFR.CAR or CD19.CAR. (A) 
Representative expression of the AFF.EGFR.amR, FN3.EGFR.amR, EGFR.CAR or 
CD19.CAR on T cells as assessed by flow cytometry. With the exception of the 
CD19.CAR, all constructs were detected using an α-FLAG Ab. The CD19.CAR was 
detected using an anti-idiotype Ab. Shaded and unshaded histograms indicate non-
transduced and specific mAb, respectively. (B) AFF.EGFR.amR-Ts, FN3.EGFR.amR-Ts 
or EGFR.CAR-Ts were co-cultured with BV173-WT or BV173-EGFR cells at 1:5 E:T for 
3 days. CD19.CAR-T cells were used as a positive control. Cells were collected and T 
cells (CD3+) and tumor cells (CD19+) were quantified by flow cytometry. Representative 
flow plots are illustrated. (C) Quantification of BV173-WT or BV173-EGFR cells 
remaining after 3 days of co-culture (n=4), p<0.01 when comparing remaining BV173-
WT and BV173-EGFR in AFF.EGFR.amR-Ts, FN3.EGFR.amR-Ts and EGFR.CAR-Ts. 
(D) AFF.EGFR.amR-Ts, FN3.EGFR.amR-Ts or EGFR.CAR-Ts were co-cultured with 
EGFR- MCF-7 cells or EGFR+ pancreatic adenocarcinoma cell lines (AsPC-1, BxPC-3, 
HPAF-II and Panc-1) at 1:5 E:T. Cells were collected and quantified by flow cytometry 
on day 5. The frequency of residual tumor cells was identified as CD4-CD8- live cells 
(n=3-4), p<0.01 when AFF.EGFR.amR-Ts, FN3.EGFR.amR-Ts or EGFR.CAR-Ts are 
compared with control T cells. (E) IFN-γ and (F) IL-2 released in the co-culture 
supernatant by AFF.EGFR.amR-Ts, FN3.EGFR.amR-Ts or EGFR.CAR-Ts after 24 
hours of co-culture with tumor cells as assessed by ELISA (n=3-4), p<0.01 when 
64 
AFF.EGFR.amR-Ts, FN3.EGFR.amR-Ts or EGFR.CAR-Ts are compared with control T 
cells. (G) AFF.EGFR.amR-Ts, FN3.EGFR.amR-Ts or EGFR.CAR-Ts were labeled with 
CFSE and stimulated with irradiated EGFR+ AsPC-1 cells at 4:1 E:T. Representative 
CFSE dilution on day 5. (H) Proliferation index as assessed by CFSE dilution (n=4), 
p<0.01 when AFF.EGFR.amR-Ts, FN3.EGFR.amR-Ts or EGFR.CAR-Ts are compared 
with control T cells.   
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Supplementary Figure 2. 4 
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Supplementary figure 4. Alanine substitutions to the AFF.EGFR binding moiety abrogates binding to 
EGFR. (A) AFF.EGFR and Bi-EGFR, but not FN3.EGFR, binds to rEGFRvIII. 100 nM FN3.EGFR and 
AFF.EGFR were applied to a streptavidin sensor immobilized with or without 100 nM rEGFRvIII on an Octet 
QK. The background was subtracted from the resulting binding curve. (B) Alanine substitutions were made 
to the alpha helices of the AFF scaffold to generate a mutated AFF.EGFR.amR (mAFF.EGFR.amR) and a 
Bi-EGFR.amR with a mutated AFF binding moiety (mBi-EGFR.amR). Representative expression of 
mAFF.EGFR.amR and mBi-EGFR.amR in T cells upon retroviral gene transfer. Dotted and solid lines 
indicate non-transduced and specific mAb, respectively. (C) Summary of CD69 expression on total live T 
cells (n=4), p<0.01 when comparing mBi-EGFR.amR-Ts seeded in EGFR WT and EGFRvIII-coated wells. 
(D) IFN-γ released in the supernatant by NT, mAFF.EGFR.amR-Ts and mBi-EGFR.amR-T cells as 



























Supplementary Figure 2. 4. Alanine substitutions to the AFF.EGFR binding moiety 
abrogates binding to EGFR. (A) AFF.EGFR and Bi-EGFR, but not FN3.EGFR, binds 
to rEGFRvIII. 100 nM FN3.EGFR and AFF.EGFR were applied to a streptavidin sensor 
immobilized with or without 100 nM rEGFRvIII on an Octet QK. The background was 
subtracted from the resulting binding curve. (B) Alanine substitutions were made to the 
alpha helices of the AFF scaffold to generate a mutated AFF.EGFR.amR 
(mAFF.EGFR.amR) and a Bi-EGFR.amR with a mutated AFF binding moiety (mBi-
EGFR.amR). Representative expression of mAFF.EGFR.amR and mBi-EGFR.amR in T 
cells upon retroviral gene transfer. Dotted and solid lines indicate non-transduced and 
specific mAb, respectively. (C) Summary of CD69 expression on total live T cells (n=4), 
p<0.01 when comparing mBi-EGFR.amR-Ts seeded in EGFR WT and EGFRvIII-coated 
wells. (D) IFN-γ released in the supernatant by NT, mAFF.EGFR.amR-Ts and mBi-
EGFR.amR-T cells as assessed by ELISA (n=4), p<0.01 when comparing mBi-
EGFR.amR-Ts seeded in EGFR WT and EGFRvIII-coated wells.  
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Supplementary Figure 2. 5. Expression of the Bi-HER2.amR redirects the 
specificity of T cells. (A) Schematic diagram of Bi-HER2.amR. Single domain antibody 
mimics (DARPin and AFF) identified to bind to HER2 were adapted to generate amRs 
that redirect T cell specificity for bi-epitopic recognition of HER2. Bi-HER2.amR was 
constructed with the CD8α hinge (H) and transmembrane domain (TM), the CD28 
endodomain (28) and CD3ζ chain and cloned into the SFG retroviral vector. A 25-
residue PQPQ linker (solid line) was included to separate the antigen-binding domains. 
A FLAG-tag was included after the 25-residue GGGGS linker (dashed line) to detect the 
expression of the amR on the cell surface of T cells by flow cytometry. (B) Activated T 
cells were transduced with a retroviral vector encoding the Bi-HER2.amR or 
EGFR.CAR. (A) Expansion kinetics of T cells expressing the Bi-HER2.amR or 
EGFR.CAR (n=5). (C) Phenotypic composition of Bi-HER2.amR-Ts or EGFR.CAR-Ts 
10 days post-transduction (n=5). (D) Expression of HER2 in human pancreatic 
adenocarcinoma cell lines. Panc-1 tumor cell line (Panc-1-WT) was modified to express 
HER2 by retroviral gene transfer (Panc-1-HER2). Dotted and solid lines indicate isotype 
and α-HER2 Ab, respectively. (E) Bi-HER2.amR-Ts or EGFR.CAR-Ts were co-cultured 
with Panc-1-WT or Panc-1-HER2 cells at 1:5 E:T. On day 5, cells were collected and 
the frequency of residual tumor cells was identified by flow cytometry as CD4-CD8- live 
cells. Representative flow plots are illustrated. (F) Quantification of remaining Panc-1 
cells after 5 days of co-culture (n=3), p<0.01 when the frequency of Panc-1-WT or 
Panc-1-HER2 cells is compared in Bi-HER2.amR-Ts.   
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Supplementary Figure 2. 6. Characteristics of EGFR-HER2.amR expressing T 
cells. (A) Schematic diagram of bi-specific EGFR-HER2.amR. Single domain antibody 
mimics identified to bind to EGFR (FN3) and HER2 (DARPin) were adapted to generate 
amRs that redirect T cells for bi-specific recognition.  Activated T cells were transduced 
with retroviral vectors encoding EGFR.amR, HER2.amR, EGFR-HER2.amR or 
CD19.CAR. (B) Representative expression of the EGFR.amR, HER2.amR, EGFR-
HER2.amR or CD19.CAR in T cells as assessed by flow cytometry. All constructs were 
detected using an α-FLAG Ab, while the CD19.CAR was detected using a specific anti-
idiotype antibody. Shaded and unshaded histograms indicate non-transduced and 
specific mAb, respectively. (C) Summary of receptor expression (n=3). (D) Expansion 
kinetics of T cells expressing the EGFR.amR, HER2.amR or EGFR-HER2.amR (n=3). 
(E) Phenotypic composition of T cells expressing the EGFR.amR, HER2.amR or EGFR-
HER2.amR 10 days post-transduction (n=3). (F) Summary of CD69 expression on total 
live T cells (n=1-3), p<0.01 when comparing EGFR.amR-Ts and HER2.amR-Ts seeded 
in rHER2 and rEGFR-coated wells, respectively. (G) IFN-γ released in the supernatant 
by EGFR.amR-Ts, HER2.amR-Ts and EGFR-HER2.amR-T cells as assessed by ELISA 
(n=1-3), p<0.01 when comparing EGFR.amR-Ts and HER2.amR-Ts seeded in rHER2 
and rEGFR-coated wells, respectively. (H) Expression of EGFR and HER2 in BV173-
WT, BV173-EGFR and BV173-HER2 tumor cells. BV173-EGFR and BV173-HER2 cells 
were obtained upon retroviral gene transfer of the full length EGFR or a truncated form 
of HER2 to be devoid of a cytoplasmic domain, respectively. Dotted and solid lines 





CHAPTER 3: AN INVESTIGATION OF THE ANTITUMOR ACTIVITY AND TOXICITY 
OF B7-H3 CHIMGERIC ANTIGEN RECEPTOR-T CELLS IN THE TREATMENT OF 
SOLID TUMORS 2 
 
SUMMARY 
The high expression across multiple tumor types and restricted expression in normal 
tissues make B7-H3 an attractive target for immunotherapy. We generated chimeric 
antigen receptor (CAR) T cells targeting B7-H3 (B7-H3.CAR-Ts) and found that B7-
H3.CAR-Ts controlled the growth of pancreatic ductal adenocarcinoma, ovarian cancer 
and neuroblastoma in vitro and in orthotopic and metastatic xenograft mouse models, 
which included patient-derived xenograft. We also found that 4-1BB costimulation 
promotes lower PD-1 expression in B7-H3.CAR-Ts, and superior antitumor activity 
                                            
 
 
2 This chapter contains a manuscript that previously appeared as an article in Cancer 
Cell. I contributed all of the ovarian cancer work in this co-author publication and 
prepared the corresponding figures, which can be seen in Fig.3.5B-F and Fig.S3.3. I 
have also contributed to Fig.3.2H-K and Fig.3.4A-J by performing the animal injections.  
The full citation for this manuscript is as follows: Du H, Hirabayashi K, Ahn S, Kren NP, 
Montgomery SA, Wang X, Tiruthani K, Mirlekar B, Michaud D, Greene K, Herrera SG, 
Xu Y, Sun C, Chen Y, Ma X, Ferrone CR, Pylayeva-Gupta Y, Yeh JJ, Liu R, Savoldo B, 
Ferrone S, Dotti G. 2019. Antitumor Responses in the Absence of Toxicity in Solid 
Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells. Cancer Cell. 
35(2):221-37. 
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when targeting tumor cells that constitutively expressed PD-L1. We took advantage of 
the cross-reactivity of the B7-H3.CAR with murine B7-H3, and found that B7-H3.CAR-
Ts significantly controlled tumor growth in a syngeneic tumor model without evident 
toxicity. These findings support the clinical development of B7-H3.CAR-Ts. We 
developed CAR-Ts for targeting B7-H3 in solid tumors, which effectively controlled 
tumor cell growth in vitro and in orthotopic, metastatic, and patient-derived xenograft 
mouse models without causing detectable toxicity. Considering the broad expression of 
B7-H3 in solid tumors, B7-H3.CAR-Ts may provide therapeutic opportunities for cancer 
patients who are challenging to treat. Furthermore, we found that 4-1BB costimulation 
promotes lower PD-1 expression in B7-H3.CAR-Ts, leading to their superior antitumor 
activity when targeting pancreatic tumor cells that constitutively expressed PD-L1. This 
evidence provides further guidelines for the selection of appropriate costimulation for 
CAR-Ts in the clinical setting of solid tumors. 
INTRODUCTION 
 Remarkable clinical responses have been reported in B-cell malignancies treated 
by the adoptive transfer of T cells redirected with a chimeric antigen receptor (CAR) 
specific for CD19 [229, 230]. However, developing CAR-Ts for the treatment of solid 
tumors is challenging because antigens expressed on the cell surface of tumor cells are 
generally shared with some normal tissues, often intratumorly heterogeneous, and not 
broadly expressed across different tumor types [231]. 
B7-H3 is a type I transmembrane protein that belongs to the B7 immune co-stimulatory 
and co-inhibitory family and has two isoforms in humans, 2Ig-B7-H3 and 4Ig-B7H3, and 
one isoform in mice, 2Ig-B7-H3, that shares 88% amino acid identity with the human 
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2Ig-B7-H3 isoform [232, 233]. B7-H3 has immune inhibitory functions. It reduces type I 
interferon released by T cells and cytotoxic activity of natural killer cells [234]. Other 
studies support a negative immune regulatory role of B7-H3 in models of graft-versus-
host-disease, cardiac allograft rejection, airway inflammation and autoimmune 
encephalomyelitis [235-240]. Conversely, B7-H3 has also been described as a T cell 
co-stimulatory molecule in vitro and in autoimmune disease models [232, 241].  
 The B7-H3 protein has limited expression in normal human tissues, such as 
prostate, breast, placenta, liver, colon and lymphoid organs [242, 243]. However, it is 
aberrantly expressed in a high proportion of human malignancies [243-247]. In addition, 
B7-H3 is found overexpressed by the tumor-associated vasculature and stroma 
fibroblasts [243, 247]. Overexpression of B7-H3 in tumor cells frequently correlates with 
fewer tumor-infiltrating lymphocytes, faster cancer progression and poor clinical 
outcome in several malignancies, such as pancreatic ductal adenocarcinoma (PDAC), 
prostate cancer, ovarian cancer (OC), lung cancer and clear cell renal carcinoma [244-
254]. Due to its broad expression across multiple tumor types, B7-H3 is an attractive 
target for cancer immunotherapy. B7-H3 specific monoclonal antibodies (mAbs) and 
antibody-drug conjugates (ADCs) showed antitumor activity against B7-H3+ tumor cells 
in xenograft mouse models, and phase I clinical trials showed a good safety profile 
(NCT01099644, NCT02381314 and NCT02982941) [243, 255-259].  
 Here we aimed to systematically examine the safety and antitumor activity of T 
cells expressing a B7-H3 specific CAR.  
MATERIALS AND METHODS 
Cell lines and cell culture 
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Human pancreatic (PDAC) tumor cell lines Panc-1 (Source: male), BxPC-3 (Source: 
female), Panc-10.05 (Source: male), Capan-1 (Source: male) and AsPC-1 (Source: 
female), human ovarian cancer (OC) cell lines SW626 (Source: female), SK-OV-3 
(Source: female) and CaoV-3 (Source: female), and human neuroblastoma (NB) cell 
line IMR-32 (Source: male) were purchased from American Type Culture Collection 
(ATCC). Human NB cell lines CHLA-255 (Source: unknown, initially derived from a 
metastatic lesion in the brain in a patient with recurrent disease at Children’s Hospital 
Los Angeles [260]) and FFluc-CHLA-255 are gifts from Dr. Metelitsa at Baylor College 
of Medicine (Houston TX) [261], and LAN-1 (Source: male) and SKNLP (Source: 
unknown, initially derived from a patient with NB treated at Memorial Sloan-Kettering 
Cancer Center [262]) are gifts from Dr. Brenner at Baylor College of Medicine (Houston 
TX) [262]. Human PDAC cell lines PDAC2 (Source: male), PDAC3 (Source: female), 
and PDAC6 (Source: male) were established at Dana-Farber Cancer Institute and 
Massachusetts General Hospital by Dr Cristina Ferrone from ascites of PDAC patients. 
Murine pancreatic tumor cell line KPC-4662 was a gift from Dr. Yuliya Pylayeva-Gupta, 
originally obtained from Dr. Vonderheide (University of Pennsylvania) [263, 264]. The 
tumor cell line SK-OV-3 was selected three times in vivo in NSG mice to obtain a very 
aggressive clone. Capan-1 cell lines were cultured in IMDM (Gibco, Invitrogen) 
supplemented with 10% FBS (Sigma), 2 mM GlutaMax (Gibco). BxPC-3, Panc-10.05, 
PDAC-2, PDAC-3, PDAC-6, KPC-4662, SW626, CHLA-255, IMR-32, LAN-1 and 
SKNLP were cultured in RPMI1640 (Gibco) supplemented with 10% FBS and 2 mM 
GlutaMax. AsPC-1 was cultured in RPMI1640 (Gibco) supplemented with 10% FBS, 2 
mM GlutaMax and 1mM Sodium pyruvate (Gibco). Panc-1 and Caov-3 cells were 
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cultured in DMEM (GIBCO) supplemented with 10% FBS and 2 mM GlutaMax. SK-OV-
3 was cultured in McCoy's medium supplemented with 10% FBS and 2 mM GlutaMax. 
Penicillin (100 unit/mL) (Gibco) and streptomycin (100 µg/mL) (Gibco) were added to 
cell culture media. Cells were maintained in a humidified atmosphere containing 5% 
CO2 at 37°C. Panc-1, Panc-10.05, BxPC-3, Capan-1 and Aspc-1 cells were transduced 
with a retroviral vector encoding GFP. The human B-cell lymphoma Raji (Source: male) 
cell line obtained from ATCC was transduced with retroviral vectors encoding either 
human or murine B7-H3, and sorted to generate single cell clones. The murine 
pancreatic tumor cell line KPC-4662 was transduced with a retroviral vector encoding 
the murine B7-H3. Panc-1, BxPC-3 and SK-OV-3 cells were also transduced with a 
retroviral vector encoding the GFP-Firefly-Luciferase (GFP-FFluc) gene [265]. All cell 
lines were mycoplasma free, and validated by flow cytometry for surface markers and 
functional readouts as needed.  
Human and mouse tissue samples 
Frozen normal human tissue microarrays (TMA) and human ovarian cancer TMA were 
purchased from US Biomax (Rockville, USA). Frozen normal mouse TMA were 
purchased from BioChain Institute Inc. (Newark, USA). The use of this material does not 
require Institutional Review Board (IRB) approval. Frozen PDAC specimens were 
obtained from the Tissue Procurement Facility at the Lineberger Comprehensive 
Cancer Center at the University of North Carolina at Chapel Hill (UNC), and the 
specimens were collected under an Institutional Review Board (IRB) approved protocol 
(IRB 90-0573) with obtained informed consent. These deidentified samples are 
distributed by the facility under non-human subject study IRB approval. For the PDAC-
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PDX, fresh tumor samples from deidentified PDAC patients were obtained under 
protocols approved by IRB at UNC with obtained informed consent. All patient-derived 
tissues were stained with hematoxylin and eosin to confirm histology. Tumors were 
implanted orthotopically into the pancreas of 6 - 8 weeks old female NSG under 
protocols approved by the Institutional Animal Care and Use Committee at UNC. 
In Vivo Mouse Studies 
Male and female 4 - 6 weeks old NSG mice were purchased from the Animal Core 
Facility at UNC. Male and female 4 - 6 weeks old C57BL/6J mice were purchased from 
The Jackson Laboratory. All the mice were housed in the Animal Core Facility at UNC. 
All mouse experiments were performed in accordance with UNC Animal Husbandry and 
Institutional Animal Care and Use Committee (IACUC) guidelines and were approved by 
UNC IACUC. 
Plasmid construction and retrovirus production 
The full-length human 2Ig-B7-H3 (accession number NM_001329628) and 4Ig-B7-H3 
(accession number NM_001024736) genes were amplified by PCR from cDNA obtained 
from the Panc-1 cell line, and cloned into the retroviral vector SFG. Murine B7-H3 
(accession number NM_133983) was amplified by PCR from a plasmid obtained from 
InVivogene (San Diego, CA), and cloned into the retroviral vector SFG. The 2Ig-B7-H3-
GFP fusion protein was generated by fusing the coding region of 2Ig-B7-H3 
extracellular domain (1-248 amino acids) with the GFP gene by fusion PCR, and cloned 
into the retroviral vector SFG. The variable regions of the heavy and light chains of the 
376.96 mAb were cloned from the 376.96 mouse hybridoma and then cloned as a scFv 
fragment into previously validated CAR formats that include the human CD8α hinge and 
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transmembrane domain, CD28 or 4-1BB intracellular costimulatory domains and CD3ζ 
intracellular signaling domain. The B7-H3.CAR cassettes were cloned into the retroviral 
vector SFG. For the murine version of the B7-H3.CAR (mB7-H3.CAR), human CD8a, 
CD28 and CD3ζ were replaced by murine CD28 and CD3ζ. The scFv specific for 
murine CD19 was previously reported [266].  
Retrovirus preparation 
Retroviral supernatants used for the transduction of human T cells were prepared as 
previously described [265]. Briefly, 2 × 106 293T cells were seeded in 10 cm cell culture 
dish and transfected with the plasmid mixture of the retroviral vector, the Peg-Pam-e 
plasmid encoding MoMLV gag-pol, and the RDF plasmid encoding the RD114 
envelope, using the GeneJuice transfection reagent (Merck Millipore), according to the 
manufacturer's instruction. Similarly, retroviral supernatant used for the transduction of 
murine T cells was generated by cotransfecting 293T cells with the retroviral vector and 
the pCL-Eco plasmid that encodes gag/pol/env using the GeneJuice transfection 
reagent. Supernatant containing the retrovirus was collected 48 and 72 hours after 
transfection, and filtered with 0.45 µm filters.  
Preparation of the 2Ig-B7-H3-GFP fusion protein for T cell staining 
The retroviral supernatant encoding 2Ig-B7-H3-GFP was generated using the above 
described retrovirus supernatant preparation procedure. The viral supernatant was used 
to stably transduce 293T cells. The 2Ig-B7-H3-GFP expressing 293T cells were seeded 
in 10 cm cell culture dishes (5 × 106 cells/dish) and the supernatant containing the 2Ig-
B7-H3-GFP fusion protein was collected at 48 hours, filtered with 0.22 µm filter and 
used for the staining of the B7-H3.CAR-Ts (300 mL/sample) to detect CAR expression.  
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Transduction and expansion of human T cells 
Buffy coats from healthy donors were purchased from the Gulf Coast Regional Blood 
Center, Houston, TX. Peripheral blood mononuclear cells (PBMCs) isolated with 
Lymphoprep density separation (Fresenius Kabi Norge) were activated on plates coated 
with 1 µg/mL CD3 (Miltenyi Biotec) and 1 µg/mL CD28 (BD Biosciences) agonistic 
mAbs. On day 2, T lymphocytes were transduced with retroviral supernatants using 
retronectin-coated plates (Takara Bio Inc., Shiga, Japan). Briefly, non-tissue culture 
treated 24-well plates are coated overnight with 7 µg/mL retronectin in the cold room, 
washed once with 1 mL medium, coated with 1 mL of the retroviral supernatant per well 
and centrifuged at 2000 g for 90 min. After removal of the supernatant, 5 × 105 activated 
T cells are plated, and centrifuged at 1000 g for 10 min. Three days later, T cells are 
collected and expanded in complete medium (45% RPMI-1640 and 45% Click’s medium 
(Irvine Scientific), 10% FBS (Hyclone), 2 mM GlutaMAX, 100 unit/mL of Penicillin and 
100 µg/mL of streptomycin) with IL-7 (10 ng/mL; PeproTech) and IL-15 (5 ng/mL; 
PeproTech), changing medium every 2 - 3 days [267]. On day 12 - 14, cells are 
collected for in vitro and in vivo experiments. T cells were cultured in IL-7/IL-15 depleted 
medium for two days prior to being used in in vitro functional assays.  
Generation of murine CAR-T cells 
Murine CD4+ and CD8+ T cells were selected by CD4 and CD8 magnetic Microbeads 
(Miltenyi Biotec) from splenocytes obtained from C57BL/6J mice and stimulated on 
plates coated with 1 µg/mL mCD3 (eBioscience) and 1 µg/mL mCD28 mAbs 
(eBioscience) for 24 hours. Activated murine T lymphocytes were transduced with 
retroviral supernatants using retronectin-coated plates (Takara Bio Inc., Shiga, Japan) 
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with the same protocol used to transduce human T cells. After removal from the 
retronectin plates, T cells were expanded in complete medium (RPMI-1640 (Gibco), 
10% FBS (Hyclone), 2mM GlutaMAX, 100 µM β-mercaptoethanol, 100 unit/mL of 
Penicillin and 100 µg/mL of streptomycin) with IL-7 (10 ng/mL) and IL-15 (5 ng/mL) 
changing medium every 2 days. On day 6 - 7, T cells were collected and used for 
functional assays in vitro and in vivo.  
Immunohistochemistry and tissue histopathology 
Frozen PDAC specimens were sectioned by the Histology Research Core facility at 
UNC. Slides were dried for 30 minutes at room temperature, and fixed in 4% PFA in 
PBS for 15 min, blocked with 3% H2O2 (Sigma) in distilled water for 20 minutes, then 
blocked with 1% BSA and 10% normal goat serum (Sigma) in PBS for 1 hour at room 
temperature. Slides were stained with the primary Ab at 4°C overnight. Normal human 
TMA and tumor tissues were stained with the B7-H3 mAb (clone 376.96, 1:1000 
dilution, final concentration 1 µg/mL) [268]. Murine normal TMA and tumor tissues were 
stained with the B7-H3 EPNCIR122 mAb (Abcam, Cambridge, USA; 1:500 dilution, final 
concentration 1.4 µg/mL) that recognizes both human and murine B7-H3 [243]. HRP 
polymer conjugated goat anti-mouse secondary Ab (Dako, code K4000, 1:8 dilution at 
25°C for 1.5 hours) was used for human TMA and tumor tissues, while the goat anti-
rabbit secondary Ab (Dako, code K4002, 1:8 dilution at 25°C for 1.5 hours) was used for 
murine TMA and tumor tissues. Slides were developed using DAB chromogen (Cell 
signaling), counterstained with CAT hematoxylin (Biocare medical), dehydrated in 
ethanol, and cleared in xylene (Fisher chemical). Cover slips were added using 
histological mounting medium (Fisher, toluene solution). Stained TMA slides were 
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digitally imaged at 20X objective using the Aperio ScanScope XT (Leica). TMA slides 
were de-arrayed to visualize individual cores and each core was visually inspected. 
Folded tissues were excluded from the analysis using a negative pen, and all other 
artifacts were automatically excluded with the Aperio Genie software. The B7-H3 
positive score was measured using Aperio membrane v9 (cell quantification) algorithm. 
Percentage of positive cells obtained with this algorithm at each intensity level 
(negative, low, medium, high) were used to calculate the H-Score using the formula: H-
Score = (% at 1+) * 1 + (% at 2+) * 2 + (% at 3+) * 3. The Aperio color deconvolution v9 
algorithm with the Genie classifier was also applied to calculate the area and intensity of 
the positive stain and generate a Score (0-300). For the CD3 staining, formalin fixed 
and paraffin embedded tumor tissues were cut into 5 µm sections by the Histology 
Research Core facility at UNC. The sections were deparaffinized and placed in the 
antigen retrieval buffer (Thermo Scientific, TA-135-HBL). Heat-induced epitope retrieval 
was performed using a decloaking chamber for 30 seconds at 120˚C followed by 10 
seconds at 90˚C, then blocking with 3% H2O2 in distilled water for 20 minutes and 10% 
normal goat serum in TBS for 1 hour at room temperature. Slides were incubated with 
the CD3 Ab (1:250 dilution; Novus Bio, NB600-1441) overnight at 4°C and biotinylated 
goat anti-rabbit IgG secondary Ab (1:500 dilution, Jackson ImmunoResearch, 111-065-
144) for 1 hour at room temperature. Staining was visualized using a Vectastain ABC 
Elite Kit (1:50 dilution, Vector Labs, PK-6100) followed by diaminobenzidine (DAB, Cell 
signaling). Stained slides were digitally scanned at 20x magnification using the Aperio 
ScanScope-XT (Aperio Technologies, Vista, CA), and the digital images were analyzed 
using Tissue Studio software (Tissue Studio version 2.7 with Tissue Studio Library 
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version 4.4.2; Definiens Inc., Munich, Germany). Specifically, Tissue Studio’s Nuclei 
and Cell Simulation Algorithm was used to detect and enumerate cells that were 
positive and negative for murine CD3 signal. Positive cell density = the number of 
positive cells per mm2 area analyzed. Tissue sections and hematoxylin and eosin 
staining for animal tissue histopathology was performed by the Animal Histopathology & 
Laboratory Medicine Core at UNC, and scored by a mouse pathologist.  
ELISA 
T cells (1 x 105 or 5 x 105) were co-cultured with tumor cells (5 x 105) in 24-well plates 
without the addition of exogenous cytokines. After 24 hours, supernatant was collected 
and cytokines (IFNg and IL-2) were measured in duplicate using specific ELISA kits 
(R&D system) following manufacturer’s instructions. 
Flow cytometry 
We performed flow cytometry using Abs specific to human CD3, CD4, CD8, CD19, 
CD27, CD28, CD45, CD45RA, CD62L, CCR7, B7-H3, PD-1, PD-L1 and TIM3, and 
murine CD3, CD4, CD8, CD11b, CD11c, CD19, PD-1, Ly-6G and NK1.1 (from BD 
bioscience and Biolegend) conjugated with BV421, BV510, BV605, BV711, FITC, 
AF488, PerCP-cy5.5, PE, PE-cy7, APC and APC-cy7 fluorochromes. Expression of 
human B7-H3 in tumor cell lines was assessed with the 376.96 mAb and confirmed with 
another B7-H3 Ab clone 7-517 (BD bioscience) [268]. Expression of murine B7-H3 in 
BMDCs was assessed with the 376.96 Ab and the B7-H3 Ab clone EPNCIR122 
(Abcam) [243]. Expression of the B7-H3.CARs was detected using the fusion protein 
2Ig-B7-H3-GFP or the Fab Ab (Jackson ImmunoResearch Laboratories INC.). Samples 
were acquired with BD FACSCanto II or BD FACSFortessa using the BD Diva software 
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(BD Biosciences). For each sample a minimum of 10,000 events were acquired and 
data were analyzed using Flowjo 10.  
Co-culture experiments 
Tumor cells were seeded in 24-well plates at a concentration of 5 × 105 cells/well. T 
cells were added to the culture at different ratios (E:T of 1:1; 1:5, or 1:10) without the 
addition of exogenous cytokines. Cells were analyzed at day 5 - 7 to measure residual 
tumor cells and T cells by FACS. Dead cells were gated out by Zombie Aqua Dye 
(Biolegend) staining while T cells were identified by the expression of CD3 and tumor 
cells by the expression of GFP (PDAC and NB cell lines), or CD19 (Raji, Raji-2IgB7-H3, 
Raji-4IgB7-H3 and Raji-mB7H3) or mB7-H3 (KPC-4662 and KPC-4662-mB7-H3) [226, 
265].  
Proliferation Assay 
T cells were labeled with 1.5 mM carboxyfluorescein diacetate succinimidyl ester 
(CFSE; Invitrogen) and plated with tumor cells at an E:T ratio of 1:1. CFSE dilution was 
measured on gated T cells on day 5 using flow cytometry [226].  
Xenogeneic mouse models 
For the PDAC orthotopic model, FFluc-Panc-1 (2 × 105) or FFluc-BxPC-3 (1 × 105) 
tumor cells were suspended in 25 µL DPBS, mixed with 25 µL Matrigel (Corning) and 
surgically implanted into the pancreas of 8 - 10 weeks old male mice using 28-gauge 
needle. Briefly, an incision was performed in the left flank and PDAC tumor cells were 
injected using a 28-gauge needle into the tail of the pancreas. The wound was closed in 
two layers, with running 4-0 Vicryl, and polypropylene sutures for the skin. Twelve or 28 
days after tumor cell inoculation, CD19.CAR-28ζ (control), B7-H3.CAR-28ζ-Ts or B7-
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H3.CAR-BBζ-Ts were injected intravenously via tail injection (i.v.) (1 × 107 cells/mouse). 
For the PDAC metastatic model, 8 - 10 weeks old male or female mice were injected i.v. 
with FFluc-Panc-1 (1 × 106) tumor cells. On day 14 after tumor cell inoculation, 
CD19.CAR-28ζ-Ts, B7-H3.CAR-28ζ-Ts or B7-H3.CAR-BBζ-Ts were injected i.v. (1 × 
107 cells/mouse). For the Panc-1 re-challenge model, 6 weeks old female mice were 
injected i.v. with FFluc-Panc-1 (1 × 106) tumor cells. On day 14 after tumor cell 
inoculation, CD19.CAR-28ζ-Ts, B7-H3.CAR-28ζ-Ts or B7-H3.CAR-BBζ-Ts were 
injected i.v. (1 × 107 cells/mouse). Twenty-eight days after CAR-Ts treatment, mice 
were re-challenged with 1 × 106 FFluc-Panc-1 tumor cells and followed for three weeks. 
Mice received another tumor re-challenged with 1 × 106 FFluc-Panc-1 tumor cells on 
day 49 and 63 after CAR-Ts treatment. For the PDAC-PDX pancreatic orthotopic 
xenograft model, human PDAC tumor fragments were orthotopically implanted into the 
pancreas of female NSG mice. Twenty-one days after tumor engraftment, CD19.CAR-
28ζ-Ts, B7-H3.CAR-28ζ-Ts or B7-H3.CAR-BBζ-Ts (1 × 107/mouse) were injected i.v.. 
Tumor size was monitored by ultrasound (US) imaging on day -4, 15 and 31 after T cell 
infusion. Tumor volume was calculated by the formula: volume = 0.52 × length × width. 
For the NB metastatic model, 6 - 8 weeks old male or female NSG mice were injected 
i.v. with the tumor cell line FFluc-CHLA-255 (2 × 106 cells/mouse). Fourteen days after 
tumor inoculation, CD19.CAR-28ζ-Ts (5 × 106 cells/mouse) or B7-H3.CAR-28ζ-Ts (2 × 
106 or 5 × 106 cells/mouse) were injected i.v.. For the OC xenograft model, the human 
OC cell line FFluc-SK-OV-3 (5 × 105 cells/mouse) suspended in matrigel was inoculated 
intraperitoneally (i.p.) into 6 - 8 weeks old female NSG mice. Fourteen days after tumor 
inoculation, CD19.CAR-28ζ-Ts, B7-H3.CAR-28ζ-Ts or B7-H3.CAR-BBζ-Ts were 
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injected either i.p or i.v. (5 × 106 cells/mouse). No randomization was used. 
Investigators were not blinded, but mice were matched based on the tumor 
bioluminescence or tumor volume measured by US imaging before assignment to 
control or treatment groups. Tumor growth was monitored by bioluminescence imaging 
using IVIS lumina II in vivo imaging system (PerkinElmer) or by US imaging in the 
PDAC-PDX model. Mice were euthanized when signs of discomfort were detected by 
the investigators or as recommended by the veterinarian who monitored the mice three 
times a week, or when luciferase signal reached 1 × 1011 photons per second per cm2. 
Tumor specimens were collected and snap frozen for immunohistochemistry to detect 
B7-H3 and CD3 expression.  
Generation of murine bone marrow derived dendritic cells (BMDCs) 
Femur bone was removed from C57BL/6J mice and sterilized by soaking in 70% 
ethanol and then washed three times with phosphate buffer solution (PBS). Bone 
marrow cells were flushed out using PBS [269]. Red blood cells were removed by red 
blood cell lysis buffer. Mononuclear cells were seeded (1 × 106 cells per well) in non-
tissue culture treated 24-well plates and cultured with RPMI1640 medium (Gibco), 10% 
FBS (Hyclone), 2mM GlutaMAX, 100 µM β-mercaptoethanol, 100 unit/mL of penicillin 
and 100 µg/mL of streptomycin) in the presence of murine GM-CSF (20 ng/mL; 
PeproTech) and changing medium every 2 days. At day 5, cells were harvested and 
treated with 100 ng/mL lipopolysaccharide (LPS) (Invivogen). Two days later, BMDCs 
were harvested and assessed for the expression of CD11c and mB7-H3 by flow 
cytometry. BMDCs were then used in co-culture experiments with murine T cells. 
Evaluating toxicity of mB7-H3.CAR-Ts in C57BL/6J immunocompetent mice 
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Six week old male C57BL/6J mice were irradiated with 400 cGy to create a 
lymphodepleted environment that favors the expansion of adoptively transferred 
syngeneic T cells. Two days post-irradiation, mice were infused i.v. with syngeneic 
control non-transduced T cells (NT), mCD19.CAR-Ts or mB7-H3.CAR-Ts (1 × 
107/mouse by i.v. injection). Five days after T cell infusion, we assessed the blood cell 
composition by flow cytometry and counting beads. Mice were then euthanized 15 - 16 
days post T-cell infusion. Immune cell composition of the blood, spleen, bone marrow 
and lymph nodes was assessed by flow cytometry and counting beads. Tissues were 
also collected and evaluated by hematoxylin and eosin staining. A board-certified 
anatomic veterinary pathologist analyzed the slides at the Translational Pathology 
Laboratory at UNC. In parallel experiments, 6 - 8 weeks old C57BL/6J male mice 
received syngeneic NT, mCD29.CAR-Ts and mB7-H3.CAR-Ts (1 × 107/mouse) without 
irradiation.  
Murine PDAC orthotopic model in C57BL/6J mice 
The murine PDAC tumor cell line KPC-4662 was engineered to express mB7-H3 at 
similar level as observed in human PDAC, and implanted into the pancreas of six weeks 
old C57BL/6J female mice by surgery (1 × 105 cells/mouse). Seventeen days post-
tumor cell implantation, mice were irradiated with 400 cGy to create a lymphodepleted 
environment. Two days post-irradiation, mice were infused i.v. with syngeneic control 
NT or mB7-H3.CAR-Ts (1 × 107 cells/mouse). Tumor growth was monitored by US 
imaging. Mice were euthanized at day 33 - 34 post T-cell infusion. Immune cell 
composition of the blood, spleen, bone marrow and lymph nodes was assessed by flow 
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cytometry and counting beads and tissues analyzed by immunohistochemistry using 
hematoxylin and eosin staining.  
Measurement of 376.96 mAb binding affinity to human and murine B7-H3 
The binding affinity of the 376.96 mAb for human and murine B7-H3 was determined by 
Microscale Thermophoresis (MST). The h4Ig-B7-H3-His (Novus Bio, Littleton, USA), 
h2Ig-B7-H3-His (ACRO bio, Newark, USA) and mB7-H3-His (ACRO bio, Newark, USA) 
proteins were fluorescently labeled using RED-tris-NTA dye (NanoTemper Technology, 
Munich, Germany). Ten microliters of the labeled protein (50 nM) was mixed with 10 µL 
of the 376.96 mAb (concentration varying between 1 nM and 10 µM) in PBST buffer 
(PBS with 0.05% Tween 20) and loaded into 16 standard treated capillaries. The 
samples were excited by a Red LED at 50% power and the thermophoresis of each 
sample was measured at 60% MST power on Monolith NT.115 (NanoTemper 
Technology, Munich, Germany).  
Stimulation of B7-H3.CAR-Ts with plate-bound B7-H3-Fc fusion proteins 
Non-tissue culture treated 96-well plates were coated with h4Ig-B7-H3-Fc (AdipoGen 
Cor., Liestal, Switzerland), h2Ig-B7-H3-Fc (ACRO bio, Newark, USA) and mB7-H3-Fc 
(ACRO bio, Newark, USA) proteins in 100 µL PBS (concentration ranging between 1.25 
nM and 200 nM) for 24 hours at 4°C. Plates were washed three times with DPBS, and 2 
× 105 B7-H3.CAR-28ζ-Ts in 200 µL of T cell medium were added to each well. Twenty-
four hours later, supernatants were collected and IFNg was measured by ELISA.  
Measurement of mB7-H3.CAR copy numbers 
Mice inoculated with mB7-H3-CAR-Ts were sacrificed on day 33 - 34 post CAR-Ts 
treatment, and spleens and tumors were harvested. Genomic DNA was extracted 
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(Qiagen), and quantitative PCR (qPCR) performed using primers and probes (TaqMan 
TAMRA from Applied Biosystems, Thermo Fisher Scientific) spanning the scFv. qPCR 
was performed using the QuantStudio 6 Flex (Applied Biosystems, Thermo Fisher 
Scientific). Standard curves were prepared using serial dilutions of the mB7-H3.CAR 
plasmid. The copy number of unknown samples was interpolated from the standard 
curves using GraphPad Prism Software (La Jolla, CA).  
Quantification and statistical analyses  
The unpaired and nonparametric Mann Whitney test with two tailed p value calculation 
was used to measure differences between two groups. For multiple group comparisons, 
one-way ANOVA or two-way ANOVA was used to determine statistically significant 
differences between samples. Holm-Sidak test adjusted p value < 0.05 indicates a 
significant difference. Measurements were summarized as mean ± SD as noted in the 
figure legends. Difference between the bioluminescence of tumor and the survival 
curves were analyzed by the Chi-square test using GraphPad Prism v5. Experimental 
sample numbers (n) are indicated in the figure legends. The statistical analysis method 
is also described in the individual figure legends. Graph generation and statistical 
analyses were performed using the GraphPad Prism software (GraphPad, La Jolla, 
CA).  
RESULTS 
PDAC expresses B7-H3 and is targeted by B7-H3.CAR-Ts. Frozen human PDAC 
specimens were cryosectioned and stained with the B7-H3 mAb 376.96. As shown in 
Fig. 3.1A, PDAC stained strongly positive for B7-H3, with the antigen expressed by 
both tumor cells and surrounding stroma (Fig. S3.1A-C). We generated a B7-H3.CAR 
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using the single chain variable fragment (scFv) derived from the B7-H3 376.96 mAb 
[256, 257, 268] and included either CD28 or 4-1BB endodomains (B7-H3.CAR-28z and 
B7-H3.CAR-BBz, respectively) (Fig. S3.1D). The transduction efficiency of activated T 
cells was generally greater than 60%, and phenotypic analysis showed that B7-
H3.CAR-Ts contained central-memory, effector-memory, and T stem cell memory, 
without significant differences between CD28 and 4-1BB costimulation (Fig. S3.1E-I). 
B7-H3.CAR-Ts specifically recognized tumor cells expressing either the 2Ig-B7-H3 or 
4Ig-B7-H3 isoform of human B7-H3 (Fig. S3.1J-N). The antitumor activity of B7-
H3.CAR-Ts was evaluated against five human PDAC cell lines (Panc-1, BxPC-3, Panc-
10.05, Capan-1 and AsPC-1) that express B7-H3 (Fig. 3.1B). PDAC cell lines were co-
cultured with control (NT), B7-H3.CAR-28z-Ts and B7-H3.CAR-BBz-Ts at different T 
cell to tumor cell ratios. As shown in Fig. 3.1C, D, B7-H3.CAR-Ts effectively controlled 
PDAC cell growth even at the T cell to tumor cell ratio of 1 to 5. Cytolytic activity of B7-
H3.CAR-Ts was corroborated by cytokine release (IFNg and IL-2) in the culture 
supernatant (Fig. 3.1E, F), and by T cell proliferation in response to B7-H3+ target cells, 
as assessed by CFSE dilution assay (Fig. S3.1O). We also assessed how the density 
of B7-H3 expression in target cells affects the antitumor activity of B7-H3.CAR-Ts by 
generating single cell clones of tumor cells expressing different levels of the human 4Ig-
B7-H3 isoform (Fig. 3.1G). Tumor cells expressing low levels of 4Ig-B7-H3, triggered 
significantly less activity of B7-H3.CAR-Ts even when T cells were cultured with tumor 
cells at the high T cell to tumor cell ratio of 1 to 1 (Fig. 3.1H, I). 
B7-H3.CAR-Ts show antitumor activity in PDAC xenograft models. To evaluate the 
antitumor effects of B7-H3.CAR-Ts in vivo, the FFluc-transduced Panc-1 tumor cell line 
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was implanted into the pancreas of NOD/SCID/gamma(C)(null) (NSG) mice. Twelve 
days later, mice were infused with CD19.CAR-Ts, B7-H3.CAR-28z-Ts and B7-H3.CAR-
BBz-Ts via tail vein injection (i.v.), when the median bioluminescence intensity (BLI) of 
the tumors was 1.5 ± 1.5 × 109 (Fig. 3.2A). Both B7-H3.CAR-28z-Ts and B7-H3.CAR-
BBz-Ts effectively controlled Panc-1 tumor cell growth, and mice remained tumor free 
up to 80 days post-treatment, while the tumor grew in mice treated with control T cells 
(Fig. 3.2B-D). We also assessed the antitumor activity of B7-H3.CAR-Ts in a PDAC 
model with high tumor burden, by delaying the infusion of T cells until day 28 post-tumor 
injection, when the median BLI of the tumors was 2.7 ± 1.3 × 1010 (Fig. 3.2E). Both B7-
H3.CAR-28z-Ts and B7-H3.CAR-BBz-Ts effectively controlled the tumor growth (Fig. 
3.2F, G). To further investigate the efficacy of B7-H3.CAR-Ts we implemented a 
metastatic PDAC model by infusing Panc-1 tumor cells i.v. into NSG mice (Fig. 3.2H). 
As shown in Fig. 3.2I-J, B7-H3.CAR-28z-Ts and B7-H3.CAR-BBz-Ts, but not 
CD19.CAR-Ts, controlled Panc-1 tumor growth up to day 70 post-treatment when the 
experiment was terminated. Overall, B7-H3.CAR-28z-Ts and B7-H3.CAR-BBz-Ts 
showed comparable antitumor properties in Panc-1 orthotopic and metastatic PDAC 
models, and CAR-Ts persisted up to 100 days post infusion (Fig. 3.2K).  
B7-H3.CAR-Ts show antitumor activity in PDAC-patient-derived xenografts 
(PDAC-PDX). PDAC-PDX tumor models allow faithful recapitulation of histology, 
genetics and transcriptome to the donor patient-derived tumor [270]. We analyzed B7-
H3 expression in early passages of three primary PDAC cell lines established from 
ascites of three patients (PDAC-2, PDAC-3 and PDAC-6) (Fig. 3.3A), and co-cultured 
them with CD19.CAR-Ts, B7-H3.CAR-28z-Ts or B7-H3.CAR-BBz-Ts at T cell to tumor 
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cell ratios of 1 to 5 and 1 to 10. As shown in Fig. 3.3B-D, both B7-H3.CAR-28z-Ts and 
B7-H3.CAR-BBz-Ts effectively eliminated PDAC cells from the co-culture. Cytolytic 
activity was corroborated by cytokine release (IFNg and IL-2) in the culture supernatant 
(Fig. 3.3E, F), and by antigen-specific T-cell proliferation as assessed by CSFE dilution 
assay (Fig. 3.3G). PDAC-PDX tumor fragments were orthotopically implanted into the 
pancreas of NSG mice. We confirmed that PDAC-PDX retained the expression of B7-
H3 in vivo upon engraftment in NSG mice (Fig. 3.3H). Three weeks post-PDAC-PDX 
tumor implantation, mice received i.v. CD19.CAR-Ts, B7-H3.CAR-28z-Ts or B7-
H3.CAR-BBz-Ts. In the first PDAC-PDX model both B7-H3.CAR-28z-Ts and B7-
H3.CAR-BBz-Ts controlled tumor growth and eliminated the tumor in 2/5 mice in both 
groups by day 31 upon T cell infusion when the experiment was terminated because 
mice treated with CD19.CAR-Ts developed signs of graft-versus-mouse disease 
characterized by weight and fur loss and lethargy (Fig. 3.3I-J). In the second PDAC-
PDX model, sustained antitumor effect (>80 days) was observed without occurrence of 
graft-versus-mouse disease (Fig. 3.3K). 
B7-H3.CAR-Ts expressing 4-1BB have low expression of PD-1 and superior 
antitumor activity when targeting PDAC constitutively expressing PD-L1. In the 
xenograft models using the Panc-1 PDAC cell line, B7-H3.CAR-28z-Ts and B7-
H3.CAR-BBz-Ts showed comparable antitumor activity. To assess whether CD28 vs. 4-
1BB costimulation may have a different outcome in tumor re-challenge experiments, 
mice that cleared Panc-1 PDAC tumor cells upon infusion of B7-H3.CAR-28z-Ts and 
B7-H3.CAR-BBz-Ts were re-challenged with tumor cells (Fig. 3.4A). Both B7-H3.CAR-
28z-Ts and B7-H3.CAR-BBz-Ts had comparable and sustained antitumor activity (Fig. 
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3.4B-C), without showing significant differences in memory T cell subsets (Fig. S3.2A-
D). By contrast, circulating B7-H3.CAR-BBz-Ts were numerically more abundant than 
B7-H3.CAR-28z-Ts (Fig. 3.4D-F), and showed lower expression of PD-1 in CD8+ T 
cells, but not in CD4+ T cells (Fig. 3.4G-I and Fig. S3.2E). At later time points, B7-
H3.CAR-BBz-Ts also showed lower TIM3 expression (Fig. S3.2F, G). The lower 
expression of PD-1 in B7-H3.CAR-BBz-Ts was confirmed in vitro, when B7-H3.CAR-
28z-Ts and B7-H3.CAR-BBz-Ts were co-cultured with B7-H3+ target cells (Fig. 3.4J 
and Fig. S3.2H), indicating that B7-H3.CAR-BBz-Ts could be less susceptible to PD-L1 
mediated inhibition. We stressed the in vitro co-culture conditions by co-culturing B7-
H3.CAR-Ts with three PD-L1 negative (Panc-1, Capan-1 and AsPC-1) and two PD-L1 
positive (BxPC-3 and Panc-10.05) PDAC cells lines at very low T cells to tumor cells 
ratio (1 to 10). In these conditions, B7-H3.CAR-BBz-Ts showed a trend for better tumor 
elimination against the two PD-L1+ PDAC tumor cell lines (Fig. S3.2I, J). The superior 
antitumor activity of B7-H3.CAR-BBz-Ts versus B7-H3.CAR-28z-Ts in the presence of 
PD-L1 was more evident in vivo in mice engrafted with the PD-L1+ BxPC-3 tumor cell 
line (Fig. 3.4K-M).  
B7-H3.CAR-Ts show effective antitumor activity in OC and neuroblastoma (NB) 
xenograft models. Since B7-H3 is broadly expressed in multiple solid tumors, we 
investigated the antitumor effects of B7-H3.CAR-Ts in OC and NB models. Nineteen 
cryosectioned OC specimens mounted in a tumor microarray (TMA) were analyzed for 
the expression of B7-H3, and 90% stained positive with the 376.96 mAb, on both tumor 
cells and stroma (Fig. 3.5A and Fig. S3.3A-D). Three human OC cell lines (SW626, 
SK-OV-3 and CaoV-3) that expressed B7-H3 (Fig. 3.5B) were co-cultured with NT, B7-
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H3.CAR-28z-Ts or B7-H3.CAR-BBz-Ts at T cell to tumor cell ratio of 1 to 5. As shown in 
Fig. 3.5C-E, both B7-H3.CAR-28z-Ts and B7-H3.CAR-BBz-Ts effectively controlled the 
growth of OC cell lines and released cytokines in the culture supernatant. For the in vivo 
validation, the FFluc-transduced SK-OV-3 tumor cell line was inoculated 
intraperitoneally (i.p.) into NSG mice to create an intraperitoneal OC model. Two weeks 
post tumor injection, mice received CD19.CAR-Ts, B7-H3.CAR-28z-Ts or B7-H3.CAR-
BBz-Ts i.p. since this type of CAR-T delivery is currently considered in clinical trials 
(NCT02498912). As shown in Fig. 3.5F-H, B7-H3.CAR-Ts significantly controlled tumor 
growth and extended the overall survival. Antitumor activity of B7-H3.CAR-Ts was also 
observed when T cells were infused i.v. (Fig. S3.3E-G), although the i.p. inoculation 
was more effective. 
We then assessed the effects of B7-H3.CAR-Ts in NB. The cryosectioned human NB 
sample positively stained with the 376.96 mAb, as did four human NB cell lines (CHLA-
255, IMR-32, LAN-1 and SKNLP) (Fig. 3.5I, J). NB tumor cell lines were co-cultured 
with CD19.CAR-Ts, B7-H3.CAR-28z-Ts or B7-H3.CAR-BBz-Ts at T cell to tumor cell 
ratio of 1 to 5. As shown in Fig. 3.5K, B7-H3.CAR-Ts effectively controlled tumor cell 
growth. Cytolytic activity was corroborated by cytokine release in the co-culture 
supernatant (Fig. 3.5L, M). FFluc-transduced CHLA-255 tumor cells were infused i.v. 
into NSG mice to generate a metastatic NB model. To assess the dose effect of B7-
H3.CAR-Ts, two different doses of B7-H3.CAR-28z-Ts (2 × 106 and 5 × 106 
cells/mouse) were infused i.v. two weeks after tumor inoculation. B7-H3.CAR-28z-Ts 
controlled tumor growth as compared to mice treated with CD19.CAR-Ts, and the 
highest dose of T cells eliminated the tumor for more than 70 days (Fig. 3.5N-P).  
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B7-H3.CAR-Ts control tumor growth in immunocompetent mice without causing 
toxicity. We assessed the expression of B7-H3 in cryosectioned normal human TMA 
using the 376.96 mAb from which the B7-H3.CAR was derived. Slides were analyzed 
blindly by an experienced pathologist (Dr. Greene). Major organs such as heart, brain, 
lung, kidney and muscle are B7-H3 negative, while focal, weak to moderate B7-H3 
positive staining was observed in the cytoplasm of some normal human tissues (Fig. 
3.6 and Table S3.1). The highest expression was observed in the stomach, with 
moderate to strong staining of gastric epithelium, adrenal gland, with weak to moderate 
cytoplasmic staining, and salivary gland, with moderate to strong cytoplasmic staining of 
acinar epithelium. In order to develop a murine model to assess the potential toxicity of 
B7-H3.CAR-Ts, we evaluated if the 376.96 mAb cross-reacts with murine B7-H3 (mB7-
H3). As shown in Fig. S3.4A, human Raji cells engineered to express mB7-H3 were 
positively stained by the 376.96 mAb, indicating cross recognition of mB7-H3 by the 
376.96 mAb. mB7-H3 expressing Raji cells were eliminated by B7-H3.CAR-Ts and 
CD19.CAR-Ts in co-culture experiments (Fig. S3.4B, C). In addition, B7-H3.CAR-Ts 
and CD19.CAR-Ts released comparable level of IFNg and IL-2 (Fig. S3.4D, E), which 
demonstrates that B7-H3.CAR-Ts and CD19.CAR-Ts show similar activation when 
targeting mB7-H3 expressing Raji cells. We also measured directly the binding affinity 
of the 376.96 mAb to both human and murine B7-H3 proteins (Fig. S3.4F, G). Even if 
the binding affinity to mB7-H3 is lower compared to h2Ig-B7-H3, which is the human 
isoform closest to mB7-H3, B7-H3.CAR-Ts still released a significant amount of IFNg in 
response to 50 nM of mB7-H3 protein (Fig. S3.4H), indicating that an 
immunocompetent murine model may be informative concerning potential toxic effects 
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of B7-H3.CAR-Ts. We generated a murine version of the B7-H3.CAR by using the same 
scFv derived from the 376.96 mAb and replacing human signaling molecules with the 
murine CD28 and CD3ζ (mB7-H3.CAR) (Fig. S3.4I). Activated murine T cells were then 
transduced with this vector to express the CARs (Fig. S3.4J-L). A murine version of the 
mCD19-specific CAR was used as a control (mCD19.CAR) [266]. mB7-H3.CAR-Ts 
specifically targeted the murine PDAC cell line KPC-4662 engineered to express mB7-
H3 (Fig. 3.7A-D), and released cytokines (Fig. 3.7E, F). To ensure that the 376.96 mAb 
cross-reacts with the mB7-H3 endogenously expressed by murine cells, we evaluated 
the expression of B7-H3 in bone marrow derived dendritic cells (BMDCs) generated 
from C57BL/6J mice [234, 236]. While non-activated BMDCs had undetectable B7-H3 
expression, activation with LPS induced B7-H3 expression that was detected at 
comparable levels when the cells were stained with either the 376.96 mAb or another 
B7-H3 mAb [243] (Fig. 3.7G). To test whether LPS-activated BMDCs are targetable by 
mB7-H3.CAR-Ts, we co-cultured LPS-activated BMDCs with syngeneic NT, 
mCD19.CAR-Ts or mB-H3.CAR-Ts at 1 to 1 ratio. As shown in Fig. 3.7H, we observed 
very low or undetectable IFNg release by mB7-H3.CAR-Ts in response to activated 
BMDCs. We also assessed the expression of mB7-H3 in normal murine tissues and 
observed a similar distribution of B7-H3 as in human tissues (Fig. S3.5 and Table 
S3.2). To investigate the potential toxicities of mB7-H3.CAR-Ts in immunocompetent 
mice, non-tumor bearing six-week-old C57BL/6J mice were irradiated with 400 cGy, to 
create a lymphodepleted environment that favors the expansion of adoptively 
transferred T cells, and then infused i.v. with syngeneic control NT, mCD19.CAR-Ts or 
mB7-H3.CAR-Ts two days later. Five days post-T cell infusion mice receiving 
95 
mCD19.CAR-Ts showed B cell depletion, while no significant changes in blood cell 
counts and composition were observed in mice receiving mB7-H3.CAR-Ts (Fig. S3.6A, 
B). As clinical studies with adoptive transfer of CAR-Ts suggest that the maximal 
expansion mediated by CD28 costimulation and potentially lethal toxic effects occur 
within 2 - 3 weeks post T-cell infusion [230], mice were monitored for the ensuing 2 
weeks and then euthanized to assess organ toxicities. At the time of euthanasia, all 
mice were alive and healthy. Mice treated with mCD19.CAR-Ts showed persistent B 
cell depletion in blood, spleen, and bone marrow while mice treated with mB7-H3.CAR-
Ts did not show any decrease in cell counts (Fig. 3.7I-K). Similarly, no evident lesions 
or aberrant T lymphocyte infiltration were observed in tissue sections (Fig. S3.7 and 
Table S3.3). To rule out any effect due to the irradiation of the mice before the infusion 
of CAR-Ts, we also infused C57BL/6J mice with mB7-H3.CAR-Ts without irradiation. 
Mice euthanized and analyzed at day 11 after T-cell infusion did not show evident signs 
of toxicity (Fig. S3.6C-E). We further evaluated the effects of mB7-H3.CAR-Ts in tumor-
bearing mice. Briefly, 6-week-old C57BL/6J mice were orthotopically engrafted in the 
pancreas with the murine PDAC tumor cell line KPC-4662 modified to express mB7-H3. 
Seventeen days later, mice were irradiated with 400 cGy and then infused i.v. with 
syngeneic control NT or mB7-H3.CAR-Ts 2 days later (Fig. 3.8A). As shown in Fig. 
3.8B, C, mB7-H3.CAR-Ts controlled tumor growth for 4 weeks as assessed by 
ultrasound (US) measurement and tumor weight. When euthanized at day 33 – 34, 2/5 
control mice showed liver metastases in addition to the primary pancreatic tumor, while 
liver metastases were not observed in mB7-H3.CAR-Ts treated mice. At the time of 
euthanasia, in mice with tumor, we did observe a slight increase of T cell infiltration and 
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PD-1 expression at the tumor site in mB7-H3.CAR-Ts treated group compared to 
control mice (Fig. S3.8A-D). The molecular signal of mB7-H3.CAR was detectable in 
the spleen and tumor collected from mB7-H3.CAR-Ts treated mice but not in control 
mice (Fig. 3.8D,E). Mice treated with mB7-H3.CAR-Ts did not show any significant 
decrease of hematopoietic cell or immune cell counts in blood, spleen, bone marrow 
and lymph nodes, except for the decrease in monocyte counts in the peripheral blood 
(Fig. 3.8F, G and Fig. S3.8E, F), and no evident lesions were observed in tissue 
sections (Fig. 3.8H, Fig. S3.8G and Table S3.4). Overall, these results indicate that B7-
H3.CAR-Ts promote tumor control in tumor-bearing C57BL/6J mice without causing 
detectable organ toxicity. 
DISCUSSION 
 We investigated whether B7-H3 is a clinically relevant target for CAR-T-based 
immunotherapy in solid tumors. We found that B7-H3 is aberrantly expressed on the cell 
surface of PDAC, OC and NB, and that B7-H3.CAR-Ts effectively controlled tumor 
growth in orthotopic and metastatic xenografts and in PDAC-PDX models. The 
observed murine-human cross-reactivity of the 376.96 mAb from which the B7-H3.CAR 
was derived also allowed us to test the efficacy and safety of B7-H3.CAR-Ts in an 
immunocompetent mouse model. 
 The selection of appropriate target antigens in solid tumors remains challenging 
for the therapeutic development of safe and effective CAR-T-based therapies. Toxicities 
upon the infusion of CAR-Ts were observed when targeting molecules such as HER2 or 
CAIX as these molecules are expressed in some normal tissues [271-273]. On the other 
hand, the therapeutic activity of CAR-Ts can be limited due to the rapid tumor escape 
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when the targeted antigen shows heterogeneous expression within the tumor, as 
recently reported in patients with glioblastoma treated with CAR-Ts specific for 
EGFRvIII [274]. While the intratumor heterogenic expression of the targeted antigen can 
potentially be resolved by targeting multiple antigens, toxicities related to recognition of 
antigen expressed by normal tissues remains a major concern. Increasing evidence 
suggests that intrinsic characteristics of CAR molecules, such as the epitope recognized 
by the CAR and the affinity of the mAb from which the CAR is derived, may play a 
significant role in discriminating antigen recognition in normal versus malignant cells. 
For instance, two clinical studies targeting HER2 with CAR-Ts derived from two distinct 
mAbs showed different safety profiles [271, 275, 276]. Similarly, different mAbs 
targeting the same ROR1 antigen, another target evaluated for CAR-T-based therapy, 
showed different pattern of expression in normal tissues [277-279]. 
 Targeting B7-H3 with the B7-H3.CAR derived from the 376.96 mAb addresses 
critical hurdles to the clinical development of CAR-Ts against solid tumors. The 376.96 
mAb captures B7-H3 expression in several human malignancies and tumor cell lines, 
recapitulating the high expression of B7-H3 previously reported in solid tumors [244, 
246]. In our experiments, B7-H3.CAR-Ts derived from the 376.96 mAb showed 
significant antitumor activity in multiple xenografts of solid tumors indicating the high 
potential for clinical translation of B7-H3.CAR-Ts if these cells do not cause on target 
but off tumor toxicity. To assess this critical point we used the 376.96 mAb to stain 
normal human tissues and we observed focal cytoplasmic expression on endothelial 
cells of normal tissues and areas of high expression in a restricted array of tissues like 
stomach, adrenal gland and salivary gland. Other reports showed similar pattern of B7-
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H3 expression in normal tissues using other monoclonal Abs [243, 280]. Our 
immunohistochemistry analysis of normal murine tissues also showed a conserved 
pattern of B7-H3 expression between human and murine tissues. We took advantage of 
the observed cross-reactivity of the 376.96 Ab with murine B7-H3 to perform toxicology 
and efficacy studies in immunocompetent mice. We have found control of tumor growth 
without modifications of the immune cell and hematopoietic cell counts with the 
exception of monocytes in the peripheral blood, and no evidence of tissue damage. 
Despite the fact that the binding affinity of the 376.96 mAb to mB7-H3 is inferior to the 
binding affinity of the human 2IgB7-H3, the considerable amount of IFNg released by 
B7-H3.CAR-Ts exposed to 50 nM of recombinant mB7-H3 ensures that at least major 
toxic effects due to B7-H3.CAR-Ts should be captured in immunocompetent mice. Our 
observed lack of on target off tumor toxicity of B7-H3.CAR-Ts in immunocompetent 
mice may be due to the lower density of mB7-H3 in normal tissues as compared to 
tumor cells as illustrated in our experiments using clones expressing different levels of 
human B7-H3 and in murine BMDCs, and as previously reported for other CARs [281]. 
Consistent with our observation, the B7-H3 specific PBD-linked m276 mAb showed 
antitumor activity in xenograft mouse models targeting both tumor cells and tumor-
associated vasculatures, without overt toxicity [243, 255, 256]. Although different 
expression profile of B7-H3 in murine and human normal tissues remains a possibility, 
toxicology studies of an Fc-enhanced B7-H3 Ab carried out in cynomolgus monkeys 
also revealed no significant toxicities [255]. Furthermore, in a clinical study in which the 
131I-conjugated B7-H3 Ab was administered to patients with metastatic NB, no toxicity 
was encountered [258]. Finally, the clinical translation of B7-H3.CAR-Ts may be further 
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safely conducted by using either transient expression of the B7-H3.CAR in T cells as 
achieved using mRNA electroporation [282] or by further modifying B7-H3.CAR-Ts to 
include the inducible caspase9 safety switch, that provides an extra safeguard ensuring 
the rapid elimination of CAR-Ts in case of toxicities [283, 284]. 
 The optimal costimulation for CAR-Ts especially in solid tumors remains a matter 
of significant discussion. It is likely that CAR costimulation needs to be adapted to 
specific target antigens, tumor cell type and tumor microenvironment. In our study, we 
systematically compared CD28 versus 4-1BB costimulation in either orthotopic or 
metastatic PDAC models. We did not find significant differences at least in our model 
using the Panc-1 PDAC cancer cell line. In particular, phenotypic analysis in vivo did not 
show significant differences of effector versus memory T cells in mice treated with B7-
H3.CAR-Ts expressing CD28 or 4-1BB. However, 4-1BB costimulation preserved CD8+ 
T cells with lower expression of PD-1 both in vitro and in vivo, and when PDAC cell lines 
constitutively express PD-L1, B7-H3.CAR-BBz-Ts showed better antitumor activity as 
compared to B7-H3.CAR-28z-Ts. Finally, the desmoplastic nature of solid tumors in 
general and PDAC in particular impairs trafficking, penetration and survival of CAR-Ts 
[231]. PDAC-PDX tumors are characterized by stroma fibrosis that mirrors the donor 
tumor [285]. We tested B7-H3.CAR-Ts in PDAC-PDX models and found significant 
antitumor activity, although tumors were not always eradicated. Furthermore, B7-
H3.CAR-Ts controlled PDAC tumor growth in immunocompetent mice, but did not 
eradicate the tumor and showed limited persistence within the tumor suggesting that the 
activity of CAR-Ts in solid tumors should be further augmented using additional T cell 
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engineering and combination with chemotherapy, irradiation, small molecules or other 
biological agents [81, 286]. 
 In summary, we developed B7-H3.CAR-Ts that control the tumor growth of 
PDAC, NB and OC in xenograft models. B7-H3.CAR-Ts did not cause evident toxicity in 
either NSG or immunocompetent mice further encouraging their clinical application in 
difficult to treat solid tumors.  
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Figure 3. 1. B7-H3.CAR-Ts target B7-H3+ PDAC cells.  
(A) Representative micrographs of B7-H3 expression in PDAC assessed by staining 
with the 376.96 mAb at the final concentration of 1 µg/mL. Slides stained only with the 
secondary Ab were used as a negative control. Scale bars are 200 µm. (B) Expression 
of B7-H3 in five human PDAC cell lines stained with the 376.96 mAb as assessed by 
flow cytometry. (C and D) PDAC cell lines labelled with GFP were co-cultured with NT, 
B7-H3.CAR-28ζ-Ts or B7-H3.CAR-BBζ-Ts at the T cell to tumor cell ratio of 1 to 5. On 
day 5, PDAC (GFP+) and B7-H3.CAR-Ts (CD3+) were enumerated by flow cytometry. 
Representative flow cytometry plots (C) and quantification of residual tumor cells (D) are 
illustrated. Error bars denote SD. (E and F) Summary of IFNg (E) and IL-2 (F) released 
by NT, B7-H3.CAR-28ζ-Ts and B7-H3.CAR-BBζ-Ts in the culture supernatant after 24 
hours of co-culture with the indicated cell lines as measured by ELISA (n = 4). Error 
bars denote SD. (G) The Raji cell line was engineered to express h4Ig-B7-H3 via 
retroviral gene transfer. Cells were sorted based on different expression level of 4Ig-B7-
H3, and single clones were expanded. B7-H3 expression of the clones was assessed 
by staining with the 376.96 mAb and analyzed by flow cytometry. (H and I) 
Representative flow cytometry plots of Raji cells (CD4-CD8-) and T cells (CD4+ or 
CD8+) (H) and summary of residual tumor cells (I) five days after Raji WT and Raji 4Ig-
B7-H3 clones were co-cultured with NT, CD19.CAR-Ts, B7-H3.CAR-28ζ-Ts or B7-
H3.CAR-BBζ-Ts at 1 to 1 ratio (n = 5). Error bars denote SD, **p < 0.01, one-way 
ANOVA with Holm-Sidak test adjusted p value. See also Figure S1.  
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Figure 3. 2. B7-H3.CAR-Ts control PDAC growth in xenograft models. 
(A) Schema of the PDAC orthotopic xenograft model infused with CAR-Ts on day 12 
after tumor inoculation. (B) Representative bioluminescence images of FFluc-Panc-1 
tumor growth in the PDAC orthotopic model shown in A. (C) Representative ultrasound 
(US) imaging measurement of the FFluc-Panc-1 tumor on day 50 after tumor 
implantation in mice treated with CD19.CAR-Ts in the PDAC orthotopic model shown in 
A. The arrow indicates the tumor. Dimensions of the tumor were 6.85 x 5.85 mm. (D) 
Bioluminescence kinetics of FFluc-Panc-1 tumor growth (5 mice/group) in the PDAC 
orthotopic model in A. (E) Schema of the PDAC orthotopic xenograft model infused with 
CAR-Ts on day 28 after tumor inoculation. (F and G) Representative bioluminescence 
images (F) and bioluminescence kinetics (G) of FFluc-Panc-1 tumor growth (5 
mice/group) in the PDAC orthotopic model in E. (H) Schema of the PDAC metastatic 
model. (I and J) Representative bioluminescence images (I) and bioluminescence 
kinetics (J) of FFluc-Panc-1 cell growth in the PDAC metastatic model (5 mice/group) in 
H. (K) T cells in the blood, spleens and bone marrow from mice in the PDAC metastatic 
model in H euthanized 100 days after CAR-T infusion were identified by the expression 
of CD45 and CD3 by flow cytometry (5 mice/group). Days indicated in B, F and I 
represent days post-T cell infusion. The horizontal bars in K represent the mean values. 
Error bars denote SD, ***p < 0.0001, Chi-square test.   
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Figure 3. 3. B7-H3.CAR-Ts target patient-derived PDAC in vitro and in vivo. 
(A) Representative flow plots showing B7-H3 expression in early passages of three 
primary PDAC cell lines established from ascites of three PDAC patients and stained 
with the 376.96 mAb. (B) The primary PDAC cell lines were labelled with GFP and co-
cultured with NT, B7-H3.CAR-28ζ-Ts or B7-H3.CAR-BBζ-Ts at the T cell to PDAC ratio 
of 1 to 5. On day 5, tumor cells (GFP+) and T cells (CD3+) were enumerated by flow 
cytometry. (C and D) Summary of residual tumor cells after the co-culture of NT, B7-
H3.CAR-28ζ-Ts and B7-H3.CAR-BBζ-Ts with the primary PDAC cell lines at T cell to 
tumor cell ratios of 1 to 5 (C) (on day 5, n = 6) and of 1 to 10 (D) (on day 7, n = 4). Error 
bars denote SD. (E and F) Summary of IFNγ (E) and IL-2 (F) released in the culture 
supernatant by NT, B7-H3.CAR-28ζ-Ts and B7-H3.CAR-BBζ-Ts after 24 hours of co-
culture with the primary PDAC cell lines as measured by ELISA (n = 4). Error bars 
denote SD. (G) CFSE dilution of CFSE-labeled B7-H3.CAR-28ζ-Ts and B7-H3.CAR-
BBζ-Ts co-cultured with the primary PDAC cell lines for 5 days at 1 to 1 ratio analyzed 
by flow cytometry. CFSE-labeled T cells alone were used as control. (H) Representative 
micrographs of B7-H3 expression in PDAC-PDX engrafted into the pancreas of NSG 
mice assessed by staining with the 376.96 mAb at the final concentration of 1 µg/mL. 
Slides stained only with the secondary Ab were used as a negative control. Scale bars 
are 200 µm. (I-K) Representative ultrasound (US) images of tumors (dotted circles 
marked the tumors) (I) and summary of the tumor volumes measured by US imaging in 
the first (J) and the second (K) experiment of the PDAC-PDX xenograft model (5 
mice/group in each experiment). Error bars denote SD. Scale bars are 5 mm.  
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Figure 3. 4. 4-1BB co-stimulation promotes low expression of PD-1 and better  
anti-tumor activity against PDAC tumor cells constitutively expressing PD-L1. 
(A) Schema of the Panc-1 tumor re-challenge model in which mice were re-challenged 
with tumor cells at day 28, 49 and 63 after CAR-Ts infusion. (B and C) Representative 
bioluminescence images (B) and bioluminescence kinetics (C) of the FFluc-Panc-1 
tumor growth in the model shown in A (5 mice/group). (D-I) Circulating CAR-Ts 
(CD45+CD3+) (D-F) and PD-1 expression in CAR-Ts (G-I) in mice 22 days (D and G), 
48 days (E and H), and 63 days (F and I) after CAR-Ts infusion were examined by flow 
cytometry (n = 5). *p < 0.05, **p < 0.01, unpaired and nonparametric Mann Whitney test 
with two tailed p value calculation. (J) PD-1 expression in B7-H3.CAR-28ζ-Ts and B7-
H3.CAR-BBζ-Ts co-cultured with 2Ig-B7-H3+ Raji cells at the T cell to tumor cell ratio of 
1 to 1 was analyzed daily from day 1 to day 7 (n = 8). Error bars denote SD, *p < 0.05, 
***p < 0.001, unpaired and nonparametric Mann Whitney test with two tailed p value 
calculation. (K and L). NSG mice were engrafted with the FFluc-BxPC-3 PDAC tumor 
cell line that constitutively expresses PD-L1 and infused with CAR-Ts on day 14 after 
tumor inoculation. Representative bioluminescence (K) and bioluminescence kinetics 
(L) of the FFluc-BxPC-3 PDAC tumor cell line (5 mice/group). (M) Kaplan-Meier survival 
curve of mice in (K) (5 mice/group), *p = 0.0158 (B7-H3.CAR-28ζ vs B7-H3.CAR-BBζ), 
**p = 0.0039 (CD19.CAR-28ζ vs B7-H3.CAR-28ζ), Chi-square test. In this model for the 
survival curve, mice were censored when the luciferase signal reached 3.5 × 
109 photons per second. Days indicated in B and K represent the days post-T cell 
infusion. The horizontal bars in D-I represent the mean values. See also Figure S2.  
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Figure 3. 5. B7-H3.CAR-Ts target B7-H3+ OC and NB cancer cells both in vitro and  
in vivo. 
(A) Representative micrographs of B7-H3 expression in normal ovary and OC assessed 
by staining with the 376.96 mAb at the final concentration of 1 µg/mL. Scale bars are 
200 µm. (B) Expression of B7-H3 in three human OC cell lines assessed by flow 
cytometry after staining with the 376.96 mAb. (C) Summary of residual tumor cells in the 
culture on day 5 of co-culture of NT, B7-H3.CAR-28ζ-Ts and B7-H3.CAR-BBζ-Ts with 
OC cell lines at T cell to tumor cell ratio of 1 to 5 (n = 5). Error bars denote SD. (D and 
E) Summary of IFNγ (D) and IL-2 (E) released by NT, B7-H3.CAR-28ζ-Ts and B7-
H3.CAR-BBζ-Ts in the co-culture supernatant collected after 24 hours and measured by 
ELISA (n = 5). Error bars denote SD. (F and G) Representative bioluminescence 
images (F) and bioluminescence kinetics (G) of FFluc-SK-OV-3 tumor growth upon i.p. 
inoculation into NSG mice (5 × 105 cells/mouse) and treatment 14 days later with i.p. 
inoculation of CD19.CAR-Ts, B7-H3.CAR-28ζ-Ts and B7-H3.CAR-BBζ-Ts (5 × 106 
cells/mouse). Error bars denote SD, ***p < 0.0001, Chi-square test. (H) Kaplan-Meier 
survival curve of mice developing OC (5 mice/group), **p = 0.0091, Chi-square test. (I) 
Representative micrographs of B7-H3 expression in NB assessed by staining with the 
376.96 mAb at the final concentration of 1 µg/mL. Scale bars are 200 µm. (J) 
Expression of B7-H3 in human NB tumor cell lines stained with the 376.96 mAb and 
assessed by flow cytometry. (K) Summary of residual tumor cells in the culture on day 5 
of co-culture of NT, B7-H3.CAR-28ζ-Ts and B7-H3.CAR-BBζ-Ts with NB tumor cell 
lines at T cell to tumor cell ratio of 1 to 5 (n = 8). Error bars denote SD. (L and M) 
Summary of IFNγ (L) and IL-2 (M) released by NT, B7-H3.CAR-28ζ-Ts and B7-H3.CAR-
BBζ-Ts in the co-culture supernatant collected after 24 hours and measured by ELISA 
112 
(n = 8). Error bars denote SD. (N and O) Representative bioluminescence images (N) 
and kinetics of the bioluminescence (O) of the FFluc-CHLA-255 tumor growth upon 
injection i.v. into NSG mice (2 × 106 cells/mouse) and infusion i.v. with CD19.CAR-Ts (5 
× 106 cells/mouse) or B7-H3.CAR-28ζ-Ts (2 × 106 or 5 × 106 cells/mouse) 14 days later 
(5 mice/group). Error bars denote SD, ***p < 0.0001, Chi-square test. (P) Kaplan-Meier 
survival curve of mice developing metastatic NB (5 mice/group), **p = 0.0035 
(CD19.CAR-28ζ vs B7-H3.CAR-28ζ), **p = 0.0018 (B7-H3.CAR-28ζ vs B7-H3.CAR-
BBζ), Chi-square test. Days indicated in F and N represent the days post-T cell infusion. 
See also Figure S3.  
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Figure 3. 6. Pattern of B7-H3 expression in normal human tissues. 
(A and B) Representative micrographs of B7-H3 expression in PDAC (A) and in 
indicated normal human organs (B) assessed by staining with the 376.96 mAb at the 
final concentration of 1 µg/mL. Slides stained only with the secondary Ab were used as 
a negative control. Black boxes indicate three fold zoomed in cutout. Micrographs are 
representative of at least three sections per tissue. Scale bars are 200 µm. (C) 
Summary of the positive score of B7-H3 in human normal tissues. Dotted line indicates 
the background level of the staining. Error bars denote SD. See also Table S1.  
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Figure 3. 7. B7-H3.CAR-Ts do not cause loss of cell subsets in the blood, bone 
marrow, spleen and lymph nodes in immunocompetent mice. 
(A) Representative flow plots illustrating mB7-H3 expression in the WT murine PDAC 
cell line KPC-4662 and the same cell line engineered to express mB7-H3 via retroviral 
gene transfer (mB7-H3-Tg). WT and mB7-H3-Tg KPC-4662 cells were stained with the 
376.96 mAb (B) Representative flow cytometry plots of WT and mB7-H3-Tg KPC-4662 
cells five days after co-cultured with murine non-transduced T cells (NT), mCD19.CAR-
Ts or mB7-H3.CAR-Ts at T cell to tumor cell ratio of 1 to 2. WT and mB7-H3-Tg KPC-
4662 cells were identified by SSC-A and B7-H3 expression, respectively. (C and D) 
Summary of residual WT KPC-4662 cells (C) and mB7-H3-Tg KPC-4662 cells (D) in the 
co-culture experiments in B (n ≥ 3). **** p < 0.0001, one-way ANOVA with Holm-Sidak 
test adjusted p value. (E and F) IFNγ (E) and IL-2 (F) released by NT, mCD19.CAR-Ts, 
and B7-H3.CAR-Ts after 24 hours in the co-culture experiments in B as measured by 
ELISA (n = 3). Error bars denote SD. (G) Murine bone marrow derived dendritic cells 
(BMDCs) treated without or with 100 ng/mL LPS for two days were stained with the 
376.96 mAb or the EPNCIR122 mAb, and the expression of mB7-H3 was assessed by 
flow cytometry. (H) IFNg released by NT, mCD19.CAR-Ts, and mB7-H3.CAR-Ts after 
24 hours of co-culture with BMDCs treated without or with 100 ng/mL LPS for 2 days at 
T cell to target cell ratio of 1 to 1 as measured by ELISA (n = 3). Error bars denote SD. 
(I-K) C57BL/6 mice were irradiated with 400 cGy and 2 days later infused i.v. with 
syngeneic NT, mCD19.CAR-Ts or mB7-H3.CAR-Ts (1 × 107 cells/mouse). Mice were 
euthanized 15 - 16 days post-T cell infusion to analyze the immune cell composition of 
the blood (I), spleens (J), and bone marrow (K) by flow cytometry (5 mice/group), *p < 
117 
0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, one-way ANOVA with Holm-Sidak test 
adjusted p value. The horizontal bars in C, D and I-K represent the mean values. See 
also Figures S4-7 and Tables S2 and S3.  
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Figure 3. 8. B7-H3.CAR-Ts control tumor growth in immunocompetent mice 
without causing evident toxicity. 
(A) Schema of the murine PDAC orthotopic xenograft model. (B) Summary of the tumor 
volume measured by US imaging (n = 5 per group). Error bars denote SD, *p = 0.0476 
(day 9) and *p = 0.0278 (day 28), unpaired and nonparametric Mann Whitney test with 
two tailed p value calculation. (C) Summary of the tumor weight at the end of the 
experiment (day 33 - 34 after T cell infusion) (n = 5 per group), *p = 0.0157, unpaired 
and nonparametric Mann Whitney test with two tailed p value calculation. (D and E) 
Quantification of mB7-H3.CAR copy numbers by qPCR to evaluate CAR-Ts persistence 
in the spleens (D) and tumors (E) at the end of the experiment (day 33 - 34 after T cell 
infusion). (F and G) Cell subset composition of the blood (F) and spleens (G) was 
analyzed by flow cytometry (n = 5 per group), *p = 0.0159, unpaired and nonparametric 
Mann Whitney test with two tailed p value calculation. (H) Tissue pathology of the 
indicated organs was evaluated by hematoxylin and eosin staining at the end of the 
experiment (day 33 - 34 after T cell infusion). Scale bars are 200 mM. The horizontal 
bars in C-G represent the mean values. See also Figure S8 and Table S4.   
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SUPPLEMENTARY FIGURES 
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Supplementary Figure 3. 1. (Corresponds with Figure 3. 1) Characteristics and 
specificity of B7-H3.CAR-Ts. (A and B) Representative micrographs of the B7-H3 
expression in PDAC assessed by staining with the 376.96 mAb used at the final 
concentration of 1 µg/mL and showing tumor cell (A) and tumor-associated stroma (B) 
staining ranked as low (+), moderate (++), or high (+++). Scale bars are 200 µm. (C) 
Summary of the B7-H3 positivity in PDAC (n = 19). (D) Schematic structure of the 
retroviral vectors SFG encoding the B7-H3.CARs including either CD28 (B7-H3.CAR-
28ζ) or 4-1BB (B7-H3.CAR-BBζ) co-stimulatory domains. (E) Representative expression 
of the B7-H3.CARs in transduced human T cells. CAR expression was detected using 
the fusion protein 2Ig-B7-H3-GFP or the Fab Ab, and analyzed by flow cytometry. NT 
indicates non transduced T cells. (F) Summary of the B7-H3.CAR-28ζ and B7-H3.CAR-
BBζ transduction efficiency (n = 21). The horizontal bars represent the mean values. (G) 
Expansion kinetics of NT, B7-H3.CAR-28ζ-Ts and B7-H3.CAR-BBζ-Ts in vitro (n = 5). 
Error bars denote SD, *p = 0.0234, ****p < 0.0001, two-way ANOVA with Holm-Sidak 
test adjusted p value. (H and I) Phenotypic analysis of CAR-Ts at 12 days post 
transduction showing the frequency of stem cell memory T cells (Tscm, 
CD45RA+CCR7+), central memory T cells (Tcm, CD45RA-CCR7+), effector memory T 
cells (Tem, CD45RA-CCR7-), and effector T cells (Teff, CD45RA+CCR7-) in CD4+ T 
cells (H) and in CD8+ T cells (I) (n = 4). Error bars denote SD. (J) The B7-H3- human 
lymphoma cell line Raji was genetically modified to express the two human B7-H3 
isoforms (2Ig-B7-H3 and 4Ig-B7-H3) via retroviral gene transfer, and detected with the 
376.96 mAb. (K and L) Representative flow cytometry plots of WT, 2Ig-hB7-H3+ and 
4Ig-hB7-H3+ Raji cells (CD19+) co-cultured with NT, CD19.CAR-Ts, B7-H3.CAR-28ζ-Ts 
122 
or B7-H3.CAR-BBζ-Ts (CD3+) (at 1 to 1 ratio) for 5 days (K) and summary (L) (n = 4). 
Error bars denote SD. (M and N) Summary of IFNg (M) and IL-2 (N) released by CAR-
Ts after 24 hours of co-culture as measured by ELISA (n = 4). Error bars denote SD. 
(O) CFSE dilution of CFSE-labeled B7-H3.CAR-28ζ-Ts and B7-H3.CAR-BBζ-Ts co-
cultured with PDAC tumor cell lines for 5 days at 1 to 1 ratio. CFSE-labeled T cells 
alone were used as control.  
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Supplementary Figure 3. 2. (Corresponds with Figure 3. 4) Phenotypic 
characterization of B7-H3.CAR-Ts in vivo in the Panc-1 tumor re-challenge mouse 
model. (A-D) Representative flow plot gating strategy (A) and frequency of human 
CD45RA+CCR7+, CD45RA-CCR7+, CCR7-CD28+CD27+, CCR7-CD28+CD27-, CCR7-
CD28-CD27+ and CCR7-CD28-CD27- in CD4+ and CD8+ T cells on day 22 (B), 48 (C) 
and 63 (D) after CAR-Ts infusion in the Panc-1 tumor re-challenge mouse model (n = 
5). Error bars denote SD. (E and F) The percentage of PD-1+ (E) and TIM3+ (F) cells in 
CD4+ CAR-Ts (n = 5). *p = 0.0238, **p = 0.0079, unpaired and nonparametric Mann 
Whitney test with two tailed p value calculation. (G) The percentage of TIM3+ cells in 
CD8+ CAR-Ts (n = 5). *p = 0.0159, **p = 0.0079, unpaired and nonparametric Mann 
Whitney test with two tailed p value calculation. (H) Representative flow plots of PD-1 
expression in B7-H3.CAR-28ζ-Ts and B7-H3.CAR-BBζ-Ts co-cultured with 2Ig-B7-H3+ 
Raji cells (ratio of 1 to 1) for 5 days. (I) Representative flow plots of PD-L1 expression in 
PDAC tumor cell lines. (J) Summary of residual tumor cells in the co-culture of PDAC 
cell lines (GFP+) co-cultured with NT, B7-H3.CAR-28ζ-Ts or B7-H3.CAR-BBζ-Ts at the 
T cell to tumor cell ratio of 1 to 10 for 7 days (n = 4). Error bars denote SD. The 
horizontal bars in E-G represent the mean values.   
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Figure S3. (Related to Figure 5) Targeting B7-H3+ OC with B7-H3.CAR-Ts. (A and B) Representative micrographs of B7-H3
expression in OC assessed by staining with the 376.96 mAb at the final concentration of 1 μg/mL and showing tumor cell (A) and tumor-
associated stroma (B) staining ranked as low (+), moderate (++), or high (+++). Scale bars are 200 μm. (C) Summary of B7-H3 positivity in
OC specimens (n = 18). (D) Summary of the B7-H3 expression in OC in specimens collected from patients with different stage of the
disease. The horizontal bars represent the mean values. (E) Representative bioluminescence images of FFluc-SK-OV-3 tumor growth in
the OC intraperitoneal xenograft model obtained by inoculating 5×105 cells/mouse in female NSG mice and intravenous inoculation of
CAR-T cells 14 days later. (F and G) Ffluc-SK-OV-3 bioluminescence kinetics (F) and Kaplan-Meier survival curve (G) of the model in E. In























































Supplementary Figure 3. 3. (Corresponds with Figure 3. 5) Targeting B7-H3+ OC 
with B7-H3.CAR-Ts.  (A and B) Representative micrographs of B7-H3 expression in 
OC assessed by staining with the 376.96 mAb at the final concentration of 1 µg/mL and 
showing tumor cell (A) and tumor-associated stroma (B) staining ranked as low (+), 
moderate (++), or high (+++). Scale bars are 200 µm. (C) Summary of B7-H3 positivity 
in OC specimens (n = 18). (D) Summary of the B7-H3 expression in OC in specimens 
collected from patients with different stage of the disease. The horizontal bars represent 
the mean values. (E) Representative bioluminescence images of FFluc-SK-OV-3 tumor 
growth in the OC intraperitoneal xenograft model obtained by inoculating 5×105 
cells/mouse in female NSG mice and intravenous inoculation of CAR-T cells 14 days 
later. (F and G) Ffluc-SK-OV-3 bioluminescence kinetics (F) and Kaplan-Meier survival 
curve (G) of the model in E. In F error bars denote SD, ***p < 0.0001 in F and ***p = 
0.0004 in G, Chi-square test (8 mice/group from 2 independent experiments).   
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Supplementary Table 3. 1






Lung Negative Weak staining of macrophages; weak cytoplasmic staining in alveolar 
septum stroma
0.6±0.4 (3)
Heart Negative Weak cytoplasmic staining of blood vessel walls 0.9±0.2 (3)
Kidney Negative Focal weak cytoplasmic stromal staining 1.1±0.2 (3)
Skeletal muscle Negative Weak cytoplasmic staining of blood vessel 0.9±0.5 (6)
Cerebrum Negative Weak cytoplasmic staining of blood vessel walls 0.4±0.3 (3)
Cerebellum Negative Weak cytoplasmic staining of molecular layer 1.4±0.6 (3)
Spinal cord Negative No staining identified 0.2±0.0 (3)
Peripheral nerve Negative Weak cytoplasmic staining of blood vessel walls 0.8±0.1 (3)
Smooth muscle Negative Focal weak cytoplasmic staining of smooth muscle 2.3±0.6 (3)
Spleen Weak positive Focal weak cytoplasmic staining of red pulp and white pulp 8.4±6.0 (3)
Lymph node Negative Focal weak to moderate cytoplasmic staining of lymphoid cells 4.9±0.3 (3)
Esophagus Positive Weak to moderate staining of basal squamous layer, stroma, and 
submucosal glands
4.8±2.2 (3)
Ovary Weak positive Focal weak cytoplasmic staining of ovarian stroma 3.6±2.8 (3)
Ureter Weak positive Weak cytoplasmic staining of urothelium 3.5±3.1 (3)
Uterine cervix Weak positive Weak cytoplasmic staining of basal squamous layer 3.0±1.2 (3)
Thyroid gland Negative Suspicious for focal weak cytoplasmic staining of thyroid epithelium 6.2±2.2 (3)
Small intestine Positive Weak to moderate cytoplasmic staining of epithelium and stroma 7.7±6.2 (3)
Pancreas Positive Moderate cytoplasmic and membranous staining of acinar epithelium 21.8±7.9 (2)
Liver Positive Weak to moderate cytoplasmic and membranous staining of 
hepatocytes
27.5±0.2 (2)
Colon Positive Moderate to strong cytoplasmic staining of epithelium and stroma 29±9.6 (3)
Stomach positive Moderate to strong cytoplasmic staining of gastric epithelium (favor 
parietal cells)
27±8.7 (3)
Placenta Positive Focal weak to moderate cytoplasmic staining of cytotrophoblasts and 
syncytiotrophoblasts
31±12 (3)
Testis Positive Focal weak cytoplasmic staining of seminiferous tubule epithelium; 
moderate to strong stromal staining
18.6±5.9 (3)
Prostate Positive Strong cytoplasmic staining of epithelium 25±15 (6)
Skin Weak positive Weak cytoplasmic staining of basal keratinocytes 6.5±1.9 (3)
Pituitary gland Weak positive Weak to moderate cytoplasmic staining of pituitary gland epithelium 11±11 (2)
Adrenal gland  Positive Weak to moderate cytoplasmic staining (possibly of adrenal cortex) 37±3.3 (3)
Salivary gland Positive Moderate to strong cytoplasmic staining of acinar epithelium 35±31 (3)
Pancreatic 
cancer
Positive Tumor cell and tumor associated stroma fibroblasts 111±25 (19)
Ovarian cancer Positive Tumor cell and tumor associated stroma fibroblasts 92±33 (19)
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Supplementary Table 3. 1. (Corresponds with Figure 3. 6) Summary of B7-H3 
expression in normal human tissues.  
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Figure S4. (Related to Figure 7) The scFv 376.96 Ab-derived CAR cross-reacts with murine B7-H3. (A) Representative flow plot 
illustrating the expression of the murine isoform of B7-H3 (mB7-H3) in the human lymphoma tumor cell line Raji engineered to express 
mB7-H3 via retroviral gene transfer. (B and C) Representative flow cytometry plots (B) and summary (C) of WT and mB7-H3+ Raji cells 
(CD19+) co-cultured with NT, B7-H3.CAR-28ζ-Ts or B7-H3.CAR-BBζ-Ts (CD3+) (T cell to tumor cell ratio 1:1) for 5 days. Error bars 
denote SD (n = 4). (D and E) Summary of IFNγ (D) and IL-2 (E) released by CAR-Ts in the culture supernatant after 24 hours of co-
culture as measured by ELISA (n = 4). Error bars denote SD. (F and G) Binding affinity of the 376.96 mAb for human and murine B7-
H3 (F) and the KD (G). Error bars denote SD (n = 3). (H) IFNγ release by B7-H3.CAR-Ts (2 x 105 cells) cultured in plates coated with 
the fusion proteins h4Ig-B7-H3-Fc, h2Ig-B7-H3-Fc or mB7-H3-Fc for 24 hours. Error bars denote SD (n = 4). (I) Schematic structure of 
the murine CD19.CAR (mCD19.CAR) that specifically targets murine CD19, and the murine version of B7-H3.CAR (mB7-H3.CAR) in 
which the scFv 376.96 is fused with murine CD28 and ζ chain signaling domains. TM: transmembrane domain, and ICD: intracellular 
domain. (J-L) Representative flow plots of the mCD19.CAR (J) and mB7-H3.CAR (K) expression in murine T cell and summary (L) of 
transduced murine T cells. mCD19.CAR and mB7-H3.CAR expression in T cells was detected using the Fab Ab and the fusion protein 
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Supplementary Figure 3. 4. (Corresponds with Figure 3. 7) The scFv 376.96 Ab-
derived CAR cross-reacts with murine B7-H3. (A) Representative flow plot illustrating 
the expression of the murine isoform of B7-H3 (mB7-H3) in the human lymphoma tumor 
cell line Raji engineered to express mB7-H3 via retroviral gene transfer. (B and C) 
Representative flow cytometry plots (B) and summary (C) of WT and mB7-H3+ Raji cells 
(CD19+) co-cultured with NT, B7-H3.CAR-28ζ-Ts or B7-H3.CAR-BBζ-Ts (CD3+) (T cell 
to tumor cell ratio 1:1) for 5 days. Error bars denote SD (n = 4). (D and E) Summary of 
IFNg (D) and IL-2 (E) released by CAR-Ts in the culture supernatant after 24 hours of 
co-culture as measured by ELISA (n = 4). Error bars denote SD. (F and G) Binding 
affinity of the 376.96 mAb for human and murine B7-H3 (F) and the KD (G). Error bars 
denote SD (n = 3). (H) IFNγ release by B7-H3.CAR-Ts (2 x 105 cells) cultured in plates 
coated with the fusion proteins h4Ig-B7-H3-Fc, h2Ig-B7-H3-Fc or mB7-H3-Fc for 24 
hours. Error bars denote SD (n = 4). (I) Schematic structure of the murine CD19.CAR 
(mCD19.CAR) that specifically targets murine CD19, and the murine version of B7-
H3.CAR (mB7-H3.CAR) in which the scFv 376.96 is fused with murine CD28 and z 
chain signaling domains. TM: transmembrane domain, and ICD: intracellular domain. (J-
L) Representative flow plots of the mCD19.CAR (J) and mB7-H3.CAR (K) expression in 
murine T cell and summary (L) of transduced murine T cells. mCD19.CAR and mB7-
H3.CAR expression in T cells was detected using the Fab Ab and the fusion protein 2Ig-
B7-H3-GFP, respectively (n ≥ 3). The horizontal bars represent the mean values.   
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Figure S5. (Related to Figure 7) Pattern of mB7-H3 expression in murine normal tissues. (A and B) Representative micrographs 
of mB7-H3 expression in the murine pancreatic cancer cell line KPC-4662 engineered to express mB7-H3 (KPC-4662-mB7-H3-tg) and 
engrafted in C7BL/6J mice (A) and in normal murine tissue arrays (TMA) (B) as assessed by staining with the EPNCIR122 mAb used at 
the final concentration of 1.4 µg/mL. Scale bars are 200 µm. (C) mB7-H3 staining intensity quantified using the Aperio membrane v9 
(cell quantification) algorithm. Murine PDAC tumors harvested from C57BL/6J mice engrafted with the KPC-4662-mB7-H3-tg cell line 
were used as a positive control. Dotted line indicates the background level of the staining. Error bars denote SD.  
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Supplementary Figure 3. 5. (Corresponds with Figure 3. 7) Pattern of mB7-H3 
expression in murine normal tissues. (A and B) Representative micrographs of mB7-
H3 expression in the murine pancreatic cancer cell line KPC-4662 engineered to 
express mB7-H3 (KPC-4662-mB7-H3-tg) and engrafted in C7BL/6J mice (A) and in 
normal murine tissue arrays (TMA) (B) as assessed by staining with the EPNCIR122 
mAb used at the final concentration of 1.4 µg/mL. Scale bars are 200 µm. (C) mB7-H3 
staining intensity quantified using the Aperio membrane v9 (cell quantification) 
algorithm. Murine PDAC tumors harvested from C57BL/6J mice engrafted with the 
KPC-4662-mB7-H3-tg cell line were used as a positive control. Dotted line indicates the 
background level of the staining. Error bars denote SD.   
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Adrenal gland Weak positive Adrenal medulla weak cytoplasmic positive and very weak 
cortical zona glomerulosa and zona fasciculata labeling
24.7±11.9 (2)
Cerebrum Negative 18.6±4.9 (3)
Cerebellum Negative 16.1±7.6 (3)
Colon Positive Medium positive staining of cytoplasmic of glandular cells, 
particularly at the base of the crypts
42.7±8.7 (3)
Esophagus Negative Weak staining in some areas of the squamous epithelium 15.0±3.2 (3)
Heart Negative 4.9±2.9 (2)
Kidney Negative 6.1±1.5 (3)
Liver Negative 10.5 (1)
Lung Negative 5.8±2.3 (3)
Ovary Positive Moderate to strong positive staining of corpus luteum and 
atretic follicle epithelium 
47±2.6 (2)
Pancreas Weak positive Weak to medium cytoplasmic staining  47±8.3 (3)
Salivary gland Weak positive Moderate cytoplasmic staining of acinar epithelium 55.1 (1)
Sciatic nerve Negative 20.6±1.7 (2)
Skeletal muscle Negative 24.0±5.2 (2)
Skin Weak positive Weak cytoplasmic staining of basal keratinocytes 36.9±8.0 (3)
Small intestine Positive Weak to medium positive staining of the crypts 27.7±7.1 (2)
Spleen Negative 4.4±1.3 (3)
Stomach Positive Moderate to strong staining in the glandular epithelium 45.6±19.8 (2)
Testis Negative 9.6±3.1 (2)
Thymus Negative 7.0±2.0 (3)
Uterus Positive Moderate to strong staining of the epithelium and some 
weak labeling of the stroma
28.3±26.1 (2)
Uterus, Cervix Positive Moderate to strong staining of the epithelium 54.0±6.1 (2)
Tumor, IgG Negative 14.7±1.2 (2)
Tumor,  
Anti-mB7-H3
Positive Strong positive staining of both tumor cells and stroma 135.7±0.3 (2)
Murine PDAC tumors harvested from C57BL/6J mice engrafted with the KPC-4662-mB7-H3-tg cell line were used 
as a positive control. 
Supplementary Table 3. 2  
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Supplementary Table 3. 2. (Corresponds with Figure 3. 7) Summary of mB7-H3 
expression in normal murine tissues  
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Supplementary Figure 3. 6 
 
 Figure S6. (Related to Figure 7) Analysis of the cell composition in C57BL/6J mice infused with murine B7-H3.CAR-Ts. (A and B) Representative flow cytometry gating strategy (A) and quantification of the cell subsets in the peripheral blood collected on day 5 
post T cells infusion (B) in C57BL/6J mice irradiated with 400 cGy, and infused intravenously with syngeneic NT, mCD19.CAR-Ts or 
mB7-H3.CAR-Ts (1×107 cells/mouse) two days post-irradiation (5 mice/group). **p < 0.01, one-way ANOVA with Holm-Sidak test 
adjusted p value. (C-E) Quantification of the cells subset in the blood (C), spleens (D) and bone marrow (E) at day 12 in C57BL/6J 
mice infused intravenously with syngeneic NT, mCD19.CAR-Ts or mB7-H3.CAR-Ts (1×107 cells/mouse) without irradiation (5 mice/
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Supplementary Figure 3. 6. (Corresponds with Figure 3. 7) Analysis of the cell 
composition in C57BL/6J mice infused with murine B7-H3.CAR-Ts. (A and B) 
Representative flow cytometry gating strategy (A) and quantification of the cell subsets 
in the peripheral blood collected on day 5 post T cells infusion (B) in C57BL/6J mice 
irradiated with 400 cGy, and infused intravenously with syngeneic NT, mCD19.CAR-Ts 
or mB7-H3.CAR-Ts (1×107 cells/mouse) two days post-irradiation (5 mice/group). **p < 
0.01, one-way ANOVA with Holm-Sidak test adjusted p value. (C-E) Quantification of 
the cells subset in the blood (C), spleens (D) and bone marrow (E) at day 12 in 
C57BL/6J mice infused intravenously with syngeneic NT, mCD19.CAR-Ts or mB7-
H3.CAR-Ts (1×107 cells/mouse) without irradiation (5 mice/group). The horizontal bars 
in B-E represent the mean values.   
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Figure S7. (Related to Figure 7) Tissue pathology of mice infused with murine B7-H3.CAR-Ts. Tissue pathology of the indicated 
organs was evaluated by hematoxylin and eosin staining in C57BL/6J mice 15 – 16 days after treatment with syngeneic NT, 
mCD19.CAR-Ts or mB7-H3.CAR-Ts (1 × 107 cells/mouse). Scale bars are 200 µm. 








































Colon Skeletal muscle Spinal cord Prostate Pituitary gland Thyroid gland
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Supplementary Figure 3. 7. (Corresponds with Figure 3. 7) Tissue pathology of 
mice infused with murine B7-H3.CAR-Ts. Tissue pathology of the indicated organs 
was evaluated by hematoxylin and eosin staining in C57BL/6J mice 15 – 16 days after 
treatment with syngeneic NT, mCD19.CAR-Ts or mB7-H3.CAR-Ts (1 × 107 
cells/mouse). Scale bars are 200 µm.  
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Supplementary Table 3. 3
Tissues NT murine CD19.CAR murine B7-H3.CAR 
Heart WNL WNL WNL 
Kidney WNL WNL WNL 
Liver WNL WNL WNL 
Lung WNL WNL 1/5 minimal lymphoplpasmacytic perivscular cuffing 
Esophagus WNL WNL WNL 
Stomach WNL WNL 2/5 occasional scattered apoptotic cells, glandular stomach 
Small Intestine WNL WNL 2/5 multifocal mild increased lymphocytes and plasma cells 
Colon WNL WNL 3/5 multifocal mild increased lymphocytes and plasma cells 
Salivary Gland WNL WNL 1/5 Sublingual gland mild lymphocytic inflammation 
Pancreas WNL WNL WNL 
Brain WNL 1/5 severe neutrophilic meningitis WNL 
Skin WNL 1/5 multifocal lymphoplasmacytic folliculitis WNL 
Skeletal muscle WNL WNL WNL 
Prostate gland WNL 2/5 scattered apoptotic cells 2/5 occasional intraepithelial individual lymphocytes 
Adrenal gland WNL WNL WNL 
Pituitary gland WNL WNL WNL 
Thyroid gland WNL WNL WNL 
Table S3. (Corresponds with Figure 7) Tissue pathology of mice infused with murine B7-H3.CAR-Ts
WNL, Within normal limits for 5/5 specimens.
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Supplementary Table 3. 3. (Corresponds with Figure 3.7) Tissue pathology of mice 
infused with murine B7-H3.CAR-Ts  
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Neutrophils              DCs             Monocytes              NK                B cells              T cells           CD4+ T cells     CD8+ T cells
Figure S8. (Related to Figure 8) Murine B7-H3.CAR-Ts control tumor growth in immunocompetent mice without causing 
evident toxicity. (A-D) Representative micrographs of T cell infiltration (CD3) in the syngeneic pancreatic KPC-4662-mB7-H3-tg 
tumor model at days 33 - 34 post control T-cell infusion (A) and mB7-H3.CAR-Ts infusion (B). Scale bars are 200 µm. (C and D) 
Quantification of tumor infiltrating T cells (C) and PD-1 expression (D). (E and F) Quantification of the cell subsets in bone marrow 
(E) and lymph nodes (F) (n = 5 per group). *p < 0.05, unpaired and nonparametric Mann Whitney test with two tailed p value 
calculation. (G) Tissue pathology of the indicated organs was evaluated by hematoxylin and eosin staining. Scale bars are 200 µm. 


























Pituitary gland Salivary gland Thyroid gland Skin Uterus
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Supplementary Figure 3. 8. (Corresponds with Figure 3.8) Murine B7-H3.CAR-Ts 
control tumor growth in immunocompetent mice without causing evident toxicity. 
(A-D) Representative micrographs of T cell infiltration (CD3) in the syngeneic pancreatic 
KPC-4662-mB7-H3-tg tumor model at days 33 - 34 post control T-cell infusion (A) and 
mB7-H3.CAR-Ts infusion (B). Scale bars are 200 µm. (C and D) Quantification of tumor 
infiltrating T cells (C) and PD-1 expression (D). (E and F) Quantification of the cell 
subsets in bone marrow (E) and lymph nodes (F) (n = 5 per group). *p < 0.05, unpaired 
and nonparametric Mann Whitney test with two tailed p value calculation. (G) Tissue 
pathology of the indicated organs was evaluated by hematoxylin and eosin staining. 
Scale bars are 200 µm. The horizontal bars in C-F represent the mean values.   
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Tissues NT mB7-H3.CAR 
Heart WNL WNL 
Kidney WNL WNL 
Liver WNL WNL 
Lung WNL WNL 
Esophagus WNL WNL 
Stomach WNL 1/5 has focus of neutrophils below muscularis 
mucosae in glandular stomach near junction with 
squamous stomach.  
Small Intestine WNL WNL 
Colon WNL WNL 
Pancreas Focal pancreatitis, inflammation in portion of 
pancreas near to bile duct. Severe in 1/5 mice with 
mixed  inflammatory cells. 
Focal pancreatitis, inflammation in portion of 
pancreas near to bile duct. Mild in 1/5 mice with 
mixed  inflammatory cells. 
Brain WNL WNL 
Skin WNL Rare scattered individual dermal neutrophils 
Skeletal muscle WNL WNL 
Uterus WNL WNL 
Salivary Gland 1/5 small focus of periductal inflammation in 
submadibular gland  
WNL 
Adrenal gland WNL WNL 
Pituitary gland WNL WNL 
Thyroid gland WNL WNL 
Table S4. (Corresponds with Figure 8) Tissue pathology of tumor bearing mice infused with murine B7-H3.CAR-Ts
WNL, Within normal limits for 5/5 specimens.
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Supplementary Table 3. 4. (Corresponds with Figure 3.8) Tissue pathology of 








CHAPTER 4: DISCUSSION 
 
SUMMARY 
 Chimeric antigen receptor (CAR)-T cell therapy has transformed the landscape of 
adoptive immunotherapies. CARs are synthetic receptors that redirect T cell specificity 
based on the single chain variable fragment (scFv) of a monoclonal antibody when 
expressed on the surface of T cells [80]. The ζ-chain and costimulatory domains from 
the T cell receptor complex promotes CAR-T cell activation and proliferation through 
costimulatory signals [103]. The infusion of CAR-T cells targeting the CD19 antigen 
have led to remarkable progress in the treatment of lymphoid malignancies [130, 208]. 
However, there is substantial work to be done to not only improve the efficacy of CAR-T 
cell therapy, but also to overcome the relapse that occurs in up to 30% of patients that 
have already achieved remission [111, 124, 130, 190-194].  
 This dissertation proposes two strategies to address resistance to adoptive CAR-
T cell therapy. Tumor escape resulting from selective pressure by CAR-T cells is 
becoming an increasingly common cause of resistance to CAR-T cell therapy [198]. 
Chapter 2 proposes a novel strategy to prevent relapse occurring from tumor escape by 
simultaneously targeting multiple TAA using single domain antibody mimics. Inherent 
tumor heterogeneity in solid tumors is another well-recognized cause of resistance to 
adoptive CAR-T cell therapy [205, 287-290]. A TAA that is universally expressed on all 
146 
 
tumor cells but not on normal tissues could greatly reduce the chances of resistance to 
adoptive CAR-T cell therapy.  In Chapter 3, a universally and uniformly expressed TAA 
in which expression is restricted to malignant tissues is identified and a CAR developed 
against the TAA is examined for anti-tumor activity and safety profile. Altogether, this 
dissertation provides a foundation upon which to refine and improve the efficacy of 
adoptive CAR-T cell therapy.  
PART I – A STRATEGY TO OVERCOME TUMOR ESCAPE 
 Relapse following remission is a phenomenon universal to immunotherapies and 
is classified based on the phenotype of the tumor presenting at relapse. Relapse 
patients that present with a tumor that is phenotypically similar to the tumor prior to 
treatment are thought to relapse due to poor CAR-T cell function or persistence [291]. 
The use of autologous T cells is an attractive approach to ensure that no graft versus 
host disease (GvHD) complications arise from using allogeneic donor cells. However, 
using autologous T cells from cancer patients to manufacture CAR-T cells, which is the 
current standard, poses obstacles including inherent T cell dysfunction [292] and the 
inability to isolate sufficient cells at leukopheresis for CAR-T manufacturing [293]. 
 As a result of inherently poor T cell quality and frequency, steps are being taken 
to investigate strategies that would ensure T cell resistance to exhaustion and 
persistence in vivo. One proposed strategy to overcome dysfunctional autologous T 
cells is to manufacture and administer “off-the-shelf” CAR-T cell therapies [294]. Gene 
editing technologies such as CRISPR/Cas9 [295], zinc finger [296] and transcription 
activator-like effector nucleases [297] offer the possibility of manufacturing allogeneic 
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CAR-T cell products using healthy donor T cells. Yet, gene edited T cells may not 
entirely resolve the risk of GvHD because the infused allogeneic CAR-T cell product 
may not be 100% pure, leaving patients at risk for lethal GvHD [298]. Until investigators 
are able to understand the threshold for minimum purity, allogeneic CAR-T cell 
therapies may not offer the safety profile of autologous CAR-T cell therapies. An 
alternative allogeneic strategy being heavily investigated is to use cell subsets less 
likely to mediate GvHD to manufacture CAR-redirected cells. NK [299], iNKT [300], γδ T 
[301] and induced pluripotent stem cells [302] are non-T cell adoptive therapies in 
various phases of preclinical and clinical trials.  
 When relapse patients present with tumors that are phenotypically different from 
the tumor at the start of treatment, tumor escape due to the selective pressure of CAR-T 
cells is thought to be the cause. Several mechanisms of tumor escape have been 
reported: antigen loss [192], antigen down regulation [199] and lineage switch [200]. A 
strategy to overcome tumor escape by the above-mentioned mechanisms may be to 
simultaneously target multiple epitopes on a single antigen or to target multiple 
antigens. Currently, CAR-T cell multi-specificity is being achieved by various means. 
Vectors may be designed to encode for two independent CAR molecules to be 
expressed on the surface of the same cell. However, due to the large transgene, CAR 
expression is reduced, potentially compromising the efficacy of the CAR-T cells. [303] 
Alternatively, T cells can be transduced to each express a different CAR and be co-
administered into patients. The disadvantage of doing so is the increased costs of 
producing two different CAR-T cell products. [304] The most popular method of 
achieving multi-redirected CAR-T cells is to develop a tandem CAR. Tandem CARs are 
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bivalent CARs encoded on a single vector that redirect T cell specificity based on two 
different scFvs [305]. While tandem CARs have demonstrated efficacy and improved 
potency in in vitro and preclinical studies, it is uncertain whether tandem CARs will 
perform in vivo due to the fact that the bulky extracellular scFvs may misfold and inhibit 
efficient antigen recognition, but several clinical trials are underway (NCT03241940, 
NCT03233854, NCT03448393, NCT03019055) to understand the improved efficacy 
tandem CARs may offer. All in all, the current strategies to multi-redirect T cells 
compromise cost or efficacy. Novel strategies that are cost efficient and do not 
compromise anti-tumor activity are needed to multi-redirect T cells. 
 We have proposed the use of single domain antibody mimics to redirect T cell 
specificity. Single domain antibody mimics confer the advantages of being small, highly 
stable monomeric proteins that can accommodate high sequence variation [306]. We 
selected three single domain antibody mimics that are currently being tested in clinical 
trials for therapeutic and diagnostic purposes: the fibronectin type III (FN3) based 
monobody [213]; the ankyrin domain based DARPin [215]; the Staphylococcus protein 
A based affibody [307]. Antibody mimics that were evolved to target members of the 
ErbB family of receptor tyrosine kinases were constructed into monomeric, biepitopic or 
bispecific amRs in this proof-of-principle study to demonstrate the feasibility and 
practicality of multi-redirecting amRs over conventional scFv based CARs. Importantly, 
we showed that the resulting amRs were equal in phenotype and efficacy compared to 
the conventional scFv based counterparts in all of the phenotypic and functional 
parameters examined. [308] 
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 As the use of single domain antibody mimics for T cell redirection grows, it will be 
important for investigators to thoroughly optimize multi-redirecting amRs for efficient 
recognition and activation. The optimal affinity of each ligand binding domain should be 
determined within the context of observations that conventional CARs, due to their 
crude construction and simplicity, require much higher antigen density and form 
irregular immune synapses compared to TCRs [206, 207]. However, a simple increase 
in the affinity of the ligand binding domains does not necessarily translate in improved 
function. This has been highlighted in our study, as well as others, and suggests that 
there is a point in which affinity enhancement for improved activity plateaus. [84, 308, 
309] The affinity and avidity by which each domain and the combination of domains 
binds their respective antigens will have significant effects on the quality of T cell 
activation and is therefore a fundamental area of investigation [85, 310-312]. Other 
aspects of the amR that should be optimized to improve the overall function of multi-
redirecting amRs include the orientation of each antibody mimic domain and the length 
of the linker separating each domain.  
 Though we have demonstrated that the proposed approach can be adapted to 
clinically utilized therapies in terms of anti-tumor activity, examination of the 
immunogenicity of molecularly evolved antibody mimic domains remains a critical but 
unaddressed aspect of our studies. Immunogenicity to CAR transgenes is a well-
documented phenomenon and studies show that 80% of the detected humoral 
responses are directed towards the CDR regions of the scFv [313]. However, the fact 
that even fully human antibodies can be immunogenic in some patients [314] 
underscores the point that the use of non-host proteins will always carry the risk of 
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rejection, despite careful screening. In order to further minimize the risk of 
immunogenicity, we have selected antibody mimics, such as the FN3 and DARPin, 
which are derived from ubiquitously found human proteins with positive safety profiles 
that are undergoing clinical trials [315-320]. Hence the proposed use of antibody mimics 
in constructing multi-redirecting receptors for adoptive immunotherapy warrants clinical 
investigation. 
PART II – A STRATEGY TO OVERCOME TUMOR HETEROGENEITY 
 The dearth of TAA with expression restricted to malignant tissues has been a 
limiting factor in developing adoptive CAR-T cell therapies. In addition to few TAA 
meeting the criteria, solid tumors are overwhelming heterogeneous [205]. Identifying a 
target antigen that is uniformly expressed on all tumor cells but not normal cells and 
universally expressed on the surface of tumor cells across various tissues would greatly 
aid in the development of an adoptive CAR-T cell therapy for solid tumors. B7-H3 
(CD276) is an ideal target that has been identified as a pan-cancer antigen with high, 
homogenous expression in solid tumors [321, 322]. We took advantage of the fact that 
there is 88% homology between human and murine B7-H3 to probe the anti-activity and 
safety of a cross-reactive B7-H3.CAR and demonstrated that B7-H3.CAR-T cells do not 
cause on-target but off-tumor toxicity in immunocompetent mouse models [323]. 
 The results of our studies favor the use of the B7-H3.CAR-T cells in the clinic. 
However, immunohistochemistry analysis of both human and murine normal tissues has 
demonstrated that there is conserved expression of B7-H3 in select tissues such as the 
adrenal and salivary glands and the stomach [323]. While we did not observe toxicity in 
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immunocompetent mice infused with B7-H3.CAR-T cells, it is plausible that the infusion 
of B7-H3.CAR-T cells in human patients can cause unexpected lethal toxicity observed 
in trials targeting HER2 [133] and carbonic anhydrase IX [324, 325]. As we move B7-
H3.CAR-T cells to the clinic we have proposed two additional safeguards to prevent 
lethal toxicity. First, we have proposed transient B7-H3.CAR expression in T cells by 
RNA electroporation. Further, we have proposed the addition of the iCas9 safety switch 
in the B7-H3.CAR vector to ensure rapid elimination of CAR expressing T cells.  
 As we look towards the future of adoptive CAR-T cell therapies more emphasis 
may need to be placed on examining the cancer mutanome to identify targets for CAR-T 
cell therapy. Current technologies being used to identify target antigens are significantly 
limited in predicting in vivo safety and put patients at risk. While in depth mutanome 
analyses have not been pursued in the past due to the costly and labor-intensive 
procedures required to identify a target antigen for a single patient, recent reports of 
lethal toxicity are warranting such efforts. In comparison to current methodologies, 
which include immunohistochemistry guided protein expression and cDNA microarray 
data, examining next-generation sequence data using bioinformatics approaches can 
clarify unique therapeutic targets and predict optimal combinations of antigens to target. 
[326-328] 
FUTURE CONSIDERATIONS 
 The field of adoptive immunotherapies has undergone revolutionary advances in 
the last several decades. The identification and purification of IL-2 allowed for in depth 
analyses of T cell biology, confirming early hypotheses that T lymphocytes play a critical 
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role in the rejection of tumors, and invigorated the field towards using autologous TILs 
as an adoptive immunotherapy against metastatic cancers. Unfortunately, the use of 
TILs as a cancer treatment was only effective in a few select cancers, such as 
melanoma [329]. We now understand that TIL treatment is effective in melanoma 
because TILs harbor high neoepitope reactivity. However, the vast majority of tumors 
have an underwhelming neoantigen burden and the effects of TIL therapy are transient 
to ineffective. [330-332] 
  In response to disappointing results with TIL therapy, the field utilized genetic 
engineering techniques to transduce polyclonal T cell populations with tumor-specific 
TCRs [48]. But due to MHC-dependent activation, TCR engineered T cells also failed to 
make significant advancements in the treatment of cancer patients [333, 334]. The CAR 
was born out of the idea that in order to overcome mechanisms tumors employ to 
prevent T cell activation, T cells must be endowed with MHC-independent activation. 
With CAR-expressing T cells, patients with B cell malignancies have achieved 
impressive complete durable response rates [130]. Despite the progress made thus far, 
limited options are available for patients who relapse due to adoptive CAR-T cell 
therapy resistance [198]. As the field of adoptive T cell therapy continues to mature, it 
will become increasingly critical to identify combinations of safe and homogeneously 
expressed tumor targets that effectively induce comprehensive anti-tumor responses 
and epitope spread. Epitope spread is a phenomenon in which the death of the tumor 
cells results in the release of secondary tumor antigens and a subsequent immune 
response. Epitope spreading, which has been observed in autoimmunity and infectious 
disease, can result in clinically significant responses. [335, 336] Epitope spreading has 
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not yet been studied extensively in adoptive T cell therapies. However, as more clinical 
data become available, it will be critical to investigate epitope spread induced by 
adoptive T cell therapies so that effective multi-pronged strategies can be designed. 
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